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Introduction 
 
Intestinal infections with enterotoxigenic Escherichia coli (ETEC) affect neonatal and 
recently weaned piglets. These infections cause diarrhoea and are responsible for severe 
economic loss due to growth retardation, elevated drug use and mortality. In general, most 
neonatal infections can be prevented by passive colostral and lactogenic immunity obtained 
by vaccination of the sow. However, this passive protection decreases with aging and at 
weaning lactogenic immunity disappears. Consequently, the newly weaned piglet becomes 
highly susceptible to enteropathogens. In Belgium, the losses due to ETEC induced 
postweaning diarrhoea (PWD) are estimated to be approximately 13 000 000 euro/year 
(Snoeck, 2004). 
PWD occurs within 10 days of weaning, often the first 4-5 days after weaning and is 
characterised by greyish brownish or watery diarrhoea (Hampson, 1994). The diarrhoea is 
usually transient and resolves within 3-5 days but may persist and cause death from 
dehydration. Even when the diarrhoea is transient, marked reduction in the rate of daily 
weight gain may occur. ETEC are the most important pathogens in the PWD complex. They 
can be carried into the weaner house by healthy suckling pigs which have the organism in 
their lower part of the intestinal tract (Hampson et al., 1985). Upon weaning, proliferation of 
these ETEC can occur with spread of the bacteria to other pigs. However, colonisation of the 
recently weaned pigs can also occur following their exposure to the contaminated 
environment of a weaner house that has contained infected pigs (Hampson et al., 1987) or by 
mechanical transmission of the bacteria.  
Porcine pathogenic E. coli involved in PWD typically belong to serogroups O8, O138, 
O139, O141, O147, O149 and O157, of which O149 seems to be the predominant serogroup 
in most countries (Sojka, 1965; Blanco et al., 1997; Frydendahl et al., 2002; Naomani et al., 
2003). ETEC can cause severe diarrhoea in newborn and weaned piglets by the production of 
heat-labile enterotoxin (LT) and/or heat-stable enterotoxins (STa or STb). These enterotoxins 
are extracellular proteins or peptides, which are able to cause diarrhoea by changing the water 
and electrolyte balance of the small intestine (Blanco et al., 1997). 
The bacteria possess adhesins which enable them to bind specific receptors on the 
intestinal epithelium and subsequently to colonize the small intestine. Of these adhesins, F4 
(K88) fimbriae are the best characterised (Van den Broeck et al., 2000). The F4 fimbriae are 
long proteinaceous appendages mainly composed of several hundreds identical 27.5 kDa 
FaeG subunits. Some parts of the FaeG subunits are conserved, whereas in other regions a 
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certain degree of variation exists. As a consequence, 3 antigenic variants of F4 have been 
identified, called F4ab, F4ac and F4ad (Ørskov et al., 1964; Guinée and Jansen, 1979). 
Among these, F4ac is the most prevalent (Westerman et al., 1988).  
The receptors for F4+ ETEC are not present in every pig and absence of the F4-receptors 
(F4R) causes resistance to F4+ ETEC-induced diarrhoea. Presence of the F4R gene is 
genetically determined, with presence of this gene being the dominant character (Gibbons et 
al., 1977). However, expression of the F4R gene is influenced by epistatic genes, causing 
variation in the degree of F4R expression (Bijlsma and Bouw, 1987). Pigs become resistant to 
F4+ ETEC infection with increasing age by release of higher amounts of F4R in the intestinal 
mucus layers (Conway et al., 1990).   
Although ETEC play a central role in PWD, the etiology of PWD is more complex as 
several weaning-associated factors predispose the pig to PWD. (1) The withdrawal of specific 
(anti-adhesin and anti-toxin antibodies) and non-specific (anti-bacterial agents such as 
lactoferrin and transferrin) protective effects contained in sow’s milk (Nagy et al., 1979; 
Deprez et al., 1986). (2) A temporarily decrease in gastric acidity, allowing ingested bacteria 
to survive and to gain access to the small intestine (Schulman, 1973). (3) A lack of dietary 
intake (Kelly et al., 1984), hypersensitivity to new dietary antigens (Miller et al., 1984), 
change from a liquid (milk) diet to a dry diet, an inflammatory response to bacterial toxins 
and/or digestion products (Kenworthy, 1976) or viral infection (Lecce et al., 1982) resulting 
in changes in structure of the small intestine and enterocyte brush border enzyme activities. 
These changes include a decrease of the villus height, increase of the crypt depth, decrease of 
brush border lactose and sucrase activity, sodium-dependent alanine transport and capacity for 
xylose absorption. The net result is a reduction in the intestinal digestive and absorptive 
function encouraging the development of osmotic diarrhoea, whilst the unabsorbed intestinal 
content acts as substrate for ETEC (Miller et al., 1986). (4) The incompletely developed large 
intestinal microflora causing a limited fermentation, diminishing water and electrolyte 
adsorption (Hampson, 1987). (5) The amount of diet consumed and the physical form of the 
diet. It is suggested that there is a positive correlation between the amount of diet consumed 
and the duration of faecal ETEC excretion and the occurrence of PWD (Hampson and Smith, 
1986). On the other hand, the changes in small intestinal structure and enzyme activities are 
reduced if the weaner diet is fed as a liquid slurry (Deprez et al., 1987).  (6) Exposing the pigs 
to cold temperatures or temperature fluctuations (Wathes et al., 1989). 
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It was previously shown that oral immunization of weaned F4-receptor positive (F4R+) 
pigs with F4 fimbriae results in an antigen-specific secretory IgA (sIgA) response at the 
intestinal mucosa, protecting these pigs against a subsequent F4+ ETEC challenge (Van den 
Broeck et al., 1999a). However to protect newly weaned pigs, the immune system should 
already be primed during the suckling period. Most suckling pigs have maternal antibodies 
against F4 fimbriae, hampering their use as a vaccine.  
DNA vaccines can reach their target cells in the presence of maternal antibodies and 
produce their encoded antigen endogenously, so maternal antibodies won’t interfere with the 
induction of cellular immunity by these vaccines. Therefore, we suggested that priming with a 
DNA vaccine encoding the adhesive subunit of F4, the FaeG, could be an interesting 
approach to obtain protective immunity against PWD. 
The best route to induce an intestinal mucosal immune response is the oral route. However, 
oral DNA vaccination is difficult as it involves overcoming several challenges. These include 
depurination by low pH in the stomach, enzymatic degradation by DNases in the gut, crossing 
the physical barrier imposed by the mucus layer and overcoming the epithelial barrier to reach 
the intestinal mucosal inductive sites. Parenteral vaccination seems more appropriate, but this 
stimulates the systemic rather than the mucosal immune system. However, when using protein 
vaccines, parenteral vaccination has successfully induced mucosal responses if a mucosal 
boost or immunomodulating adjuvants were included. One such adjuvant is 1α,25(OH)2D3, 
the active form of vitamin D3 (vitD3). When added to protein antigens, vitD3 appears to 
modulate a systemic immune response towards a mucosal one in mice (Daynes and Araneo, 
1994; Daynes et al., 1996; Enioutina et al., 1999, 2000) and to a lesser extend in pigs (Van 
der Stede et al., 2001, 2003, 2004). Although vitD3 has traditionally been associated with 
calcium homeostasis, it is now appreciated to exert pronounced effects on the mammalian 
immune system. VitD3 exerts its actions through a nuclear vitamin D receptor (nVDR) 
(Bouillon et al., 1995) present on most cells of the immune system such as monocytes, 
macrophages, dendritic cells (DC) (Adorini et al., 2001), T- and B-lymphocytes (Morgan et 
al., 1994, 1996, 1999). VitD3 stimulates the differentiation and maturation of monocytes (Abe 
et al., 1981) while DC differentiated from bone marrow precursors in presence of vitD3 
acquire a less mature phenotype (Berer et al., 2000; Griffin et al., 2000, 2003). VitD3 also 
suppresses T cell proliferation as well as production of the T-helper 1 (Th1) cytokines IFN-γ 
and IL-2 (van Etten and Mathieu, 2005; Bhalla et al., 1986; Reichel et al., 1987). On the other 
hand, vitD3 is able to enhance the production of Th2 cytokines such as IL-4 and IL-10 
(Daynes and Araneo, 1994; Daynes et al., 1996; Cantorna et al., 1998; Adorini et al., 2001) as 
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well as of the Th3 cytokine TGF-β (Fukaura et al., 1996; Weinreich et al., 1999). TGF-β and 
IL-10 are involved in IgA isotype switching (Defrance et al., 1992). Consequently, vitD3 is 
able to mimic in the local draining lymph node (LN) the cytokine pattern normally produced 
in the intestinal Peyer’s patches following oral immunization, which was originally believed 
to promote the mucosal response to parenteral protein vaccines (Daynes and Araneo, 1994; 
Daynes et al., 1996). Later, the same group demonstrated that mainly the migration of 
antigen-pulsed DC to the Peyer’s patches and the activation and differentiation of antigen-
specific B cells in these tissues, is responsible for the induction of the mucosal response to 
parenteral vaccines (Enioutina et al., 1999, 2000). Antigen uptake by DC is normally 
followed by a maturation process that includes a decline in expression of inflammatory 
chemokine receptors allowing the release of DC from the immunization site, with a parallel 
upregulation of the chemokine receptor CCR7 and enhanced responsiveness to sphingosine-1-
phosphate (S1P) resulting in their traffic through the afferent lymphatic vessels and their 
eventual sequestration into a draining LN (Caux et al., 2002; Czeloth et al., 2005). However 
when DC are stimulated in tissue environments containing vitD3, they are capable of avoiding 
draining LN sequestration. Mechanisms responsible for this altered migratory pattern include 
a reduced expression level of CCR7, a temporary inhibition of chemotaxis towards CCR7 
ligands but not towards S1P and an upregulated surface expression of the α4β7 integrin 
responsible for homing to mucosa-associated lymphoid tissues (Enioutina et al., 2007). The 
ability to change the migratory properties of antigen-pulsed DC is not unique to vitD3, but 
also seems to occur when enhancers of cyclic AMP (cAMP) such as cholera toxin, LT or 
forskolin are added to cutaneously administered protein vaccines (Enioutina et al., 2000; 
Belyakov et al., 2004). Enioutina et al (2000) hypothesized that this might be due to the 
capacity of cAMP to stimulate the expression of 1,α-hydroxylase, which converts the normal 
circulating 25(OH)D3 into vitD3. However, such a relationship between the ability of vitD3 
and cAMP to promote priming of mucosal responses remains to be determined. 
In the present thesis, we examined if parenteral FaeG DNA vaccination in the presence or 
absence of immunomodulating adjuvants could prime an intestinal mucosal immune response. 
The pcDNA1/faeG19 DNA vaccine previously developed at our lab only induced marginal 
immune responses following parenteral immunization of pigs. In order to enlarge our chances 
on successful mucosal priming, we first applied several strategies to enhance the 
immunogenicity of our FaeG DNA vaccine. Furthermore, given the critical role of antigen-
presenting cells (APC) in the induction of mucosal immunity, granulocyte-macrophage 
colony-stimulating factor, a well known chemo-attractant of APC was included in our 
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vaccination strategy. Part I (Chapter 1) reviews the literature on DNA vaccination. In part II, 
the specific aims of the study are described. The experimental work is presented in part III 
(chapter 2 to 5). Part IV contains the general discussion and the overall conclusions and future 
perspectives (chapter 6).    
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  Chapter 1: DNA vaccination in the pig 
1.1 Introduction
The concept of DNA as a vaccine originates from the observation that delivery of DNA 
into an animal could lead to in vivo gene expression. In the 1950’s, experiments aiming to 
understand the fundamental nature of cancer tested the delivery of crude tumour DNA 
preparations to rodents and observed tumour growth (Stasney et al., 1950; Ito et al., 1961). A 
decade later, Atanasiu and colleagues extended these early observations by the finding that 
subcutaneous administration of crude polyoma virus DNA into hamsters not only resulted in 
tumour development but also in the generation of antibodies against the virus (Atanasiu et al., 
1962; Orth et al., 1964). Later Israel et al (1979) extended the initial findings to recombinant 
viral DNA. All together, these data suggested the idea of DNA transfer to drive protein 
expression and activate the immune system.  
In the early 1980’s, two independent studies demonstrated the in vivo expression and the 
biological activity of plasmid encoded gene products (Will et al., 1982; Nicolau et al., 1983). 
However, the major turning point regarding the in vivo expression of plasmid encoded genes 
comes from a study by Wolff et al. (1990) reporting that the in vivo activity of a reporter gene 
could be detected for up to 2 months following intramuscular ‘plasmid or naked’ DNA 
injection into mice. Their data suggested that, at least in mice, antigens could be delivered at 
high enough levels to give persistent signals.  
In 1992, a critical study published by Tang et al. (1992) utilizing DNA coated gold beads 
to transfect cells in vivo reported the generation of an antibody response against the DNA 
encoded proteins. This manuscript highlighted that small amounts of DNA delivered to the 
skin could stimulate an antigen specific humoral immune response. Soon thereafter, several 
investigators demonstrated the induction of both humoral and cellular responses against true 
human pathogens like influenza (Ulmer et al., 1993; Fynan et al., 1993), HIV (Wang et al., 
1993) and hepatitis B (Davis et al., 1994). Importantly, these studies also showed that DNA 
vaccination could impact on viral replication. Since then, DNA vaccines have been reported 
to induce protective immunity against an array of pathogens, including viruses, parasites and 
bacteria (Donnelly et al., 1997; Watts and Kennedy, 1999). However, most of these studies 
were performed in mice, whereas experiments in large animals and man were generally less 
successful, especially with regard to antibody responses. Therefore, improving the immune 
potency and deliverability of DNA vaccines has become a central issue during the last decade 
and new formulations, new adjuvants and more sophisticated constructs have been developed 
(Laddy and Weiner, 2006; Liu et al., 2006; Leitner et al., 1999). However, studies have 
demonstrated that the success of DNA vaccines to induce immune responses in mice still does 
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not necessarily translate itself to large animals and man (Laddy and Weiner, 2006). 
Nevertheless, two DNA vaccines have recently been approved for veterinary use; one for 
West Nile Virus in horses (Powell, 2004)  and a second for Infectious Haematopoietic 
Necrosis in salmon (Lorenzen and LaPatra 2005). Hence, DNA vaccines finally appear to 
gain a position on the market. However, the challenge remains to make future vaccines more 
potent and cheaper to manufacture to allow them to become routinely used.   
 
1.2 Principle of DNA vaccines 
The principle of DNA vaccination is relatively simple: a gene encoding a specific antigen 
is inserted into a DNA plasmid that can be replicated in bacteria, purified and directly 
inoculated into the host to be vaccinated. The plasmid insert then becomes transcribed and 
translated by the host cells and the protein produced initiates an immune response. However, 
many details regarding the uptake of the plasmid into the host cell and the following transport 
to the nucleus remain unclear. 
Plasmid design 
The DNA plasmids are bacteria-derived, circular DNA molecules equipped with a unit for 
plasmid propagation in bacteria and a transcriptional unit to allow eukaryotic expression 
(Figure 1). The transcriptional unit minimally includes a strong eukaryotic or viral promoter 
to drive transcription in mammalian cells, a multiple cloning site to allow the insertion of 
foreign genes and a polyadenylation sequence to provide stabilization of mRNA transcripts. 
These sequences are discussed in more detail later (1.5.1, vector elements). The unit for 
plasmid propagation in bacteria includes an origin of replication and a marker to enable 
plasmid selection during bacterial growth. Often, the E. coli ColE1 origin of replication is 
used because it provides high copy numbers, allowing the purification of high yields of 
plasmid DNA. As selection markers, bacterial antibiotic resistance genes are most commonly 
used. Since it is recommended to avoid resistance to therapeutic antibiotics, kanamycin or 
neomycin resistance genes are better suited for this purpose than the frequently used 
ampicillin resistance gene.  
In addition, bacterial plasmid DNA contains immunostimulatory CpG motifs which may 
enhance the immunogenicity of the DNA vaccine (Sato et al., 1996). 
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nal by the innate immune system. The basic formula for such a CpG motif has 
bed as 5′-X1X2CGY1Y2-3′, where X1 is a purine (adenine (A) or guanine (G), X2 is 
 a thymine (T), while Y1 and Y2 are pyrimidines (cytosine (C) or T) (Krieg et al., 
 recognition of CpG-motifs by the innate immune system is species-specific 
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t al., 1996). They also directly activate monocyte/macrophages and dendritic cells 
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to secrete interferon (IFN)-α, IL-6, IL-12, granulocyte-macrophage colony-stimulating factor 
(GM-CSF), chemokines and tumor necrosis factor (TNF)-α. Similarly, either directly or 
through the cytokines produced by APC, they stimulate NK cells to produce IFN-γ and to 
increase killer activity. In addition to their ability to support cytokine and Ig secretion, CpG 
motifs could contribute to the development of an immune response by upregulating cell 
surface expression of MHC class II (MHCII) and other co-stimulatory molecules, such as 
B7.1 and B7.2. As a result of these activities, CpG motifs rapidly stimulate host defenses and 
polarize immune responses to a T-helper (Th)1-like response in both DNA vaccines as well as 
if used as an adjuvant with protein vaccines (Weiner et al., 1997; Krieg et al., 1998).  
 
…X1X2CGY1Y2… 
IFN-γ
B cell NK cell 
Monocyte 
Macrophage
DC 
IFN-α 
TNF-α MHCII Proliferation 
IL-6 IL-12 B7.1 
IL-6 B7.2 IL-10 
Chemokines Ig  
Figure 2. Effects of CpG motifs on leukocytes. CpG motifs stimulate B cells to proliferate 
and secrete IgG, IL-6 and IL-10. They directly activate monocytenomacrophages and
dendritic cells to secrete IFN-α, IL-6, IL-12, GM-CSF, chemokines and TNF-α. Either 
directly or through the cytokines produced by APC, they stimulate NK cells to produce IFN-
γ and to increase killer activity. In addition, CpG motifs induce upregulation of cell surface 
expression of MHCII and other co-stimulatory molecules, such as B7.1 and B7.2. 
 
 
1.3 Immunogenicity of DNA vaccines
The ability of DNA vaccines to elicit antibody responses and both CD4+ and CD8+ T cell 
responses has been well documented. Each of these responses generally require the antigen to 
be encountered differently: B cells can directly recognize the antigen, whereas CD4+ T cells 
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primarily recognize peptide-MHC class II complexes on the surface of antigen-presenting 
cells (APC) that have taken up and processed exogenous antigens, and CD8+ T cells are 
generally restricted to peptide-MHC class I complexes derived from endogenous proteins that 
have undergone proteasome-dependent intracellular processing. The exact mechanism by 
which DNA vaccination results in the activation of these 3 arms of the immune system 
remains to be determined. 
Role for somatic cells in the induction of immunity following DNA vaccination
Somatic cells (for example keratinocytes, myocytes or other MHC class II-negative cells) 
are the primary cell type that becomes transfected following DNA vaccination. Although 
these cells express MHC class I molecules, they generally don’t express costimulatory 
molecules and thus are unlikely to function as effective APC (Pardoll and Beckerleg, 1995). 
Evidence for this was first provided by studies using bone marrow chimeras. In a study by 
Corr and colleagues (1996), parent into F1 bone marrow chimeras were generated by 
destroying the bone marrow of H-2bxd F1 mice by irradiation and substituting them with either 
parental H-2b or parental H-2d T cell-depleted bone marrow. So, these mice had myocytes 
whose MHC molecules expressed both parental haplotypes, T cells that recognize both 
parental haplotypes (due to an F1 thymus) and APC expressing MHC molecules from only 
one of the parents. The CTL response generated on subsequent DNA vaccination of these 
mice was found to be restricted to the haplotype of the reconstituted bone marrow. Similar 
findings were observed for epidermal gene gun immunization (Iwasaki et al., 1997). These 
data strongly indicate that myocytes and keratinocytes are not converted into APC by DNA 
transfection and that bone marrow-derived APC are necessary to prime CTL responses after 
genetic immunization.  
In studies attempting to more clearly define the exact role of myocytes or keratinocytes in 
the induction of an immune response following DNA vaccination, Torres et al (1997) 
reported that needle-injected muscle tissue is not critical to raise responses, whereas gene 
gun-bombarded skin is. Indeed, excision of the injected muscle within 10 minutes of DNA 
inoculation did not affect cellular or humoral responses. This implies  that the events which 
lead to immune responses following intramuscular DNA vaccination take place in more distal 
tissues and are either initiated by rapidly migrating free DNA, by transfected hemopoietic 
cells in blood or by transfected APC migrating from the injection site into blood or lymph 
(Torres et al., 1997). Although the injected muscle is known to retain plasmid DNA and to 
produce antigen for up to 18 months (Wolff et al., 1990), the data by Torres et al suggested 
that the muscular antigen production is not needed to induce immune responses and 
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consequently that the antigen producing cells responsible for immune induction remain to be 
identified. 
On the contrary, they demonstrated that the integrity of the targetted skin was required for at 
least 3 days to induce maximal responses following gene gun immunization. This correlates 
with the temporal expression of the antigen in the skin and could reflect the time keratinocytes 
serve as antigen factories or the time it takes directly transfected Langerhans’ cells (LC) to 
migrate out of skin, or both (Torres et al., 1997). At least some role for directly transfected 
LC is suggested by the appearance of DNA-expressing DC in draining lymph nodes within 24 
h of gene gun bombardment (Condon et al., 1996), whereas a role for keratinocytes as antigen 
factories was proven by the use of a keratinocyte-specific promoter (K14). Antigen expression 
driven by this promoter generated comparable humoral and cellular responses than antigen 
expression driven by the frequently used cytomegalovirus (CMV) promoter , which is active 
in all eukaryotic cell types (Hon et al., 2005). In addition, the data by Hon and colleagues 
demonstrated that also B cells play a strong role in cross-priming T cell responses from 
keratinocyte-derived antigen. Indeed, in addition to DCs, the B cell population isolated from 
the draining LN of mice immunized with both the CMV and the keratinocyte-specific 
expression construct induced significant CD8+ T cell proliferation. Furthermore, B cell-
deficient mice immunized with the keratinocyte-specific construct showed only minimal 
CD4+ and CD8+ T cell responses.  
The importance of skin but not muscle to DNA-raised responses might reflect the better 
immune surveillance function of the skin. Indeed, LC constitute about 5% of the epidermal 
cells. Furthermore, keratinocytes are specialized to enhance the immune surveillance function 
by secreting cytokines in response to injury or infection. These cytokines upregulate MHC 
class II molecules on LC and stimulate LC migration (Salmon et al., 1994; Belsito et al., 
1989). In muscle, the lower frequency of resident DC or the low ability of transfected 
myocytes to enhance the recruitment and activation of APC may account for the minimal role 
of muscle in DNA vaccination. However, an important limitation of all these studies is that 
they were performed in mice in which the intramuscular immunization generally includes the 
injection of a large volume (typically 50-100 µl) into a relatively small muscle. This makes it 
likely that DNA becomes forced out of the muscle into the vessels and other surrounding 
tissues. Indeed, one hour post-vaccination, plasmid DNA could already be detected in most 
highly vasculated tissues, including blood, bone marrow and spleen (Parker et al., 1999). 
Furthermore, it should be mentioned that when surveying muscle-associated plasmid, these 
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studies only focused on the injected muscle, whereas muscle tissue separate from the injection 
site might also be transfected.     
Professional APC are responsible for priming cellular and humoral responses following 
DNA vaccination 
There are at least 3 different ways by which APC might be involved in T cell priming: they 
can capture antigen secreted by other transfected cells, resulting in MHC class II-restricted 
presentation, pick up antigen from transfected cells by an as yet ill-defined mechanism, 
resulting in MHC class I-restricted “cross”-presentation or they can be transfected themselves, 
resulting in MHC class I presentation of plasmid encoded antigens (Figure 3) (Takashima and 
Morita, 1999).  
DNA vaccine
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Figure 3. CD4+ and CD8+ T cell activation by DNA vaccination. Following transfection of somatic cells 
(left), antigen can be processed and presented to CD8+ T cells via MHC-I molecules. However, as these 
cells do not express B7.1 and/or B7.2 costimulatory molecules, they are not able to activate naive CD8+ 
T cells. APC express costimulatory molecules and can activate CD8+ as well as CD4+ T cells in 
different ways. They can capture antigen secreted by other transfected cells resulting in MHC class II-
restricted presentation, pick up antigen from transfected cells in an as yet ill-defined mechanism 
resulting in MHC class I-restricted cross-presentation or they can become transfected themselves, 
resulting in MHC class I presentation of plasmid encoded antigen. More detailed information can be 
found in the text. 
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Several studies undertaken to clarify the contribution of direct priming and “cross”-
priming in the induction of CD8+ T cell responses support both mechanisms. Evidence for 
direct priming was provided in a study by Bot et al (2000). In that study, mice were 
intradermally injected with plasmid DNA and migratory cells were subsequently analyzed for 
coexpression of the plasmid encoded antigen and MHC class II molecules. Upon adoptive 
transfer into naïve recipient mice, transfected MHC class II+ cells were far more efficient at 
priming cytotoxic T lymphocyte (CTL) responses as compared to MHC class II- cells, arguing 
in favour of direct priming. Direct priming was also suggested by earlier studies 
demonstrating the migration of in situ transfected (DNA containing) DC to the local draining 
lymph nodes (Condon et al., 1996; Casares et al., 1997; Akbari et al., 1999). Such cells were 
able to activate specific CD8+ T cells (Casares et al., 1997; Akbari et al., 1999; Chattergoon 
et al., 1998). The role of directly transfected DC in the induction of CTL responses was 
further pinpointed by co-transfection with plasmid encoding an antigen and plasmid DNA 
encoding a membrane marker allowing for the selective depletion of directly transfected cells 
(Porgador et al., 1998). In that study depletion of transfected cells from total or DC enriched 
LN cells reduced presentation by 60-70%.   
In contrast, other studies point to cross presentation as the main mechanism by which DNA 
vaccines prime immune responses. To evaluate whether direct transfection of migratory cells 
was necessary to prime CTL responses, Corr et al (1999) used an expression-suppressible 
construct that allowed to separate transport of the plasmid versus this of the protein from the 
injection site. Mice lacking B and T cells were immunized in the presence or absence of the 
suppressor. Splenocytes (APC) from these mice were injected into recipient mice and 
assessed for their ability to prime CTL responses. Recipient mice that received splenocytes 
from mice without suppressor mounted a greater CTL response, suggesting that exogenous 
transfer rather than endogenous production was important for the magnitude of the response. 
Similarly, studies comprising transplantation of transfected myoblasts (Ulmer et al., 1996; 
1997) and tumor cells (Huang et al., 1994) together with studies using chimeric mice 
generated subsequent to DNA inoculation (Doe et al., 1996) suggested that antigen transfer 
between somatic cells and bone marrow-derived APC may be important for CTL priming.  
A few factors may account for these discrepancies: the heterogeneity of the models 
employed regarding the route and dose of vaccination, the type of antigen and particularly the 
presence or absence of targeting signals. Furthermore, it is likely that both mechanisms co-
exist to a certain degree.    
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1.4 Advantages of DNA vaccines over current vaccines 
DNA vaccination provides many advantages over current vaccines that use live-attenuated 
pathogens, protein- or peptide-based subunit vaccines or killed micro-organisms. As observed 
following live infection, DNA vaccination results in stimulation of both the cellular and the 
humoral arm of the immune system, whereas subunit vaccines or killed micro-organisms 
mainly induce antibody responses. In addition, it is possible to tailor the immune response to 
either a strong humoral or a strong cellular response depending on the route of delivery and 
the costimulatory molecules administered with the plasmid. Several studies have 
demonstrated that DNA vaccines can successfully induce immune responses in neonates, 
observing minimal interference from maternal antibodies (Monteil et al., 1996; Fischer et al., 
2003; Hassett et al., 1997; Van Loock et al., 2004; Bot and Bona, 2002). In addition, they 
may overcome immaturity of the neonatal immune system due to the presence of CpG motifs 
(Bot and Bona, 2002). Another advantage of DNA vaccines includes safety, with no evidence 
of injection site reactions which are often observed with subunit or killed vaccines mixed in 
adjuvants, no risk of reversion to virulence which might occur with live-attenuated vaccines 
and no need to culture dangerous pathogens. Despite the initial concern that plasmid DNA 
may cause tumour genesis, integrate into the host chromosome (Nichols et al., 1995) or 
induce anti-DNA auto-immunity (Donnelly et al., 1997), yet little evidence has supported 
these phenomenon. Indeed, the rate of integration of plasmid DNA into the host chromosome 
appears to be much lower than the spontaneous mutation rate for mammalian genomes 
(Nichols et al., 1995; Martin et al., 1999) and the initiation of nucleic acid auto-immunity is 
not supported by data obtained in mice and cattle. In mice, anti-DNA antibodies to 
mammalian DNA could not be observed unless BSA or Freunds’ adjuvant were co-
administered to generate an antibody response (Gilkeson et al., 1993, 1996), whereas in cattle, 
no anti-DNA response could be observed for up to 8 months following 5 immunizations with 
1 mg of plasmid DNA (Van Drunen Little-van den Hurk et al., 1998). Moreover, the results 
of all clinical studies reported so far indicate that DNA vaccines appear to be safe and well  
tolerated in humans  (reviewed by Donnely et al., 2003). Furthermore, DNA vaccines are easy 
to produce. They are also considered more temperature-stable than conventional vaccines, 
removing the need for a cold chain which is a very costly and difficult issue. This is also of 
great significance in veterinary medicine, especially in developing countries.  
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1.5 Strategies applied to enhance the efficacy of DNA vaccines in pigs 
Despite the numerous advantages of DNA vaccines, they are often hampered by poor 
efficacy, especially in large animals and man. Several advances have therefore been made to 
enhance the potency of these vaccines, and there still exists room for improvement. In the 
present review, we mainly focus our discussion on approaches that have been employed in 
pigs, since they are one of the most attractive large animal models. This is because they are 
easy to handle and the costs of obtaining and housing them are substantially lower compared 
to other large animals. Furthermore, as swine diseases have a large economical impact, most 
of their pathogens are well characterized. A third reason for the popularity of pigs in 
vaccination studies is that they are physiologically very similar to man, which allows them to 
be used as a model. We will also include relevant data obtained in mice if necessary to 
highlight areas that require further investigation.   
 
1.5.1 Expression optimization 
As DNA vaccination requires the in vivo expression of the encoded antigen, it is clear that 
the level of protein expression can have a direct impact on the magnitude of the induced 
response (Montgomery et al., 1993). Therefore, plasmids should be optimized to enable 
efficient protein expression. There is a rationale behind engineering plasmids that express 
high levels of antigen which involves the inserted gene sequence as well as vector elements. 
Elements involved in expression are discussed below. 
The inserted sequence 
Recognition of the AUG translation initiation codon within mRNA is influenced by its 
flanking sequences. By analysing the expression of several hundred mammalian genes, the 
'Kozak' consensus sequence (-6 GCCA/GCCAUGG +4) has been described for translational 
initiation in mammals (Kozak, 1987). Hereby, especially the presence of a purine (G/A) at -3 
and a G at the +4 position has been suggested to be important for the efficiency of 
translational initiation (Kozak, 1997). As prokaryotic genes do not possess Kozak sequences, 
introducing them has been suggested to increase their expression level in eukaryotic cells 
(Garmory et al., 2003). 
While the genetic code is universal to all life as we know it, the efficiency with which an 
organism uses a particular codon varies dependent upon which tRNA pools are rate limiting 
in that particular species (Grosjean and Fiers, 1982). In general, differences in tRNA 
availability between species become larger as they are diverged earlier during evolution. 
Therefore, nucleotide sequences of many pathogens may not be optimal for translation in 
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mammalian cells. Studies in mice have reported accelerated seroconversion, increases of up to 
100-fold in antibody responses (Narum et al., 2001; Vinner et al., 1999; Deml et al., 2001) 
and improved CTL responses (Andre et al., 1998; Deml et al., 2001) by optimizing the gene 
sequence for translation in the target organism. Besides by improving tRNA availability, 
codon-optimization can also increase expression by avoiding secondary structures, internal 
splice sites and cis-acting sequences in mRNA, which all can prevent protein synthesis.  
So far, there are no published studies addressing these strategies in pigs. However, results 
obtained in mice suggest that they could represent a valuable contribution. 
Vector elements 
The cytomegalovirus immediate early (CMV IE) promoter has been shown to drive the 
highest level of transgene expression in various tissues when compared with other promoters 
(Cheng et al., 1993; Manthorpe et al., 1993; Galvin et al., 2000) and for this reason has been 
selected to drive expression of most DNA vaccines. Furthermore, it has been demonstrated 
that inclusion of the first intron (intron A) of the CMV IE gene further improved expression 
by the CMV IE promoter (Chapman et al., 1991; Van Drunen Littel-van den Hurk et al., 
1999; Wang et al., 2006). This beneficial effect has been credited to binding of transcription 
factors (Chapman et al., 1991) and to an enhanced rate of RNA polyadenylation and/or 
nuclear export associated with splicing (Huang and Gorman, 1990).  
Much less attention has been given to the sequences and genetic elements included in the 
3’ sequences that flank the gene of interest. This region contains not just the polyadenlyation 
sequences required for stabilization of mRNA and transcription termination, but may also 
contain enhancer sequences that can dramatically alter the level of gene expression. Most 
DNA vaccines contain the 3’ region derived from the bovine growth hormone (BGH) or the 
SV40 polyadenylation site (polyA). A few studies demonstrated higher expression levels 
when the BGH polyA was used for transcriptional termination in vitro (Montgomery et al., 
1993) as well as in vivo in mice (Norman et al., 1997), although in a study by Xu et al (2001), 
the activity of both BGH and SV40 polyA appeared to be cell line and tissue depended. A 
more recent study in mice demonstrated that the use of the HBV polyA significantly increased 
antigen expression and immune induction when compared with the BGH polyA, suggesting 
that further optimization of polyA sequences may be valuable (Zinckgraf and Silbart, 2003). 
Self-replicating vectors 
Another strategy that has been employed to obtain high level protein expression is the use 
of self-replicating alphavirus DNA-based vectors (Karlsson and Liljestrom, 2004; Nordstrom 
et al., 2005). Unlike conventional DNA vaccines in which an RNA polymerase II dependent 
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promoter drives transcription of a heterologous gene, these vectors utilize the eukaryotic RNA 
polymerase II dependent promoter to transcribe a self-replicating alphavirus RNA transcript 
(replicon). This replicon is essentially an alphavirus genome containing the sequences 
necessary for replication but having the structural genes replaced by the heterologous gene. 
Consequently, virus formation does not occur. Due to the presence of the replicase genes, the 
mRNA will directly be replicated in the cytoplasm leading to an estimated 200,000 copies per 
cell, resulting in an extremely high protein expression (Lundstrom, 2000). However, this is 
only transient as the cytoplasmic replication eventually triggers apoptosis. Additional factors 
that may contribute to the enhanced immunogenicity of these vectors compared to 
conventional DNA vaccines include the ability of replicating dsRNA to stimulate innate 
antiviral pathways in the transfected cell (Leitner et al., 2003) and the release of antigenic 
material for cross-presentation following apoptosis (Leitner et al., 2004). An extra advantage 
is that the induction of apoptosis alleviates the concern of chromosomal integration. Self-
replicating DNA vectors have been described based on the Semliki forest virus (Berglund et 
al., 1996) and the Sindbis virus replicon (Dubensky et al., 1996). 
Dufour and de Boisséson (2003) were the first to evaluate the potential benefits of using a 
Sindbis virus DNA-based expression vector (pSIN) in pigs. They compared the efficacy of 
three pSIN plasmids encoding the gB, gC and gD major envelope glycoproteins of 
Pseudorabies virus (PRV) to three pcDNA3 vectors encoding the same antigens. Two 
intramuscular injections of the same plasmid copy numbers of both vectors types only 
induced weak antibody and T cell responses and resulted in equivalent protective immunity 
against PRV. Consequently, a greater efficiency of the pSIN vectors could not be observed. 
Those results were in contrast to a study by Hariharan and colleagues (1998) in mice in which 
pSIN was superior to a conventional plasmid (pCI) in the induction of all tested immune 
parameters. Moreover, Hariharan et al demonstrated that 100- to 1,000-fold lower doses of 
pSIN were needed to obtain the same responses as achieved with the conventional plasmid. A 
dose-dependent analysis of the PRV gB, gC and gD encoding pSIN plasmids in pigs was done 
by Dory et al (2005b) in a single shot immunization protocol. Pigs were immunized 
intramuscularly either with 340 µg of each of the pSIN plasmids corresponding to the quantity 
used by Dufour and de Boisséson (2003), with 68 µg of each plasmid (5-fold lower dose) or 
with 13 µg of each plasmid (25-fold lower dose). Although the induction of humoral 
immunity was dose-dependent, effective CTL responses and similar clinical protection were 
achieved with all three plasmid doses. These data indicated that also in pigs pSIN-based DNA 
vaccination allows for considerable reduction of the plasmid DNA dose. This is not only 
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important from an economical point of view but also regarding safety. More recently, the 
efficacy of a Semliki forest virus DNA-based vector (pSFV) was demonstrated in pigs (Li et 
al., 2006). In that study, intramuscular immunization of pigs with 600 µg of pSFV encoding 
the E2 glycoprotein of classical swine fever virus resulted in detectable antibody responses 
and conferred complete protection against lethal challenge. 
 
 
 
 
 
 
 
 
   
 
Figure 4. Potential factors contributing to the high immunogenicity of self-replicating 
genetic vaccines. (Starting in the upper centre and moving clockwise). Accumulation of 
antigen in the transfected cell can result in highly efficient MHC-I-loading. A number of 
‘danger signals’ may be generated such as IFN production and IFN release from infected 
cells resulting from the presence of dsRNA. IFN may also be produced by bystander cells in 
response to dsRNA released from lysed transfected cells. Heat shock proteins (HSP) have 
also been shown to be produced in response to the presence of dsRNA. Ingestion of antigen-
loaded apoptotic cells by APCs can also result in the elicitation of powerful immune 
responses. Finally, the local release of large amounts of antigen at the site of injection by 
transfected  cells may be fed into resident APC. Adapted from Leitner et al.,2000. 
1.5.2 DNA delivery 
In the past years, it has become apparent that the way a DNA vaccine is delivered may 
affect the type of response generated. It appears likely that both the site and method of 
inoculation may affect the magnitude and type of the induced response. In most studies 
concerning DNA vaccination of pigs, plasmid DNA has been delivered by the intramuscular 
(IM) or intradermal (ID) route, either by needle injection (Table 1), via a “gene gun” (Table 
2) or jet injector (Table 3).  
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In gene gun-mediated delivery, gold particles coated with plasmid DNA are propelled by 
helium or CO2 pressure into the skin. Hereby, plasmid DNA is directly deposited into cells of 
the epidermis and dermis, directly transfecting up to 20% of the cells of the target area 
(Williams et al., 1991). Although only a small portion of these cells are DC, tissue stress 
resulting from the blast leads to a massive activation of DC in the target area, inducing them 
to migrate to draining lymph nodes where they provide necessary signals for effective T cell 
activation (Porgador et al., 1998). While needle immunization generally requires large 
amounts of plasmid DNA, gene gun immunization requires approximately 100- to 1000- fold 
less DNA to induce comparable antibody responses as achieved by needle injection. 
Furthermore, gene gun immunization differs strikingly from needle injection in terms of the 
type of immune response induced. While IM or ID injection generally result in a Th1-like 
response, a predominantly Th2-like response is induced by gene gun immunization (Barry 
and Johnston, 1997; Feltquate et al., 1997). Although the exact reason remains unclear, these 
differences were initially attributed to the low amount of plasmid DNA used with gene gun 
immunization, containing ‘not enough’ Th1-modulating CpG motifs. However, more recent
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Needle injection simply involves the direct injection of plasmid DNA dissolved in water, 
saline or a formulation (as later discussed). Following needle injection, plasmids can be 
actively taken up by cells in the injected area, but only few cells are directly transfected (Raz 
et al., 1994; Davis et al., 1993; 1995). Contradicting findings were observed when the 
efficacy of ID and IM needle injection was compared in pigs (Table 1). Using a cocktail DNA 
vaccine encoding pseudorabies virus (PRV) gB, gC and gD, van Rooij et al (1998) observed 
significantly stronger antibody responses and cell-mediated immunity, and better protection 
against challenge infection by ID than by IM injection. Their data are in line with results 
obtained in cats and cattle (Van Drunen Little-van den Hurk et al., 1998; Osorio et al., 1999) 
and may reflect the better immune surveillance function of the skin as compared to muscle (as 
earlier discussed). However, in another PRV trial in pigs, partial protection against PRV 
challenge could only be observed following IM needle injection. Furthermore, the IM 
injection was more efficient in the induction of an antibody response than ID needle injection 
(Gerdts et al., 1997). These opposite findings are likely a result from the fact that not only the 
site and method of inoculation, but also the encoded antigen determine the outcome of the 
immunization. Whereas van Rooij and colleagues (1998) used a gB, gC, gD cocktail DNA 
vaccine, only the gC plasmid was used by Gerdts et al (1997).  
Gene gun delivery 
Intramuscular versus intradermal injection 
 
Table 1. Summary of DNA vaccines tested in pigs by needle injection. 
Pathogena Antigenb Routec Number of 
immunizations and 
dose 
Abd CMIe Protectionf Reference 
F4+ ETEC FaeG IM 3 x 600 µg + ± ND Verfaillie et al., 2004 
 
PRV gB + gC+ gD IM or ID 3 x, 400 µg each  ID > IM  ID > IM  ID > IM > controls van Rooij et al., 1998 
 
PRV gC or gD 
gC 
 
 
IM 
IM or ID 
4 x 50 µg 
3 x 1, 10 or 50 µg 
 
gC > gD 
IM > ID;  
50 > 10 > 1 µg   
ND 
ND 
 
gD: / ;  gC: partial 
ID: /; IM: partial  
 
Gerdts et al., 1997 
PRV gB + gD IM 1 x 200 µg each  + ND Partial  Somasundaram et al., 
1999 
PRV gD IM 1 or 2 x 400 µg In absence of Mat Ab  ND / Monteil et al., 1996 
 
 
FMDV P1-2A3C3D IM + ID 3 x 300 µg + ± Partial  Cedillo-Baron et al., 
2001 
 
PRRSV GP5 IM + ID 3 x 100 µg  + + Partial Pirzadeh and Dea, 1998 
 
Taenia solium cC1 IM 2 x 500 µg ND ND Partial Wang et al., 2003b 
a ETEC: enterotoxigenic E. coli, PRV: pseudorabies virus, FMDV: foot and mooth disease virus, PRRSV: porcine reproductive and respiratory syndrome virus 
bg/GP: glycoprotein, P1-2A: FMDV structural protein precursor, 3C3D: FMDV non-structural proteins  
c IM: intramuscular, ID: intradermal 
dAb: antibody response, >: better than, +: induced,  ND: not determined 
e CMI: cell-mediated immunity, ±: few animals 
f /: not induced 
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studies demonstrate that the gene gun bombardment process itself induces Th2-balancing 
‘danger’ signals which can not be overwritten by CpG motifs present in the plasmid backbone 
(Liu et al., 2005; Weiss et al., 2002).  
Haynes and colleagues (1996) were the first to describe the efficacy of the gene gun in pigs. 
They noted the induction of strong protective levels of immune responses with as little as 3 µg 
of plasmid DNA. Soon thereafter, Fuller et al (1997) described that gene gun delivery of three 
0.5-1.5 doses of a hepatitis B DNA vaccine induced protective antibody responses 
comparable to those observed following three doses of a licensed recombinant protein 
vaccine. Similarly, gene gun administration of two 9 µg doses of an influenza DNA vaccine 
elicited similar protection in swine as compared to a commercially available inactivated 
whole-virus vaccine (Macklin et al., 1998). Furthermore, gene gun administration of two 2-5 
µg doses of a DNA vaccine against foot and mouth disease has resulted in partial (Beard et 
al., 1999; Benvenisti et al., 2001) or complete protection (Wong et al., 2000) against viral 
challenge. In a study by Barfoed et al (2004a), gene gun administration of a porcine 
respiratory and reproductive syndrome virus (PRRSV) DNA vaccine induced an antibody 
response that was higher and appeared earlier than the antibody response seen following 
IM/ID needle injection of a one order higher dose and although gene gun immunization did 
not protect the pigs against PRRSV challenge infection, it did result in an earlier appearance 
of virus neutralizing antibodies. In another trial, gene gun administration of  two 60 µg doses 
of a PRRSV DNA vaccine failed to induce a detectable antibody response or virus-specific 
lymphocyte proliferation. Nevertheless, it did reduce viral shedding and accelerated viral 
clearance (Rompato et al 2006). Finally, although gene gun immunization against F4+ ETEC 
of an FaeG DNA vaccine was inferior to IM injection in inducing serum antibodies, it did 
induce stronger FaeG-specific lymphocyte proliferation following 3 administrations of a 60-
fold lower dose (Verfaillie et al., 2004).      
Jet injection 
DNA vaccines can also be delivered by needle-free liquid jet-injectors. With these 
injectors, liquid is shot directly into the skin by applying high-pressure onto the jet stream. 
The vaccine can be delivered intradermally, subcutaneously or intramuscularly depending on 
the force and distance of the jet stream from the skin surface. The fluid is spread throughout 
the tissue because it follows the path of least resistance, with some liquid penetrating cell 
membranes. This method allows the plasmid to directly transfect some cells, thereby 
improving the transfection efficiency (reviewed by Van drunen Little-van den Hurk et al., 
2004).  
Table 2. Summary of DNA vaccines tested in pigs by gene gun  
Pathogena Antigenb Number of 
immunizations 
and dose 
Abc CMId Protection Comparison with conventional vaccine or 
alternative delivery routee
Reference 
Hepatitis B HBsAg 2 x 3 µg + ND ND ND Haynes et al., 1996 
Hepatitis B HBsAg 3 x 0.5-1.5 µg + 
 
ND   
  
 
 
  
ND ND Fuller et al., 1997 
Influenza HA
   NP 
2 x 7.5 µg 
2 x 7.5 µg 
+ 
+ 
ND 
ND 
Partial 
   / 
Ab response <, protection = inactivated virus 
Ab response <,  protection < inactivated virus 
 
Macklin et al., 1998 
FMDV entire FMDV
genome with 
mutation in cell 
binding site 
 2 x 3 µg 
Empty capsid 
 
 
 
2 x 3 µg 
 > empty 
capsid 
 
 
< entire 
genome 
ND 
 
 
 
ND 
+ 
 
 
 
/  
Ab response <, protection < inactivated virus  
 
 
 
Ab response <, protection < inactivated virus  
 
 
Beard et al., 1999 
FMDV F1-scIgG 2 x 2 µg + + + Ab response <, CMI > , protection = 
commercial vaccine  
 
Wong et al., 2000 
FMDV Serotype O1
P12A3CD 
 2 x 5 µg 
O1 VP1, Asia 
VP1, O1 C3 
 
 
2 x 5 µg 
/ 
 
/ 
ND 
 
ND 
Partial 
 
Partial, < P12A3CD DNA 
Protection < commercial vaccine  
 
Protection < commercial vaccine 
Benvenisti et al., 2001 
PRRSV NP 4 x 32 µg + ND ND 
 
Ab response > IM+ID injection Barfoed et al., 2004 
PRRSV N 2 x 60 µg / / Partial 
 
ND Rompato et al., 2006 
F4+ ETEC FaeG 3 x 10 µg /  + ND CMI >, Ab response < IM injection Verfaillie et al., 2004 
a FMDV : foot and mouth disease virus, PRRSV : porcine respiratory and reproductive syndrome virus, ETEC: enterotoxigenic E. coli.  
b HBsAg: hepatitis B surface antigen, HA: hemagglutinin, NP: nucleoprotein, F1-scIgG:  epitopes 141-160 and 200-213 of FMDV viral protein 1 fused to swine IgG heavy chain, 
P12A3CD: the FMDV structural proteins P1 and 2A together with the  non-structural proteins 3C and 3D in one reading frame, VP1: viral protein 1
c Ab: antibody response, +: induced, >: better than, <: smaller than, /: not induced 
d CMI: cell-mediated immunity, ND: not determined 
e =: comparable to 
Table 3. Summary of DNA vaccines tested in pigs by jet injection 
 Pathogena Antigenb Number of 
immunizations 
and dose 
Routec Injector Abd CMIe Protectionf Comparison with conventional 
vaccine or alternative delivery 
routeg 
Reference 
Hepatitis B HBsAg 2 x 500 µg  ID BioJect + ND ND Ab response = ID needle 
injection  
(in absence of electroporation) 
  
Babiuk et al., 
2003a 
PRV gC 3 x 1,10 or 50µg 
 
 
 
 
ID  
 
IDAL
 
 
 
50 > 10 > 1 
µg   
 
 
50µg: + 
1 or 10 µg: 
ND 
Partial  
 
 
Ab response > IM and ID needle 
injection, protection > ID needle 
injection, = IM needle injection  
CMI < attenuated PRV 
 
Gerdts et al 1997 
PRV gB+gC+gD+gE 3 x 12.5 µg each  
gC 
 
gB+gC+gD 
3 x 50 µg  
 
3 x 15 µg each  
ID 
ID 
 
ID 
IDAL 
 
 
IDAL 
+, > gC  
+ 
 
+  
ND 
ND 
 
ND 
Partial  
/ 
 
Partial  
ND 
ND 
 
protection > adjuvanted 
inactivated vaccine,  
< attenuated live vaccine 
 
Gerdts et al., 1999 
PRV gB+gC+gD 3 x 400 µg each  ID PigjetTM + + Partial CMI <, Ab response <, protection 
< ID needle injection 
 
Van Rooij et al., 
1998 
CSFV Gp55 2 x 50, 100 or 200 
µg or 1 x 200 µg 
ID Panjet +, 2 x 200µg 
dose best 
 
ND + Ab response > intra-lymph node 
or gene gun inoculation 
Andrew et al., 
2000 
- hGH 1 or 2 x 0.5 or 0.05 
mg/kg  
IM or sc Medi-
JectorTM 
+ ND ND Ab response > needle injection 
 
Anwer et al., 1999 
aPRV: pseudorabies virus, CSFV: classical swine fever virus  
b HBsAg: Hepatitis B surface antigen, g/gp: glycoprotein, hGH: human growth hormone 
c ID: intradermal, IM: intramuscular, sc: subcutaneous 
d Ab: antibody response, +: induced, > better than 
e CMI: cell-mediated immunity,  ND: not determined 
f /: not induced 
g =: comparable to, < smaller than 
  Chapter 1: DNA vaccination in the pig 
Contradicting findings were obtained when these needle-free liquid jet-injectors were 
tested in pigs, which may be due to the fact that distinct types of jet-injectors were used in the 
different studies. Babiuk et al (2003a) demonstrated that ID needle-free delivery of plasmid 
DNA using the BioJect resulted in higher transgene expression levels than ID needle 
injection. However, in the absence of electroporation (see below), BioJect delivery did not 
induce a clearly stronger Ab response (Babiuk et al., 2003a). In another trial, Van Rooij et al 
(1998) compared the efficacy of the needle-free PigjetTM injector and ID needle injection to 
induce an immune response against a cocktail DNA vaccine encoding PRV gB, gC and gD. In 
that study, the needle-free injector was not superior to needle injection in inducing antibody 
responses, cell-mediated immunity or protection against challenge infection. In a similar 
experiment, Gerdts et al (1997) vaccinated pigs with a DNA vaccine encoding PRV gC by 
either ID or IM needle injection, or by the needle-free IDAL injector. In contrast to the 
findings of Van Rooij, the IDAL injector was most efficient in inducing neutralizing antibody 
responses and elicited partial protection against challenge infection. Moreover, although jet 
injection of the PRV cocktail DNA vaccine was less effective than a live-attenuated vaccine, 
it was superior to a commercially available inactivated vaccine (Gerdts et al., 1999). In 
agreement with the results of Gerdts et al, ID delivery of CSFV gp55 DNA via the Panjet 
appeared to be superior for the induction of a virus neutralizing Ab response than intralymph 
node injection or gene gun delivery (Andrew et al., 2000). 
Besides ID, needle-free delivery was also tested in pigs by the IM and the subcutaneous route 
using the Medi-JectorTM (Anwer et al., 1999). The needle-free delivery by both routes was 
superior to needle injection for the induction of antibody responses, resulting in 3- to 4-fold 
higher serum IgG titers.   
The IDAL jet-injector is commercially available and is used to deliver conventional 
vaccines against PRV and PRRSV in pigs.     
Electroporation 
Another promising means to improve the potency of DNA vaccines is electroporation. This 
physical process exposes the target tissue to brief electric pulses that induce temporary and 
reversible pores in cell membranes such as the plasma, nuclear and organelle membranes 
(Morgan and Day, 1995). Electroporation has been shown to increase both the number of 
transfected cells and the number of plasmids taken up by each cell (Aihara and Miyazaki, 
1998). Consequently, gene expression levels can be improved by as much as 1 or 2 orders of 
magnitude over plasmid injection alone (Aihara and Miyazaki, 1998; Mathiesen, 1999). The 
increase in gene expression (Widera et al., 2000), but also tissue damage and ensuing 
 38  
  Chapter 1: DNA vaccination in the pig
inflammation caused by electroporation have been suggested to be important mechanisms for 
enhancing immune responses to DNA vaccines (Babiuk et al., 2002; 2004). Although 
electroporation has most often been applied to muscle and skin, successful electroporation of 
various other tissues, such as lungs (Dean et al., 2003), cornea (Blair-Parks et al., 2002) and 
spinal cord (Lin et al., 2002), has been described. Furthermore, electroporation has been 
shown to enhance plasmid expression and plasmid induced responses in a variety of animal 
models, including pigs (Table 4). In pigs, electroporation was shown to enhance gene 
expression up to 83-fold following ID injection of plasmid DNA (Drabick et al., 2001). 
Importantly, these investigators also demonstrated that a non-invasive plate electrode is 
equally effective as a penetrating needle array electrode in enhancing gene expression. The 
efficacy of needle-free electroporation in pigs was also evaluated by Babiuk et al (2003a, 
2003b). They reported a 1 to 2 log increase in transgene expression and concomitantly, a 1 to 
1.5 log higher antibody titer following 2 DNA vaccinations and a protein boost when needle-
free electroporation was applied to ID needle injection or needle-free delivery (Babiuk et al., 
2003a, 2003b). The same investigators also evaluated the impact of electroporation on IM 
immunization in pigs, using plasmids encoding two different genes (bovine herpesvirus gD 
and hepatitis B surface antigen) and two different types of electrodes, a single-needle and a 
six-needle electrode (Babiuk et al., 2002). Electroporation resulted in a 100- and a 1000-fold 
increase  in transgene expression for the single- and six-needle electrode, respectively. 
Furthermore, an up to 1 and up to 2 log increase in antibody titer could be observed following 
two DNA vaccinations when using a single- or a six-needle electrode, respectively. So, 
although encouraging results were obtained with the less-invasive needle-free electroporation 
strategies, muscle electroporation currently remains more effective in eliciting immune 
responses to DNA vaccines than any other approach (Babiuk et al., 2002, 2003a, 2003b).  
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Table 4. The influence of electroporation on DNA vaccines tested in pigs  
Pathogena Antigenb Methodc 
 
Number of 
immunizations 
and dose 
Type of 
electrode 
Gene expression Abd CMIe Reference 
 Luciferase  ID needle
injection 
 
 
ID needle 
injection  
 
1 x 50, 100, 200 
or 300µg 
 
 
100 µg 
 
Penetrating (2 
rows of seven 7-
mm pins) 
 
Penetrating  
non-invasive 
83-fold increase at 50 µg 
dose, decreasing on with 
increasing DNA dose 
 
26-fold increase  
26-fold increase  
 
ND 
 
 
 
ND 
ND 
 
 
 
ND 
Drabick et al., 
2001 
 
 
 
 
 
 
Hepatitis B 
Luciferase 
 
 
 
 
 
HBsAg 
 
 
 
 
 
ID needle 
injection 
 
ID needle free 
delivery (BioJect) 
 
ID needle 
injection 
 
ID needle free 
delivery (BioJect) 
 
100 µg 
 
 
100 µg 
 
 
2 x 500 µg 
 
 
2 x 500 µg 
non-invasive  
 
 
non-invasive  
 
 
non-invasive  
 
 
non-invasive  
2 log increase 
 
 
1 log increase 
 
 
ND 
 
 
ND 
 
ND 
 
 
ND 
 
 
1.5 log higher (after  
protein boost) 
 
1log higher (after 
protein boost) 
ND 
 
 
ND 
 
 
ND 
 
 
ND 
 
Babiuk et al., 
2003a, 2003b 
 
 
 
Babiuk et al., 
2003a, 2003b 
 
 
 
BHV, 
Hepatitis B 
gD, HBsAg IM needle 
injection 
2 x 1 mg of gD or 
HBsAg or both   
single-needle  
 
six-needle  
2 log increase 
 
3 log increase 
 
 
Up to 1 log higher 
 
Up to 2 log higher 
Higher proliferation 
 
Higher proliferation, 
Th1-biasing 
Babiuk et al., 
2002 
a BHV: bovine herpes virus.  
bg: glycoprotein, HBsAg: Hepatitis B surface antigen. 
c ID: intradermal, IM: intramuscular 
d Ab: antibody response, ND: not determined 
e CMI: cell-mediated immunity 
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1.5.3 Adjuvants 
Several approaches undertaken to enhance the potency of DNA vaccines have focused on 
the use of adjuvants. Adjuvants can be broadly separated into genetic and conventional 
adjuvants, based on their origin. Genetic adjuvants are expression vectors encoding cytokines, 
chemokines, costimulatory molecules or their ligands, or other molecules that can modulate 
immune responses when administered with a vaccine antigen. Conventional adjuvants are 
chemical compounds that enhance, prolong, or modulate antigen-specific immune responses. 
The use of an appropriate adjuvant can be pivotal in optimizing not only the magnitude but 
also the nature of the induced response. Moreover, DNA vaccines themselves possess their 
own intrinsic adjuvant activity through CpG motifs (Sato et al., 1996).  
CpG motifs 
Co-administration of synthetic CpG oligodeoxynucleotides (ODN) has been shown to 
activate the immune system and to augment the immunogenicity of protein-based vaccines 
(Davis et al., 1998, McCluskie et al., 2002, Klinman, 2006). However, contradicting results 
were obtained when the influence of CpG motifs on DNA vaccines was evaluated. In mice, it 
was demonstrated that the response elicited by suboptimal amounts of plasmid DNA could be 
boosted by co-administration of free CpG ODN (Klinman et al., 2004). In line with these 
results, Dory et al (2005a) demonstrated that mixing of a porcine-specific CpG ODN to 
plasmids encoding PRV gB, gC and gD increased PRV-specific humoral and cellular immune 
responses and resulted in better clinical protection of pigs against a PRV challenge infection. 
On the contrary, other studies in mice, horses and pigs observed no effect or even a reduction 
(Cantlon et al., 2000; Van Rooij et al., 2002; Weeratna et al., 1998). Interestingly, Weeratna 
et al (1998) reported a dose dependent reduction of the immune response when CpG ODN 
were co-administered with high levels of a DNA vaccine. It was hypothesized that this 
reduction in immune response was due to competition between plasmid DNA and CpG ODN 
for entry into the target cells. Thus, inclusion of the CpG motifs into the plasmid backbone is 
likely to be more beneficial. Indeed, several studies suggested that CpG motifs present in the 
plasmid backbone might contribute to the immunogenicity of DNA vaccines in outbred 
animals as well as in mice. For example, methylation of all cytidines in pcDNA3 abolished 
IFN-α secretion when the plasmid was incubated with porcine leukocytes (Magnusson et al., 
2001), whereas insertion of an optimal number of immunostimulatory CpG motifs into the 
plasmid backbone enhanced the induction of vaccine-specific immune responses in mice 
(Krieg et al., 1998; Ma et al., 2002; Kojima et al., 2002). Similarly, a study in cattle using 
plasmids containing 0, 40 and 88 ruminant-specific CpG motifs showed a dose-dependent 
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increase in antigen-specific cellular immune responses. However, they did not observe a 
quantitative effect on humoral immunity (Pontarollo et al., 2002).  
So far, there are only few studies addressing this issue in large animals. Therefore 
additional, more comprehensive studies are necessary to completely establish the efficacy of 
CpG adjuvanting of DNA vaccines in large animals. For example, it remains to be determined 
whether different motifs can preferentially induce different types of immune response and 
thus can be used to direct the immune response differently. Furthermore, as CpG ODN have 
been described to have the most effect when small doses of plasmid DNA are used (Weeratna 
et al., 1998), dose-response studies in outbred species need to be performed.  
Genetic cytokine adjuvants 
Genetic adjuvants encoding a large number of cytokines have been used to enhance the 
magnitude of the induced response and/or to modify the response towards either a strong Th1- 
or a strong Th2-type response. The studies performed in pigs using DNA encoded cytokines 
as adjuvants are summarized in Table 5.  
A frequently tested genetic adjuvant is the GM-CSF gene. In mice, GM-CSF DNA has 
been shown to enhance humoral and CD4+ T cell responses, in most cases without shifting the 
balance between Th1 and Th2 type responses. This is likely a result of the effect of GM-CSF 
on APC. GM-CSF has been described not only as a growth and differentiation factor for APC 
but also as a chemo-attractant for these cells (Kaplan et al., 1992). Indeed, plasmid encoded 
GM-CSF has been shown to recruit APC to the injection site and expand the number of APC 
in the draining lymph node in mice (Bowne et al., 2000; Haddad et al., 2000). In pigs, 
plasmid encoded GM-CSF has been shown to enhance neutralizing antibody titers (Andrew et 
al., 2006; Cedillo-Baron et al., 2001), IgG1 and IgG2 responses (Somasundaram et al., 1999) 
and both Th1- and Th2-cell responses (Dufour et al., 2000), and to result in enhanced 
protection against viral challenge (Somasundaram et al., 1999, Andrew et al., 2006). While 
the above mentioned studies have co-injected plasmid encoded GM-CSF with the DNA 
vaccine, several studies suggest that the time of cytokine DNA injection relative to the time of 
the DNA vaccine injection might be critical for obtaining a maximal adjuvant effect 
(Kusakabe et al., 2000; Barouch et al., 1998). However so far, there are no studies that 
examined the influence of the interval between GM-CSF administration and the DNA 
vaccination on its adjuvanticity.  
Th1-inducing cytokine genes evaluated in pigs include IL-2, IL-12, IL-18 and IFN-γ. 
Plasmid encoded IL-2 has been shown to enhance the induction of virus specific cell-
mediated immune responses following DNA vaccination against PRRSV (Rompato et al., 
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2006) and FMDV (Wong et al., 2002). Conversely, Somasundaram et al (1999) could not 
observe an adjuvant effect when IL-2 or IFN-γ were co-administered with a PRV DNA 
vaccine. Other investigators also failed to demonstrate significantly stronger immune 
responses or better protection against challenge infection by co-delivery of IFN-γ or IL-12 
with a PRV DNA vaccine (Van Rooij et al., 2002). The immunomodulatory effects of 
plasmid encoded IL-12 and IL-18 were evaluated on DNA vaccination of pigs against 
classical swine fever (Wienhold et al., 2005). An earlier appearance of serum antibodies, a 
reduced B cell deficiency and a better protection against challenge infection were observed 
when IL-18 was co-administered with the DNA vaccine. In contrast, co-delivery of IL-12 
reduced the antibody titer as well as protection against lethal challenge infection. Conversely, 
IL-12 DNA was shown to enhance the protective efficacy of a DNA vaccine against 
Schistosoma japonicum (Zhu et al., 2004).     
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Another means of improving the efficacy of DNA vaccines is by targeting antigen to APC. 
In this regard, targetting the B7 (CD80/86) costimulatory molecules on the surface of APC  
CD154 (CD40 Ligand) is expressed on NK cells, DC and activated lymphocytes. Its 
interaction with CD40 influences and sustains co-stimulatory signalling in APC which is 
essential for T cell dependent antibody responses. Co-delivery of the CD154 gene with a 
CSFV DNA vaccine in pigs resulted in an earlier appearance of serum antibodies, reduced B 
cell deficiency after infection and protection against a lethal CSFV challenge infection 
(Wienhold et al., 2005).  
Studies evaluating the influence of Th2-type cytokine genes in pigs are restricted to IL-4 
and IL-6. Rompato et al (2006) evaluated the influence of plasmid encoded IL-4 on the 
induction of cellular and humoral immunity following PRRSV DNA vaccination. Co-
administration of IL-4 DNA had an inhibitory effect on the induction of cell-mediated 
immunity and did not enhance humoral immunity. The lack of a positive effect on antibody 
responses led the authors to hypothesize that IL-4 by itself may not have a critical role in the 
development of a Th2 immune response and that other Th2 cytokines, like IL-6 and IL-13 
may be necessary for the generation of such responses in swine. However, also co-
administration of plasmid encoded IL-6 with an influenza DNA vaccine did not significantly 
enhance serum antibody responses or protection from challenge infection (Larsen and Olsen, 
2002). Immunomodulatory effects of the IL-13 gene remain to be tested.  
As far as we know, plasmid encoded chemokines have not been tested in pigs. Therefore, 
they will not be discussed in this review.  
Other genetic adjuvants 
 
Table 5. Influence of co-administration of genetic adjuvants on DNA vaccine efficacy in pigs. 
  Pathogena Antigenb Adjuvant Method and
routec 
Ab responsed 
 
CMIe protection Reference 
            VN Total
IgG 
 IgG1 IgG2 IgA IgM CTL Prolife-
ration 
 
Th1 Th2
CSFV or 
Influenza 
Gp55 or HA GM-CSF 
IL-3 
Needle free 
delivery 
(Panjet) 
 
+ 
+ 
ND 
ND 
ND 
/ 
ND 
/ 
ND 
/ 
ND 
+ 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
+ 
+ 
Andrew et al., 
2006 
FMDV P1-
2A3C3D 
GM-CSF IM + ID needle 
injection 
 
+           
    
   
              
+ ND ND ND ND ND ND ND ND + Cedillo-Baron et 
al., 2001 
PRV gB, gD GM-CSF
IL-2 
IFN-γ 
 
IM needle 
injection 
/ 
/ 
/ 
+ 
/ 
/ 
+ 
/ 
/ 
+ 
/ 
/ 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
+ 
/ 
/ 
Somasundaram et 
al., 1999 
PRV gB, gC, gD GM-CSF 
IFN-α 
 
IM needle 
injection 
 
ND 
ND 
/ 
/ 
/ 
/ 
/ 
/ 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
+ 
/ 
+ 
/ 
+ 
/ 
Dufour et al., 
2000 
PRRSV NP IL-2
IL-4 
 
Gene gun 
 
ND 
ND 
- 
- 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
+ 
/ 
ND 
ND 
ND 
ND 
- 
- 
Rompato et al., 
2006 
FMDV VP1(141-
160), 
VP1(200-
213) 
 
IL-2 IM needle
injection 
/ ND ND ND ND ND ND + ND ND / Wong et al., 2002 
a CSFV: classical swine fever virus, FMDV: foot and mooth disease virus, PRV: pseudorabies virus, PRRSV: porcine reproductive and respiratory syndrome virus 
b HA: hemagglutinin, gp/g: glycoprotein, P1-2A3C3D: FMDV structural protein precursor P1-2A and the FMDV non-structural proteins 3C3D, NP: nucleoprotein, VP: viral 
protein  
c  IM: intramuscular, ID: intradermal 
d Ab: antibody, VN: virus neutralizing antibodies,  +: positive effect, /: no effect, -: negative effect, ND: not determined 
e CMI: cell-mediated immunity 
Table 5. Influence of co-administration of genetic adjuvants on DNA vaccine efficacy in pigs.Continued. 
  Pathogena Antigenb Adjuvant Method and
routec 
Ab responsed CMIe protection Reference 
             
         
VN Total
/ IgG 
 IgG1 IgG2 IgA IgM CTL Prolife-
ration 
 
Th1 Th2
PRV gB, gD IFN-γ 
IL-12 
 
ID needle 
injection 
/ 
/ 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND ND / ND ND +
+ 
Van Rooij et al., 
2002 
CSFV   
              
                
              
gp55 IL-12
IL-18 
CD154 
IM needle 
injection 
- 
+ 
+ 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
 
ND 
ND 
ND 
- 
+ 
+ 
Wienhold et al., 
2005 
Schistosoma 
japonicum 
 
SjC23 IL-12 IM needle
injection 
ND + ND ND ND ND ND ND ND ND + Zhu et al., 2004 
Influenza HA IL-6 Gene gun / / ND ND / ND ND ND ND ND / Larsen and Olsen,
2002 
OVA CTLA4 (as a
fusion with 
OVA) 
   Gene gun NA + + + + / ND ND ND ND Tachedjian et al., 
2003 
 
a PRV: pseudorabies virus, CSFV: classical swine fever virus 
b g/gp: glycoprotein; HA: hemagglutinin; OVA: ovalbumin  
c ID: intradermal, IM: intramuscular 
d Ab: antibody response, VN: virus neutralizing antibodies; NA: not applicable; +: positive effect; /: no effect; -: negative effect; ND: not determined 
e CMI: cell-mediated immunity 
  Chapter 1: DNA vaccination in the pig 
via CTLA-4 antigen fusions has been reported to improve protein (Huang et al., 2000) and 
DNA vaccines in mice (Boyle et al., 1998; Deliyannis et al., 2000), rabbits and monkeys (Jia 
et al., 2006), sheep (Chaplin et al., 1999; Drew et al., 2001) and pigs (Tachedjian et al., 
2003). When pigs were immunized by gene gun with a DNA vector expressing a CTLA4-
ovalbumine fusion protein, they developed  enhanced ovalbumine-specific serum IgG, IgA, 
IgG1 and IgG2 responses compared to pigs immunized with the same vector expressing only 
ovalbumine (Tachedjian et al., 2003).  
Conventional adjuvants 
 There are only few published studies addressing the use of conventional adjuvants for 
DNA vaccines, suggesting that these adjuvants might not be as successful for DNA vaccines 
as they are for conventional vaccines. However, some conventional adjuvants, such as 
aluminum salts, (+)-N-(2-hydroxyethyl)-N,N-dimethyl-2-3-bis(tetradecyloxy)-1-propane-
minium bromide and 1,2-dioleyl-sn-glycero-3-phosphoethanolamine (DMRIE-DOPE) and 
dimethyldioctadecylammonium bromide (DDA) have shown a beneficial effect on DNA 
vaccination in large animals (Ulmer et al., 1999; Fischer et al., 2003b; van Rooij et al., 2002). 
Co-delivery of DDA with a PRV DNA vaccine in pigs resulted in enhanced neutralizing 
antibody and T cell responses as well as reduced viral shedding following challenge, whereas 
co-delivery of plasmid encoded IL-12 or IFN-γ failed to do so (van Rooij et al., 2002).    
 
1.5.4 Formulations 
DNA injection in vivo has been shown to result in extremely low transfection efficiencies 
and rapid clearance of the plasmids from the inoculation site (Kawabata et al., 1995; Lew et 
al., 1995). It follows that protecting plasmid DNA from extracellular degradation by 
improving its formulation should optimize DNA uptake. Unfortunately, only few studies have 
been performed on formulation of DNA vaccines in pigs as well as in other large animals. The 
most popular approaches in mice include the use of liposomes and polymers. 
Liposomes are microscopic vesicles consisting of an aqueous core surrounded by a 
phospholipid bilayer. They are employed by many modern cell transfection techniques, such 
as Lipofectamine (Invitrogen) and Tranfectam (Promega) to deliver DNA. Positively charged 
lipids assist in DNA complexation, can protect the DNA from nuclease degradation and aids 
in delivery to and association with the cell membrane. However, cellular toxicity associated 
with cationic lipids has been shown in vitro and in vivo (Filion and Phillips, 1997; 
Lappalainen et al., 1994) and the future of this delivery technique in DNA vaccination 
remains uncertain (reviewed by Laddy and Weiner, 2006). 
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The combination of DNA and conventional vaccines (heterologous prime –boost 
immunization) has been used in various ways to couple the benefits of both vaccine types, 
thereby providing stronger protective immunity. Generally, the immunization strategy begins 
with one or more doses of the first vaccine type (in most cases the DNA vaccine) (priming) 
followed by one or more doses of the other vaccine type (boosting). Heterologous prime – 
boost immunizations performed in pigs are presented in Table 6. A heterologous IM DNA 
prime (1x) – IM protein boost (2x) immunization was evaluated by Guo et al (2004) and 
compared to 3 IM protein immunizations. They observed a Th1-biased response 
(predominantly IgG2, strong lymphocyte proliferation) by the DNA prime – protein boost and 
a Th2-biased response (predominantly IgG1) following the 3 protein immunizations, with a 
longer duration of protection against Taenia solium cysticercosis using the heterologous 
protocol. Other investigators demonstrated that priming with DNA and boosting with 
recombinant virus was able to induce protective immunity in pigs against PRV (Dory et al., 
2006), post-weaning multisystemic wasting syndrome (Blanchard et al., 2003) and classical 
swine fever (Hammond et al., 2001). 
In addition to liposomes, polymer-based systems can be applied to protect plasmids from 
degradation. Polyvinylpyrrolidone (PVP) has been tested in both pigs and dogs by needle 
injection or needle-free delivery of a plasmid encoding human growth hormone (Anwer et al., 
1999). In that study, PVP formulation clearly increased antibody responses following needle 
injection as well as following needle-free delivery. One of the most promising polymer-based 
compounds used for delivery of DNA vaccines are cationic poly(lactide-co-glycolide) (PLG) 
microparticles (reviewed by Vajdy and O’Hagan, 2001; Singh et al., 2006). The rationale for 
the use of these microparticles is based on their ability to be taken up by APC. After entering 
the phagocytic pathway, they produce antigen with access to both MHC class I and II 
pathways and are able to elicit antibody responses (Hedley et al., 1998; Jones et al., 1997; 
1998). Furthermore, the PLG polymer has already been approved as a component of a number 
of drug delivery systems and has a long history of safe use in humans (Okada and Toguchi, 
1995). While initial studies have encapsulated the plasmid within the PLG microparticles, a 
more recent technology involves the adsorption of plasmid DNA onto the outer surface of the 
microsphere (Vajdy and O’Hagan, 2001; Singh et al., 2006). This technology has been shown 
to be immunogenic in humans and is in phase I clinical trials through the HIV Vaccine Trials 
Network (Laddy and Weiner, 2006).  
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Table 6. Influence of a heterologous prime - boost on DNA vaccine efficacy in pigs. 
   Pathogena Prime – boost vaccinationb Total/
VNc 
IgG IgG1 IgG2    IgA CMI Mucosal 
immunity 
Protection Reference
Taenia solium IM DNA prime (1x) – IM protein boost (2x) 
IM protein immunization (3x) 
 
ND      ND +
++ 
++ 
+ 
ND ++
+ 
ND ++
+ 
Guo et al., 2004 
HRV Oral AttHRV  prime (1x) – IM DNA boost (2x) 
IM DNA prime (2x) – oral AttHRV boost (1x) 
IM DNA immunization (3x) 
Oral AttHRV prime (1x) – IM empty vector (2x) 
 
ND      
    
        
++++
+++ 
+++ 
+++ 
 
ND 
 
ND ++++
++ 
+ 
+++ 
ND ++++
++ 
+ 
+++ 
++++ 
++ 
+ 
+++ 
Yuan et al., 2005 
PRV IM pSIN prime (1x) – IM ORFV boost  (1x) 
/                                – IM  ORFV boost (1x) 
IM pSIN prime (1x) – /  
 
 
+++ 
+ 
++ 
ND +++
+ 
++ 
+++ 
++ 
++ 
ND 
 
+++ 
+ 
++ 
ND +++
+ 
++ 
 
 
Dory et al., 2006 
PCV2 Trial 1 : 
IM DNA prime (2x) – IM protein boost (1x)  
 
Trial 2 
IM DNA vaccination (2x) 
IM protein (2x) 
ND ND ND ND ND ND ND
+ 
 
 
+ 
++ 
Blanchard et al., 2003 
CSFV Trial 1: weaned pigs 
ID DNA (1x) – sc rPAV (1x) 
ID DNA (1x) – IM DNA (1x) 
ID DNA (1x) 
Sc rPAV (1x) 
 
 
Trial 2: suckling pigs 
ID DNA (1x) – sc rPAV (1x) 
Sc rPAV (1x) 
 
++++ 
++ 
+ 
+++ 
 
 
 
++ 
+ 
ND 
 
 
 
 
 
 
ND 
ND 
 
 
 
 
 
 
ND 
ND 
 
 
 
 
 
 
ND 
ND 
 
 
 
 
 
 
ND 
ND 
 
 
 
 
 
 
ND 
ND 
 
 
 
 
 
 
ND 
 
++++ 
++++ 
++ 
+++ 
 
 
 
++ 
+ 
Hammond et al., 2001 
a HRV: human rotavirus, PRV: pseudorabies virus, PCV2: porcine circovirus type 2, CSFV: classical swine fever virus  
b IM: intramuscular, ID: intradermal, sc: subcutaneous, AttHRV: attenuated human rotavirus, pSIN: Sindbis virus-based DNA vector, ORFV: Orf virus, parapoxvirus, rPAV: recombinant 
porcine adenovirus.  
c ND: not determined, +, ++, +++ and ++++ represent the strength of the response relative to the other strategies in the same experiment (+ < ++ < +++ < ++++)
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Yuan and colleagues (2005) compared the IM DNA prime (2x) – oral boost strategy with oral 
priming using attenuated rotavirus and boosting with the DNA vaccine or 3 IM DNA 
immunizations in a human rotavirus infection model in pigs. Priming with the attenuated virus 
and boosting with DNA appeared to be the most effective strategy resulting in significant 
protection and the highest IgA response.    
 
1.6 DNA vaccines for mucosal immunity  
The mucosal surfaces are the primary site of transmission of most infectious diseases. 
Therefore vaccines which induce protective mucosal immunity will be highly effective in 
reducing morbidity and mortality. The vast majority of DNA vaccines are delivered 
parenterally, resulting in systemic immune responses which can react against pathogens in the 
body. However, they are generally not effective in inducing mucosal immunity and therefore 
can not prevent mucosal colonization or invasion. In contrast, mucosally delivered DNA 
vaccines might induce local mucosal as well as systemic immune responses. Furthermore, 
mucosal immunization at one site with antigen or attenuated microorganisms has been shown 
to induce immunity at distant mucosal sites as is the case for gut – mammary gland and for 
nasal mucosa – genital tract. However, several barriers are encountered before a mucosally 
administered DNA vaccine can reach the mucosa-associated lymphoid tissue. These include 
(i) an enzymatic barrier, caused by luminal secreted, luminal membrane bound and cytosolic 
enzymes; (ii) a diffusion barrier, by the mucus layer covering gastrointestinal epithelia; and 
(iii) an epithelial barrier. In this section, some of the strategies that have been explored to 
overcome these barriers, such as formulations, bacterial delivery and heterologous prime – 
boost immunizations will be discussed.  
 
1.6.1 Formulations to improve mucosal DNA vaccination 
When formulating DNA vaccines, it should be noted that effective mucosal immunization 
often correlates with the uptake of antigen at mucosal inductive sites, such as the Peyer’s 
patches (PP) of the gut and nasal-associated lymphoid tissues. These inductive sites are 
equipped with specialized epithelial cells, called M cells. M cells are responsible for sampling 
of antigen from the lumen and for delivering it to antigen presentating cells underneath the 
epithelium.   
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PLG microparticles 
Biodegradable PLG microparticles (< 10 µm) directly bind to and are subsequently taken 
up by M cells (Jepson et al., 1993). They have been studied extensively as candidates for 
vaccine delivery via the oral and the nasal route.  
Following initial studies on oral delivery of proteins, some groups evaluated the potential 
of PLG microparticles for oral delivery of DNA vaccines. Jones et al (1997) were the first to 
describe the successful induction of systemic and mucosal antibody responses following oral 
delivery of a DNA vaccine entrapped in PLG microparticles. Subsequently, two independent 
groups described the induction of protective mucosal immunity against rotavirus challenge in 
mice following oral immunization with plasmid DNA entrapped in PLG (Chen et al., 1998; 
Herrmann  et al., 1999). Studies so far involve only rodent models and require relatively high 
doses in these species, indicating the need for significant improvements. Indeed, it appears 
clear that the approach of DNA encapsulating still has several limitations. These include 
plasmid damage by the encapsulation  process and low encapsulation efficiency, resulting in a 
low DNA load and hereby limiting the total amount of DNA that can be administered. In 
addition, it seems likely that uptake of these microparticles into the GALT is insufficient to 
allow the successful development of oral vaccines (reviewed by O’Hagan et al., 2004).   
To overcome the limitations of the encapsulation process, a novel technology has been 
developed involving the adsorption of the plasmid onto the surface of cationic PLG 
microparticles. Important advantages of the adsorption approach include enhanced DNA 
stability and formulation loading efficiency, making this process much more amenable to 
commercial development. Intranasal administration of DNA vaccines adsorbed onto cationic 
PLG microparticles has shown some promise and outperformed naked DNA (Singh et al., 
2001).  
Bioadhesive agents 
Other promising delivery vehicles for mucosal DNA vaccines are chitosan micro- or 
nanoparticles. Chitosan is a polycation comprising copolymers of glucosamine and N-
acetylglucosamine. It strongly interacts with negatively charged sialic acid residues in mucin 
(Lehr et al., 1992), providing an intimate contact with the mucosal membrane and thereby 
increasing the halftime of clearance and promoting more efficient uptake (Alpar et al., 2005). 
Chitosan can easily form complexes with DNA and it has been shown to effectively protect 
DNA from degradation (Mao et al., 2001; Richardson et al., 1999). It is also able to increase 
transcellular and paracellular transport across mucosal epithelia (Artursson et al., 1994) and 
chitosan microparticles smaller than 10 µm have been demonstrated to be taken up by M cells 
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Another strategy that has been applied to improve DNA uptake through  the NALT in mice 
includes the attachment of M cell ligands to the surface of DNA-polymer complexes. M cell 
ligands tested include the plant lectin Ulex europaeus agglutinin 1 (UEA-1) (Wang et al., 
2005) and reovirus σ1 protein (Wang et al., 2003a; Wu et al., 2001). When DNA is 
conjugated to reovirus σ1 protein via polylysine, the reovirus σ1 protein can still bind the 
apical surface of nasal M cells (Wu et al., 2001). Consequently, intranasal immunization with 
σ1-polylysine-DNA complexes induced prolonged mucosal IgA (Wu et al., 2001) as well as 
cell-mediated immunity compared to naked DNA or polylysine complexed DNA (Wu et al., 
2001; Wang et al., 2003a). Similarly, mice nasally immunized with UEA-1-polylysine-DNA 
complexes showed elevated systemic and mucosal antibody responses as well as elevated 
CTL responses compared to intranasal immunization with naked DNA (Wang et al., 2005).  
Although both σ1 protein and UEA-1 are able to bind Peyer’s patch M cells as well 
(Amerongen et al., 1994; Clark et al., 1995), their ability to improve the induction of mucosal 
immune responses following oral DNA vaccination has not yet been evaluated. 
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(van der Lubben et al., 2001; 2002; Beier and Gebert, 1998). Several studies have 
demonstrated the successful use of chitosan as gene delivery vehicle via the oral (Chew et al., 
2003; Roy et al., 1999) and the intranasal route (Kumar et al., 2002; Iqbal et al., 2003; Xu et 
al., 2004) in mice. However, as far as we know, these particles have not yet been tested for 
mucosal delivery of DNA vaccines in large animals. 
Live bacteria have also been used to deliver DNA vaccines to mucosa-associated lymphoid 
tissues. With a few exceptions, these are virulence-attenuated strains of enteroinvasive 
bacteria such as Salmonella, Shigella or Listeria (reviewed by Schoen et al., 2004), which 
cross the mucosal barrier via M cells and are then taken up by macrophages and DC at local 
sites (Neutra et al., 1996; Siebers and Finlay, 1996; Sansonetti, 2002) or in systemic lymphoid 
tissues after spreading. After phagocytosis, the enteropathogens normally replicate within 
phagosomes (Salmonella spp) or escape from these phagosomes and replicate within the 
cytosol (Shigella and Listeria spp) (Schoen et al., 2004). As a result of their metabolic 
attenuation, they only replicate for a few cycles whereafter they die and release the plasmid 
DNA inside the mammalian cell. After transport of the plasmid to the nucleus, the antigen 
becomes expressed and either processed and directly presented to T cells or released
 
 
Table 7. Vaccination of rodents or chicken against viral diseases using bacteria-mediated delivery of DNA vaccine plasmids 
 Pathogena Antigenb Species Attenuated bacterial
carrierc 
 Delivery Systemic responsed Mucosal response Protection Reference 
           Ab CMI Ab CMI
HIV          
        
        
        
           
      
     
      
          
       
  
        
        
        
         
gp120 Mouse S. flexneri Intranasal ND + ND ND + Shata and Hone., 2001
gp120 Mouse S. flexneri, S. typhi 
and S. typhimurium 
Intranasal + + + ND ND Vecino et al., 2002 
 
Env Mouse S. typhimurium Intragastric ND + ND + ND Shata et al., 2001 
Gag
 
Mouse S. flexneri Intranasal ND + ND + ND Xu et al., 2003 
HBV HbsAg Mouse S. typhimurium Oral + + ND ND ND Woo et al., 2001  
HCV 
 
NS3 region Mouse S. typhimurium Oral ND + ND ND + Wedemeyer et al., 
2001 
Measles virus Fusion protein, 
hemagglutinin, 
nucleoprotein 
Mouse S. flexneri and 
S. typhi 
Intranasal 
Intraperitoneal 
+ + ND ND ND Fennelly et al., 1999 
Hemagglutinin Cotton rat  S. flexneri and 
S. typhi 
Intranasal 
Intranasal 
 
+ + ND ND + Pasetti et al., 2003 
 
HSV-2 gD, gB Mouse S. typhimurium Oral + + - + + Flo et al., 2001 
 
MCMV MCMV-BAC Mouse E. coli Intramuscular, 
subcutaneous, 
intraperitoneal 
 
+ ND ND ND + Cicin-Sain et al., 2003 
 
PRV gD
gD, ProT 
ProT 
Mouse 
Mouse 
Mouse 
E. coli  
S. choleraesuis 
S. choleraesuis 
Intramuscular 
Oral 
Oral 
ND 
+ 
+ 
+ 
+ 
+ 
ND 
ND 
+ 
ND 
ND 
ND 
+ 
+ 
+ 
Shiau et al., 2001a 
 Shiau et al. 2001 b; 
Shiau et al., 2005 
gB
 
Mouse S. typhimurium Oral + + + + (+) Eo et al., 2006 
PRRSV 
 
Gp5 Mouse S. typhimurium Oral + ND ND ND ND Jiang et al., 2004 
Influenza hemagglutinin Mouse S. flexneri Intranasal + + + ND + Vecino et al., 2004 
 
IBDV VP2/4/3 Chicken S. typhimurium Oral + ND ND ND + Li et al., 2006 
a HIV: human immunodeficiency virus; HBV: hepatitis B virus; HCV: hepatitis C virus; HSV: herpes simplex virus-2; MCMV:  murine cytomegalovirus; PRV: pseudorabies virus; 
PRRSV: porcine reproductive and respiratory syndrome virus; IBDV: infectious bursal disease virus  
b Gp/g: glycoprotein; HBsAg: Hepatitis B surface antigen; NS: non-structural; BAC: herpesvirus bacterial artificial chromosome; ProT: prothymosin α; VP2/4/3: precursor polyprotein  
c S. flexneri: Shigella flexneri; S. typhi : Salmonella typhi ; S. typhimurium: Salmonella typhimurium; E. coli: Escherichia coli; S. cholerasuis: Salmonella cholerasuis 
d ND: not determined, +: induced; -: not induced  
 
Table 8. Vaccination of rodents against bacterial diseases using bacteria-mediated delivery of DNA vaccine plasmids 
   Pathogen Antigena Species Attenuated
bacterial carrierb 
Delivery Systemic responsec Mucosal response Protection Reference 
           Ab CMI Ab CMI
Listeria 
monocytogenes 
ActA and LLO 
 
Mouse S. typhimurium Oral      
     
         
     
      
        
       
+ + +
 
+ + Darji et al. 1997, 
2000 
 
Mycobacterium 
tuberculosis 
 
Ag85A, 
Ag85B, 
MPB/MPT51 
 
Mouse L. monocytogenes Intraperitoneal 
intravenous 
ND + ND ND + Miki et al., 2004 
Chlamydia 
trachomatis 
MOMPe Mouse S. typhimurium Oral ND ND ND ND + Brunham and Zhang,
1999 
 
Brucella 
abortus 
BFRf and P39 Mouse Y. enterocolitica Intragastric + + ND ND + Al-Mariri et al. 2002 
 
 
Clostridium 
tetani 
Tetanus toxin 
fragment C 
Guinea pig 
Mouse 
 
S. flexneri  
S. typhi 
Intranasal 
Intranasal 
+ 
+ 
ND 
+ 
+ 
ND 
 
ND 
+ 
+ 
ND 
Anderson et al., 2000  
Pasetti et al., 1999 
Helicobacter 
pylori 
HP-NAP 
 
Mouse S. typhimurium Oral + ND + ND ND Sun et al., 2006 
Mycoplasma 
hyopneumoniae 
 
P97R1 Mouse S.  typhimurium Oral - + - ND ND Chen et al., 2006a 
NrdF Mouse S.  typhimurium Oral - + - ND ND Chen et al., 2006b  
 
a ActA: actin nucleator; LLO: Listeriolysin; Ag: antigen; MPB/MPT51: mycobacterial protein secreted by M. bovis /mycobacterial protein secreted by M. tuberculosis; MOMP: 
major outer membrane protein; BFRf: bacterioferritin; HP-NAP: Helicobacter pylori neutrophil activating protein; P97R1: P97 adhesin repeat region R1; NrdF: ribonucleotide reductase 
R2 subunit 
b  S. typhimurium: Salmonella typhimurium; L. monocytogenes: Listeria monocytogenes; Y. enterocolitica: Yersinia enterocolitica; S. flexneri: Shigella flexneri; S. typhi : Salmonella typhi  
c ND: not determined, +: induced; -: not induced  
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from the cell (e.g. by apoptosis) and presented by bystander APC (Janeway and Medzhitov, 
2002; Schoen et al., 2004; Xu and Ulmer, 2003). Furthermore, an innate immune response 
could be generated that promotes the development of adaptive immune responses against the 
expressed antigens because a short-lived infection is established after delivery of these 
bacteria (Xu and Ulmer, 2003). This bacteria-mediated delivery of DNA vaccines to rodents 
has successfully been used for vaccination against a variety of infectious diseases of both viral 
(Table 7) and bacterial origin (Table 8). Immunizations were orally with S. typhimurium and 
intranasally with Shigella and a mucosal as well as a systemic immune response could be 
demonstrated. 
 
1.6.3 Heterologous prime – boost immunization for enhanced mucosal immunity 
In efforts to improve mucosal immune responses to naked DNA vaccines, heterologous prime 
– boost strategies combining parenteral DNA vaccination with mucosal delivery of live 
attenuated microorganisms or protein-based vaccines have also been proposed. Weeratna and 
colleagues (2000) reported the induction of antigen-specific IgA by parenteral priming of 
mice with DNA followed by a mucosal protein boost, whereas this was not observed with 
either route alone. In line with these results, parenteral priming with a DNA vaccine followed 
by oral boosting with a recombinant Salmonella strain, both encoding the structural subunit of 
ETEC CFA/I fimbriae, elicited systemic (serum IgG) and mucosal (fecal IgA) antibody 
responses (Lasaro et al., 1999; 2004). In addition, dams vaccinated by the heterologous 
protocol passively protected their suckling pups against a lethal intragastric ETEC challenge, 
whereas this was not the case for dams vaccinated by either route alone (Lasaro et al., 2005). 
These data suggest that, at least in mice, parenteral DNA vaccination followed by a 
heterologous mucosal boost is an effective strategy for the induction of mucosal immunity. 
However, less promising results were obtained when this strategy was applied to pigs (Yuan 
et al., 2005). In pigs, IM priming with DNA followed by an oral boost with attenuated human 
rotavirus (AttHRV) failed to induce significant protection against virus shedding after 
rotavirus challenge (Yuan et al., 2005). Conversely, significant protection against rotavirus 
shedding could be observed when the oral AttHRV vaccine was given to prime and the IM 
DNA vaccine to boost the immune system of pigs. The higher protection obtained by the oral 
AttHRV prime – IM DNA boost immunization was associated with higher mucosal IgA and 
IgG responses and significantly higher serum IgA titers (Yuan et al., 2005). Their data 
indicate that the mucosal route is more effective than the parenteral route to prime a mucosal 
response and therefore might be more suitable to obtain protective immunity in large animals. 
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Aims of the study 
 
Enterotoxigenic Escherichia coli (ETEC) are a major cause of diarrhoea in recently 
weaned piglets. To obtain protective immunity against ETEC, early priming of the intestinal 
mucosal immune system is necessary. At present no commercial vaccine allows successful 
vaccination. This is partly due to the presence of maternal antibodies hampering the induction 
of cellular and humoral immunity following conventional vaccination. Conversely, maternal 
antibodies won’t interfere with the induction of cellular immunity by DNA vaccines, as these 
vaccines produce their encoded antigen endogenously. Hence, DNA vaccination could be an 
interesting approach to prime immunity against postweaning diarrhoea. However, parenteral 
immunization with our previous pcDNA1/faeG19 DNA vaccine encoding the fimbrial 
adhesin (FaeG) of F4+ ETEC only induced poor systemic immune responses in pigs.  
The general aims of this study are to improve the immunogenicity of the FaeG DNA 
vaccine and to analyze whether parenteral DNA vaccination could reach the intestinal 
mucosal immune system.  
 
For the optimization of the parenteral FaeG DNA vaccine, the following questions are 
addressed: 
• What is the optimal route for parenteral FaeG DNA vaccination, the intradermal or the 
intramuscular route? (Chapter 2) 
• Does plasmid encoded granulocyte-macrophage colony-stimulating factor (GM-CSF) 
pre-treatment enhance the immunogenicity of the FaeG DNA vaccine? (Chapter 2) 
? Can we demonstrate a chemotactic effect of GM-CSF DNA on professional 
antigen-presenting cells (APC)? (Chapter 3) 
• Does optimization of the FaeG expression and/or co-administration of plasmid vectors 
encoding the A and B subunit of the thermolabile enterotoxin (LT) of E. coli (the LT 
vectors) enhance the immunogenicity of our parenteral DNA vaccine? (Chapter 4) 
 
To analyze priming of the intestinal mucosal immune system, the following issues are 
investigated: 
• Does priming with the FaeG DNA vaccine in the presence or absence of the LT 
vectors followed by an oral F4 protein boost induce intestinal mucosal antibody 
responses? (Chapter 4) 
? Does this protocol protect against challenge? (Chapter 4) 
 57  
  Aims of the study 
• Does co-administration of 1alpha,25-dihydroxyvitamin D3 (vitD3) to the optimized 
DNA vaccine further enhance this mucosal priming and/or further modulate the 
antibody response towards IgA? (Chapter 5) 
• What is the importance of the oral F4 boost in the induction of systemic and/or 
mucosal immunity? (Chapter 5) 
• If co-administration of the LT vectors and/or vitD3 enhance systemic and/or mucosal 
immunity, is this accompanied by an altered cytokine expression profile at the 
immune induction site? (Chapter 5) 
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Plasmid-encoded GM-CSF 
induces priming of the F4-specific 
serum IgA response by FaeG DNA 
vaccination in pigs 
 
 
 
 
 
 
 
 
 
Based on: Melkebeek V, Verdonck F, Stuyven E, Goddeeris B, Cox E. (2006). Plasmid-
encoded GM-CSF induces priming of the F4-specific serum IgA response by FaeG DNA 
vaccination in pigs. Vaccine 24 : 4592-4594.  
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ABSTRACT 
 
We have used FaeG DNA to immunize piglets by the intradermal (ID) and the 
intramuscular (IM) route in a heterologous prime/boost model. ID immunization with DNA 
resulted in a better induction of cellular immunity, whereas only the IM immunization could 
prime an F4-specific serum IgA response. However, ID administration of plasmid-encoded 
GM-CSF one week before the ID immunization enhanced the F4-specific humoral and 
cellular immune response and even primed the F4-specific IgA response more efficiently than 
the IM immunization did. 
 
INTRODUCTION 
 
Newly weaned piglets are highly susceptible to F4+ enterotoxigenic E. coli (ETEC) 
induced diarrhea. To protect piglets against this infection, an F4-specific immune response 
should be induced during the suckling period, often in the presence of maternal antibodies. 
Since DNA vaccines are believed to be superior to protein vaccines in priming immune 
responses in young animals in the presence of maternal antibodies (Bot and Bona, 2002), 
priming with DNA during the suckling period combined with an F4 protein boost after 
weaning could be an interesting approach to obtain protection shortly after weaning. Hereto, 
an FaeG DNA vaccine (pWRGFaeG) encoding the adhesin of F4 fimbriae was constructed. In 
the present study, the capacity of the pWRGFaeG DNA vaccine was tested to prime B- and T-
cell responses in F4-seronegative pigs by ID or IM injection. Hereby we also analysed the 
effect of the ID delivery of plasmid DNA encoding the porcine GM-CSF (pcDNA3-rpGM-
CSF) (Inumaru and Takamatsu, 1995) on ID immunization. 
 
METHODS  
 
The sequence encoding the mature FaeG was obtained by PCR from E. coli strain GIS 26 
(O149:F91:F4ac, LT+STa+STb+) and digested with NheI and BamHI (sites specified by the 
PCR primers) for insertion in the pWRG7079 vector, resulting in pWRGFaeG. The 
pWRG7079 vector contains the coding sequence for the human tissue plasminogen activator, 
allowing the extracellular secretion of proteins whose coding sequence is inserted in the 
correct reading frame at the NheI site. Expression and secretion of the FaeG was 
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demonstrated in COS-7 cells (data not shown). Subsequently, an immunization experiment 
was performed using 21 8-week-old conventional F4-seronegative pigs (Table 1). Seven days 
before the first immunization, 7 pigs were injected ID in the neck with 250 µg pcDNA3-
rpGM-CSF (n=5) or the empty pcDNA3 vector (n=2). These pigs were immunized ID at the 
injection site with 500 µg pWRGFaeG (GM-CSF + ID group) or pWRG7079 (GM-CSF + ID 
controls) respectively on days 0 and 31. The remaining pigs were immunized both these days 
with 500 µg pWRGFaeG by the IM (n=5, IM group) or the ID route (n=5, ID group) or with 
500 µg pWRG7079 by the ID (n=2, ID controls) or the IM route (n=2, IM controls). Four 
weeks after the second DNA immunization (day 59), all the pigs were intramuscularly 
boosted with 100 µg purified F4 fimbriae (Van der Stede et al., 2002). F4-specific serum IgG 
and IgA responses were determined by an F4-specific ELISA and F4-specific cellular 
immune responses were analysed by a lymphocyte proliferation assay (Verdonck et al., 
2005). Differences between the groups in log2 antibody titers and in lymphocyte proliferation 
(stimulation indexes, SI) were tested for statistical significance (P<0.05) using General Linear 
Model (Repeated Measure Analysis of Variance) with the Bonferroni adjustment for multiple 
comparisons and a Mann-Whitney U test, respectively.  
 
Table 1: Experimental design 
Group n D-7 D0 and D31 D59 
IM 5 / IM pWRGFaeG IM F4  
ID 5 / ID pWRGFaeG IM F4  
GM-CSF+ ID 5 ID pGM-CSF ID pWRGFaeG IM F4 
Control 2 
2 
2 
/ 
/ 
ID pcDNA3 
IM pWRG7079 
ID pWRG7079 
ID pWRG7079 
IM F4 
IM F4 
IM F4 
 
 
RESULTS 
 
F4-specific serum antibody responses 
After the second immunization with pWRGFaeG, a weak F4-specific serum IgG antibody 
response was seen in 3 out of 5 pigs of both the ID and the IM group and in all 5 pigs of the 
GM-CSF + ID group. No F4-specific IgG antibodies were detected in the control animals and 
none of the pigs showed an F4-specific IgA antibody response (Figure 1).  
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Figure 1. Kinetics of the F4-specific IgG and IgA serum response following intradermal 
injection of pcDNA3-rpGM-CSF (GM-CSF, day -7), 2 intramuscular (IM) or intradermal 
(ID) immunizations (days 0 and 31 post primary immunization (dppi), black arrows) with 
pWRGFaeG or pWRG7079 (controls) and an F4 protein boost (day 59, all pigs, grey arrow) . 
Significant differences (P<0.05) between the GM-CSF + ID group and the control group are 
indicated with * and between the GM-CSF + ID group and the ID group with ** . 
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+ ID group (P= 0.045), respectively, compared to the control group where no F4-specific 
antibody response could be observed at this time. Two days later, the mean IgG titer remained 
highest in the GM-CSF + ID group and became comparable in the IM and the ID vaccinated 
groups. At this time, the mean IgG titer in the control group was increased and only remained 
3-fold lower compared to the IM and the ID group and 4.8 fold lower compared to the GM-
CSF + ID group. A secondary F4-specific serum IgA response was also observed in the GM-
CSF + ID and the IM group with, 5 days after the F4 boost, a 1.6- and a 2-fold increase in 
mean serum antibody titer, respectively. The mean serum IgA titer further increased in the 
GM-CSF + ID group and was significantly higher compared to the control pigs (P= 0.039) 
and the ID group (P= 0.021) 2 weeks after the boost.  
 
F4-specific lymphocyte proliferation  
Although stimulation indexes (SI) were low 11 days after the second DNA immunization, 
a significantly higher mean SI could be observed in each pWRGFaeG vaccinated group (IM 
group: P= 0.045; ID group: P= 0.028; GM-CSF + ID group: P= 0.011) compared to the 
control group. Furthermore, although not significant, the GM-CSF + ID group showed a 
higher mean SI than the IM group (P= 0.117). Thirteen days after the F4 protein boost, SI 
were increased in all groups and only the ID group still had a significantly higher mean SI (P= 
0.028) than the control group. 
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Figure 2. F4-specific proliferation of PBMC 11 days after the second immunization (day 42) 
and 13 days after the protein boost (day 72). Results are presented as means of the SI + SEM. 
Significant differences (P<0.05) with the control group are indicated with *. 
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DISCUSSION 
 
Our results have demonstrated that pWRGFaeG could efficiently prime F4-specific 
humoral and cellular immune responses in pigs. Moreover, results obtained with this plasmid 
were better than those observed with our previous FaeG DNA vaccine (Verfaillie et al., 
2004). In the absence of pcDNA3-rpGM-CSF, cellular immune responses were best induced 
after ID immunization, whereas only the IM immunization primed an IgA response. Injection 
of pcDNA3-rpGM-CSF 7 days before the first ID DNA vaccination improved F4-specific 
cellular and humoral immune responses and even primed a serum IgA response. The immune 
enhancing effect of plasmid-encoded GM-CSF is in line with previous studies (Bowne et al., 
1999; Somasundaram et al., 1999) and may be due to a better transfection efficiency of APC 
since DNA encoded GM-CSF has been shown to recruit these cells to the injection site in 
mice (Bowne et al., 1999). However, it remains to be proven whether this is also the case in 
pigs. Alternatively, GM-CSF expression might improve the functional capacities of DC 
(Curiel-Lewandrowski et al., 1999).  
To our knowledge, this is the first report demonstrating that GM-CSF is able to induce an 
IgA priming following intradermal immunization. Priming for a serum, and in addition a 
mucosal IgA response was also seen in mice with vitamin D or ADP-ribosylating toxins 
following intradermal protein immunization and was associated with an altered maturation 
and migration of antigen-pulsed DC resulting in their enhanced localization in the Peyers 
patches (Enioutina et al., 2000). Further research will be necessary to elucidate if a similar 
mechanism is responsible for the GM-CSF induced priming of IgA and thus if ID GM-CSF 
will result in a priming of the mucosal immune system. This priming is necessary to stimulate 
immunity against ETEC.  
In conclusion, pWRGFaeG has the potential to prime F4-specific humoral and cellular 
immune responses in pigs following IM and ID immunization. A good priming of the FaeG-
specific serum IgA response however, was only induced if pcDNA3-rpGM-CSF was injected 
ID 1 week before the first ID DNA vaccination. These results implicate that the combination 
of GM-CSF and ID DNA immunization is best suited to prime immune responses in 
vaccination trials against ETEC and other mucosal pathogens. 
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colony-stimulating factor on antigen-
presenting cells in pigs 
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ABSTRACT 
 
We previously demonstrated that intradermal (ID) delivery of plasmid DNA encoding the 
porcine granulocyte-macrophage colony-stimulating factor (GM-CSF) seven days before 
DNA vaccination enhances both cellular and humoral responses in pigs. In the present work, 
we studied the effect of the GM-CSF gene on antigen-presenting cells (APC) in pigs. We 
demonstrated that ID delivery of this gene significantly increased the number of epidermal 
CD1+ cells (Langerhans’ cells, skin dendritic cells) at the injection site at day seven. This was 
accompanied by an enhanced  percentage of APC at the immune induction site following 
DNA vaccination, whereas a positive effect on APC maturation could not be demonstrated. 
Taken together, our data suggest that both DC recruitment to the immunization site and 
expansion of APC in the draining LN following DNA vaccination might contribute to the 
immune enhancing effect of plasmid encoded GM-CSF in pigs. 
 
INTRODUCTION 
 
Professional antigen-presenting cells (APC) are critically involved in the induction of 
immunity following DNA vaccination by presenting antigen to T cells via MHC class I when 
directly transfected or through cross-presentation and via MHC class II when antigen is 
captured (Shedlock and Weiner, 2000). Furthermore, untransfected lymph node APC might 
also contribute to the immune response by production of cytokines induced by the DNA, so 
improving the conditions for T cell priming. Consequently, it is likely that adjuvants that 
expand the APC pool and/or enhance the potency of these cells would greatly improve the 
efficacy of DNA vaccines. In this regard, GM-CSF has received considerable attention given 
its role not only as a growth and differentiation factor for APC but also as a chemo-attractant 
for these cells (Kaplan et al., 1992). Indeed, plasmid encoded GM-CSF has been shown to 
recruit APC to the injection site and expand the number of APC in the draining lymph node in 
mice (Bowne et al., 2000; Haddad et al., 2000). In pigs, plasmid encoded GM-CSF has been 
observed to enhance antibody responses (Andrew et al., 2006; Cedillo-Baron et al., 2001; 
Somasundaram et al., 1999), Th1- as well as Th2-cell responses (Dufour et al., 2000) and 
protection against viral challenge (Somasundaram et al., 1999; Andrew et al., 2006). While 
these studies co-injected the plasmid encoded GM-CSF with the DNA vaccine, several other 
studies suggest that the period between cytokine DNA injection and DNA vaccination might 
be critical for obtaining a maximal adjuvant effect (Kusakabe et al., 2000; Barouch et al., 
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1998). We have previously evaluated the adjuvant effect of plasmid encoded GM-CSF on ID 
DNA vaccination in pigs by injecting it 7 days before the first immunization, as plasmid 
encoded GM-CSF has been shown to attract APC to the injection site in mice with a maximal 
effect on day 7 (Bowne et al., 2000). This protocol resulted in enhanced cellular and humoral 
responses and in priming of a serum IgA response in pigs (Melkebeek et al., 2006). However, 
as results obtained in mice often do not translate to larger animals (Hengge et al., 1996), 
further research on the mechanism of action of GM-CSF might be helpful to understand and 
fully exploit its immune enhancing effect in these species.  
In the present study, we evaluated the influence of ID injection of GM-CSF DNA seven 
days prior to DNA vaccination on the density of epidermal APC at the immunization site and 
on the percentage of APC at the immune induction site following DNA vaccination of pigs. 
 
 
MATERIALS AND METHODS  
 
Plasmids 
The pcDNA3-rpGM-CSF plasmid encoding the porcine GM-CSF was a gift of Pirbright 
Laboratories, IAH. The pWRGFaeGopt DNA vaccine was constructed as previously 
described (Melkebeek et al, 2007). pcDNA3-rpGM-CSF, the empty pcDNA3.1 vector 
(Invitrogen, Leek, The Netherlands) and pWRGFaeGopt were propagated in E. coli DH5α. 
Strains were grown in Luria Broth supplemented with ampicillin (100 µg/ml) and plasmids 
were purified using the Endofree Plasmid Mega kit (Qiagen, Germany). 
 
Monoclonal antibodies 
The monoclonal antibodies (mAb) used are presented in Table 1.  
 
Table 1. Monoclonal antibodies 
 
 
 
 
 
 
 
Specificity Clone References Distribution 
CD1 76-7-4 Pescovitz et al., 1984 cortical thymocytes, B cells, Langerhans 
cells, thymus DC, monocyte-derived DC, 
skin DC 
MHCII MSA3 Hammerberg and Schurig, 
1986 
Monocytes, macrophages, Langerhans 
cells, DC, B cells 
SWC3a 74-22-
15 
Pescovitz et al., 1984 Monocytes, macrophages, granulocytes, 
thymus DC, monocyte-derived DC, 
subpopulation of skin DC,  
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Experimental design 
Fifteen conventional pigs (Belgian Landrace x Piétrain) were weaned at the age of 4 
weeks. Subsequently, they were housed in isolation units where they obtained water and food 
ad libitum. At the age of 5 weeks, all pigs obtained at the left site of the neck an intradermal 
(ID) injection with 250 µg of pcDNA3-rpGM-CSF, whereas the right site was injected with 
250 µg of the empty pcDNA3.1 vector (n=7, vector group), with sterile PBS (n=7, PBS 
group) or was not injected (n=1, control). Seven days later, at the same moment that 
immunization occurred in our previous study (Melkebeek et al., 2006), the control pig, 1 pig 
of the vector group and 2 pigs of the PBS group were euthanized and punch biopsies with a 
diameter of 8 mm were taken at each injection site and also at an uninjected site of the neck to 
analyze the influence of GM-CSF on the density of APC at the immunization site. These 
biopsies were snap frozen in liquid-nitrogen-cooled isopropanol and stored at -70°C. At the 
same time, the remaining pigs were ID immunized with 500 µg of pWRGFaeGopt at the 
injection sites in the left and right site of the neck to analyze the effect of GM-CSF on DC 
recruitment to the immune induction site. Two and 4 days post immunization (pi), 2 PBS and 
2 pcDNA3.1 controls and 7 days pi 1 PBS and 2 pcDNA3.1 controls were euthanized and the 
local draining cervical superficial dorsal lymph nodes (Cerv LN) were isolated to analyze the 
percentage of APC (Table 2). Euthanasia was performed by intravenous injection of 
pentobarbital (24 mg/kg; Nembutal®, Sanofi Santé Animale, Brussels, Belgium) followed by 
exsanguination.  
Each ID injection was performed by multiple injections of plasmids diluted in a total 
volume of 1 ml sterile PBS.  
 
Table 2. Experimental design 
D2 D4 D7 Group n D-7 
   left             right 
injection     injection 
D0 
Euthanasia                    Immunization 
                                         (left + right) 
Euthanasia 
          
control 1 pGM-CSF / 1 / / / / 
PBS control 7 pGM-CSF PBS 2 pWRGFaeGopt (n=5) 2 2 1 
Vector control 7 pGM-CSF pcDNA3 1 pWRGFaeGopt (n=6) 2 2 2 
 
Quantification of APC cells in porcine epidermis 
To quantify the numbers of APC in the epidermis, the CD1+ cells (Table 1) were counted 
since CD1 expresion in this tissue is restricted to Langerhans’ cells and skin DC. Hereto, 
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transversal 5 µm thick cryostat sections from the skin biopsies were fixed in acetone at -20°C 
for 10 min, air dried and washed in PBS. Subsequently, sections were sequentially incubated 
in a humidity chamber at 37° C with 10% sheep serum for 30 min to block non-specific 
binding sites, with a CD1-specific mAb for 1 h to identify APC and with a sheep anti-mouse 
IgG (whole molecule) Fab-fragment labelled with FITC (Sigma, Bornem, Belgium) for 1 h. 
After each step, the sections were washed 3 times with PBS. Finally, they were air-dried and 
mounted in a glycerin solution containing DABCO. Quantification of CD1+ cells was 
performed on digital micrographs using the AnalySIS 3.2 software. On each micrograph, the 
epidermal basal membrane was marked polygonally and epidermal CD1+ cells were counted 
and expressed per mm basal membrane. Only CD1+ cells with clearly visible cell bodies were 
counted. For each biopsy, a minimum of 5 sections (at least 50µm apart) with a total basal 
membrane length of at least 20 mm were analyzed (Figure 1).  
 
# 8
553,8 µm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. CD1-positive cells in the epidermis at day 7 after injection of PBS. The epidermal 
basal membrane was polygonally marked and fluorescent cells with a clearly visible cell body 
were counted. 
 
Isolation of cervical superficial dorsal lymph node monomorphonuclear cells  
Monomorphonuclear cells (MC) were isolated from the draining Cerv LN as described by 
Vremec and Shortman (1997) with minor modifications. Cerv LN were cut into small pieces 
in medium [RPMI-1640 (GIBCO BRL, Paisley, Scotland) + 20 mM HEPES (GIBCO BRL) + 
2% FCS + 100 IU/ml penicillin (GIBCO BRL) + 100 µg/ml streptomycin (GIBCO BRL) + 
0.01% (wt/vol) DNase I (Boehringer Mannheim, Brussels, Belgium)] to which 0.005% 
(wt/vol) collagenase (SERVA, Polylab, Antwerp, Belgium) was added. After vigorous 
pipetting, the medium, containing cells in suspension, was collected. The remaining tissue 
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pieces were further digested in this medium supplemented with 0.1% (wt/vol) collagenase for 
25 min at room temperature while gently shaking. Then, EDTA (pH 7.2) was added to a final 
concentration of  10 mM to disrupt DC-T cell complexes and incubation was continued for 5 
min. Next, undigested tissue was removed by passage through a cell strainer whereafther cells 
in suspension were pelleted by centrifugation (380g at 18 °C for 10 min) and resuspended in 
washing buffer [equal volumes of PBS and Alsever’s solution + 100 IU/ml penicillin + 100 
µg/ml streptomycin + 1% FCS + 0.1 mM EDTA].  
MC were isolated by density gradient centrifugation (500g at 18 °C for 45 min) on 
Lymphoprep® (Invitrogen, Merelbeke, Belgium). Finally, the MC were washed with washing 
buffer and resuspended in ice-cold staining buffer (PBS + 2% sheep serum + 0.2 mM EDTA) 
at a final concentration of 107 cells/ml.  
 
Flow cytometric analysis 
MC were analysed for expression of cell surface antigens by flow cytometry. Hereto, cells 
(106 cells/ well) were incubated for 30 min on ice in staining buffer containing a swine CD1-, 
MHC class II (MHCII)- or SWC3-specific mAb (Table 1) and subsequently in staining buffer 
containing the FITC-labelled sheep anti-mouse IgG. Staining buffer without Ab was used as a 
negative control. Incubations occurred for 30 min on ice after which the cells were washed 3 
times in staining buffer. Finally, cells were resuspended in 600 µl staining buffer 
supplemented with 6µl  propidiumiodide (1 µg/ml) to exclude death cells during analysis. 
Flow cytometric analysis was performed on a FACSCanto flow cytometer (Becton Dickinson 
Immunocytometry systems) and at least 10,000 viable cells were analysed per run.  
 
 Statistical analysis 
Data were tested for normal distribution with a Shapiro-Wilk test. Statistical analysis was 
done using a paired-sample T-test (SPSS 12.0 for windows). P<0.05 was considered as 
statistically significant.  
 
RESULTS AND DISCUSSION 
 
pcDNA3-rpGM-CSF increases APC numbers in the epidermis 
Seven days after ID injection of plasmid encoded GM-CSF, an increase in epidermal CD1-
positive cells was observed in all four examined pigs (mean increase of 36 % compared to 
uninjected epidermis; P=0.004). This effect was due to the expression of GM-CSF rather than 
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to the presence of CpG motifs in the vector or to inflammation caused by the injection on 
itself as no clear increase could be observed following injection of the empty pcDNA3.1 
vector or PBS, respectively (Table 3). 
These data are in line with studies in mice demonstrating APC recruitment by plasmid 
encoded GM-CSF (Bowne et al., 1999; Haddad et al., 2000), Flt3-ligand and/or MIP1α 
(McKay et al., 2004; Sumida et al., 2004). In these studies, APC recruitment was consistently 
accompanied by an enhanced vaccine induced immune response. Moreover, the Sumida study 
demonstrated that blocking DC recruitment, by disrupting the chemokine gradient with a 
high-dose of MIP-1α protein or by delivering the chemokine plasmids at a site different from 
the DNA vaccine, abrogated the adjuvanticity of the plasmid encoded cytokines, confirming 
the importance of locally recruited APC in mice. Likewise, the increased number of CD1+ 
cells in the present study suggests that APC recruitment to the immunization site has also 
contributed to the immune enhancing effect of plasmid GM-CSF in pigs (Melkebeek et al., 
2006). Possible mechanisms for an enhanced immunogenicity by APC recruitment include a 
higher transfection efficiency and/or an enhanced uptake of plasmid encoded antigen by these 
cells. 
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Table 3: Number of CD1+- cells per mm epidermal basal membrane at the immunization site  
Group GM-CSF injection site Control site 
Uninjected                    PBS                        pcDNA3 
control 18.9 15,3 / / 
PBS control 17.9 12,4 14.3 / 
PBS control 18.9 14,0 14.6 / 
Vector control 22.3 15,5 / 14.3 
Mean ± SEM 19.5 ± 1.0* 14.3 ± 0.7 14.4 ± 0.2 14.3 
* : significant difference between the pcDNA3-rpGM-CSF and the uninjected site 
 
cDNA3-rpGM-CSF injection increases the percentage of APC in the local draining 
erv LN 
To evaluate the influence of GM-CSF pre-treatment on the percentage of APC at the 
mmune induction site following DNA vaccination, we analysed the percentage of MHCII+, 
D1+ and SWC3+ cells in the Cerv LN at days 2, 4 and 7 pi with pWRGFaeGopt. At day 2 pi, 
he percentage of CD1+, SWC3+ and MHCII+ cells was 2.3- to 2.7-fold increased at the 
cDNA3-rpGM-CSF injection site compared to the PBS pre-treatment site (n=2), whereas no 
ncrease for MHCII and only a 1.4- to 1.8- fold increase for CD1 and SWC3 was observed 
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compared to the pcDNA3.1 pre-treatment site (n=2) (Figure 2). The increases in the 
percentage of CD1+ (P=0.042) and SWC3+ cells (P=0.021) were only significant when the 
PBS and the vector pre-treated site were considered together (n=4; further referred to as the 
control site) (Figure 2). Later on, the positive effect of plasmid GM-CSF pre-treatment 
steadily disappeared. Indeed, at day 4 pi, GM-CSF pre-treatment only significantly increased 
the percentage of SWC3+ cells (P=0.035) and at day 7 pi, no significant effects were observed 
anymore. However, it can not be excluded that a better T cell proliferation at the GM-CSF 
pre-treated site, resulting in a higher number of T cells, masked the effect of GM-CSF on 
APC recruitment at these later time points. Indeed, an increased lymphocyte proliferation has 
been observed after DNA vaccination of pigs which were pre-injected with the GM-CSF 
plasmid (Melkebeek et al., 2006).  
As surface expression of MHCII becomes increased several fold during APC maturation 
(Villadangos et al., 2005), surface MHCII expression was used to evaluate APC maturation. 
A positive effect of GM-CSF on APC maturation could not be demonstrated at any of the 
examined time points as surface expression of MHCII on lymph node APC was similar at the 
GM-CSF and the PBS or vector pre-treated site (data not shown). 
Our present results are in agreement with observations in mice demonstrating a positive effect 
of GM-CSF pre-treatment on APC recruitment into the draining LN 24 h after gold particle 
bombardment (Bowne et al., 1999). Moreover, Curiel-Lewandrowski et al (1999) observed a 
correlation between the enhanced migratory capacity of DC and their enhanced capacity to 
induce primary responses following GM-CSF gene transfection. Taken together, their and our 
data suggest that both DC recruitment to the immunization site and expansion of APC in the 
draining LN following DNA vaccination might contribute to the enhanced immunogenicity 
observed following plasmid GM-CSF pre-treatment. However, a possible contribution of 
other factors independent of APC to the immune enhancing effect of plasmid GM-CSF, such 
as extension of the life span of germinal centers favoring the interaction between follicular 
DC and B cells, a direct effect on follicular DC or an enhanced avidity of the interactions 
between B- and T-cells (Gerloni et al., 1998) was not addressed in the present study. 
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ABSTRACT 
One of the problems hindering the development of DNA vaccines is the relatively low 
immunogenicity often seen in animals and humans compared to that in mice. In the present 
study, we tried to enhance the immunogenicity of a pcDNA1/faeG19 DNA vaccine in pigs by 
optimizing the FaeG expression plasmid and by co-administration of plasmid vectors 
encoding the A and B subunit of the E. coli thermo-labile enterotoxin (LT). Insertion of a 
Kozak sequence and optimization of vector- (cellular localization, expression) and both 
vector- and codon-usage were all shown to enhance the in vitro FaeG expression compared to 
pcDNA1/faeG19. Subsequently, pcDNA1/faeG19 and the vector- and vector- + codon-
optimized construct were tested for their immunogenicity in pigs. In line with the in vitro 
results, antibody responses were better induced with increasing expression. The LT vectors 
additionally enhanced the antibody response, although not significantly, and were necessary 
to induce an F4-specific cellular response. These vectors were also added since LT has been 
described to direct the systemic response towards a mucosal IgA response in mice. Here 
however, the intradermal FaeG DNA prime-oral F4 boost immunization mainly resulted in a 
systemic IgG response, with only a marginal but significant reduction in F4+ E. coli faecal 
excretion when the piglets were primed with pWRGFaeGopt and pWRGFaeGopt with the LT 
vectors. 
 
INTRODUCTION 
Intestinal infections with enterotoxigenic Escherichia coli (ETEC) remain problematic for 
humans, pigs and calves. The bacteria possess adhesins which allow them to colonize the 
small intestine and to produce enterotoxins which act locally on enterocytes. These adhesins 
bind to specific receptors on the enterocyte brush borders, and absence of these receptors 
renders the animal resistant to bacterial colonization and consequently to ETEC induced 
diarrhea (Rutter et al., 1975). In pigs, F4 (K88) fimbriae are the best characterised adhesins 
(Van den Broeck et al., 2000). They are long proteinaceous appendages mainly composed of 
several hundreds identical adhesive subunits, called FaeG (Mol and Oudega, 1996).  
Our laboratory developed a challenge model in pigs in which new vaccination strategies 
against ETEC can be tested. In this model, it was demonstrated that oral administration of F4 
fimbriae to weaned F4R+ pigs led to protection against a subsequent F4+ ETEC infection (Van 
den Broeck et al., 1999a). In practice, a protective mucosal immune response often needs to 
be induced in the presence of maternal antibodies.  
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Several studies have shown that DNA vaccines, in contrast to conventional vaccines, can 
successfully prime immune responses in the presence of maternal antibodies, pointing out its 
potential use in young animals (Bot and Bona, 2002). Our previous pcDNA1/faeG19 DNA 
vaccine however, was only marginally immunogenic in pigs (Verfaillie et al., 2004). This is 
in agreement with other studies in large animals and man suggesting poor immunogenicity of 
DNA vaccines in these species (MacGregor et al., 1998; van Rooij et al., 1998). Several 
approaches have been explored to enhance the potency of DNA vaccines. These include 
optimization of expression (Montgomery et al., 1993; Steinberg et al., 2005), optimization of 
transfection efficiency (Babiuk et al., 2003b), targeting of DNA or the encoded antigen to 
dendritic cells (Drew et al., 2001; Singh et al., 2000) and co-administration of adjuvants such 
as vector-encoded cytokines (Kim et al., 2001; Melkebeek et al., 2006). Promising results 
were also observed when DNA vaccines were used in heterologous prime-boost models (Guo 
et al., 2004; Toussaint et al., 2005).  
In the present study, we evaluated the impact of a Kozak sequence, optimization of vector- 
usage (intron A, BGH polyA, tPA leader sequence) and codon-usage on the in vitro FaeG 
expression using 2 porcine, a human and a non-human primate cell line. Subsequently, the 
influence of expression optimization and of co-administration of plasmids encoding the LTA 
and LTB subunits (collectively named the LT vectors) was analyzed on the immunogenicity 
of the FaeG DNA vaccine in pigs. Additionally, priming of an F4-specific intestinal mucosal 
immune response was assessed in an intradermal (ID) DNA prime - oral F4 boost protocol. 
 
MATERIALS AND METHODS 
 
Isolation of F4 fimbriae 
F4 fimbriae were isolated from ETEC strains GIS26 (O149:K91:F4ac, LT+STa+STb+) and 
IMM 01 (O147:F4ac, LT+STb+) as previously described (Van den Broeck et al., 1999a). 
GIS26 F4 fimbriae were used in ELISA, ELISPOT and for oral immunizations. IMM01 
fimbrial solutions were used in the FaeG-specific lymphocyte proliferation assay as they don’t 
contain flagellin (Verdonck et al., 2004).  
 
Plasmids 
pcDNA1/faeG19 and pWRGFaeG were constructed as previously described by cloning the 
GIS26 faeG sequence into pcDNA1 and pWRG7079, respectively (Verfaillie et al., 2004; 
Melkebeek et al., 2006). The latter vector contains the tPA signal sequence which allows 
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extracellular secretion of the vector encoded protein. The faeGK fragment was derived from 
pcDNA1/faeG19 by PCR using a forward primer inserting a Kozak sequence (GCC ACC 
ATG G) around the ATG translation initiation codon (underlined) and was subsequently 
cloned into pcDNA1, resulting in pcDNA1/faeGK. The faeG sequence was optimized for 
porcine expression using Genscript’s algorithm, increasing the codon-adaptation index (Sharp 
and Li, 1987) of the faeG from 0.542 to 0.811. This codon-optimized sequence was 
constructed synthetically (Genscript corp., Edison, USA) and subsequently cloned into 
pWRG7079, resulting in pWRGFaeGopt. The pcDNA3-rpGM-CSF plasmid encodes the 
porcine GM-CSF. pJV2004 and pJV2005 (Arrington et al., 2002) encode the LTA and LTB 
subunit, respectively, behind a tPA signal sequence. Each construct was verified by 
sequencing the insert and its junction site and large-scale purification was conducted by 
Qiagen Endofree plasmid kits (Qiagen GmbH, Germany).  
 
In vitro expression of recombinant FaeG 
Swine kidney (SK-6 and PK-15), human embryonic kidney (293T) and monkey kidney 
(COS-7) cells were grown in DMEM (GIBCO BRL, Paisley, Scotland) supplemented with 
penicillin (100 IU/ml) (GIBCO BRL), streptomycin (100 µg/ml) (GIBCO BRL), L-glutamine 
(400 mM) (GIBCO BRL) and 10% FCS. The cells (2x105 cells for each transfection) were 
transfected transiently using LipofectamineTM 2000 (Invitrogen, Merelbeke, Belgium) 
following the manufacturer’s protocol. Twenty-four, 48, 72 and 96 hours after transfection, 
culture media (supernatants) were collected and centrifugated to remove cell debris, after 
which transfected cells were collected, resuspended in PBS and lysed by 3 times freezing (-80 
˚C) and thawing. Each transfection was done 4 times. The amount of FaeG was quantified by 
an F4-specific ELISA as described (Verfaillie et al., 2004) using a serial dilution of a known 
concentration of purified F4 to establish the standard curve.  
 
Immunization experiment 
Thirty-three F4-seronegative conventionally bred pigs (Belgian Landrace x Piétrain) were 
weaned at the age of 4 weeks and housed in isolation units. Starting 1 day before weaning, all 
animals were orally treated during 5 successive days with colistine (150,000 U/kg body 
weight; Colivet, Prodivet Pharmaceuticals, Eynatten, Belgium) to prevent E. coli infections 
during the weaning period. 
The experimental setup is shown in table 1. All pigs were injected ID at the left site of the 
neck with 250 µg of pcDNA3-rpGM-CSF at the age of 6 weeks. Seven and 28 days later 
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(days 0 and 21 post primary immunization (ppi)), the pigs were ID immunized at the 
pcDNA3-rpGM-CSF injection site with 500 µg of either pcDNA1/faeG19 (n = 7, 
pcDNA1/faeG19 group), pWRGFaeG (n = 7, pWRGFaeG group), pWRGFaeGopt (n = 7, 
pWRGFaeGopt group), pWRGFaeGopt supplemented with 100 µg pJV2004 and 100 µg 
pJV2005 (n = 6, pWRGFaeGopt + LT group) or the empty pWRG7079 vector (n = 6, control 
group). Plasmids were diluted in sterile PBS and given by multiple injections of a total 
volume of 1 ml following sedation of the pigs with azaperone (2mg/kg; Stressnil®, Janssen-
Cilag, Beerse, Belgium). All the pigs were orally boosted with 1 mg F4 fimbriae at days 43, 
44 and 45 ppi as described earlier (Van den Broeck et al., 1999b). Two pigs of the control 
group and 3 pigs of each vaccinated group were euthanized at day 49 or 50 ppi to evaluate 
antibody responses in the spleen, mesenteric lymph nodes (Mes LN) (jejunal and ileal), 
jejunal Peyer’s patches (JPP), ileal Peyer’s patch (IPP) and lamina propria (LP) (Figure 3). 
The remaining pigs were challenged intragastrically with 1010 F4+ ETEC at days 51 and 52, 
respectively, as described by Cox et al. (1991). Three weeks after challenge, these pigs were 
euthanized. Euthanasia was performed by intravenous injection of pentobarbital (24 mg/kg; 
Nembutal®, Sanofi Santé Animale, Brussels, Belgium) followed by exsanguination. The 
experimental procedure was performed following the guidelines of the animal care and ethics 
committee of the Faculty of Veterinary Medicine, Ghent University (EC2004/85). 
 
Table 1. Experimental design 
Group N Day -7 Days 0 and 21 Days 43, 44, 
45 
Localization 
of ASC at 
day 49 or 50 
N 
ETEC 
challenge at 
day 51-52 
N 
pcDNA1/faeG19  7 pcDNA1/faeG19 3 4 
pWRGFaeG  7 pWRGFaeG 3 4 
pWRGFaeGopt  7 pWRGFaeGopt 3 4 
pWRGFaeGopt + LT  6 pWRGFaeGopt + 
pJV2004 + pJV2005 
3 3 
Control  6 
 
All groups : 
 
pcDNA3-
rpGM-CSF 
 
 
pWRG7079 
 
All groups : 
 
Oral F4 
protein 
2 4 
 
 
Samples and tests 
Sera were sampled at regular intervals (Figure 1) and were used to determine the F4-
specific IgG, IgA and IgM titer by an indirect ELISA (Van den Broeck et al., 1999b). The cut 
off values in this ELISA were 0.82, 0.57 and 0.29 for IgM, IgG and IgA, respectively.  
At day 35 ppi, peripheral blood MC (PBMC) were isolated (Van den Broeck et al., 1999b)  
to determine the FaeG-specific lymphocyte proliferation (Van der Stede et al., 2003).  
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At day 49 or 50 ppi, MC were isolated from the spleen, Mes LN (jejunal and ileal), JPP, 
IPP and LP to enumerate the number of IgG, IgA and IgM ASC per 5x106 MC (Van den 
Broeck et al., 1999b). Furthermore, contents were collected from the duodenum, jejunum and 
ileum (Verdonck et al., 2002) and were tested for FaeG-specific IgG and IgA by an indirect 
ELISA (Van den Broeck et al., 1999b). Cut off values were 0.22 and 0.26 for IgG and IgA, 
respectively.  
After challenge infection, faecal samples were collected daily till day 7 post challenge and 
the F4+ E. coli in these samples were enumerated by dot blotting as described (Van den 
Broeck et al., 1999a).  
The F4-receptor (F4R) status of all pigs was determined by an in vitro villus adhesion 
assay on small intestinal villi (Van den Broeck et al., 1999c). 
 
Statistical analysis  
Statistical analysis was done using SPSS 12.0 for Windows. Differences in FaeG 
expression between different constructs within each cell line were tested with a paired-sample 
t test. Differences in log2 serum antibody titers and in log10 faecal ETEC excretions between 
groups were analyzed using General Linear Model (Repeated Measures Analysis of Variance) 
with the Bonferroni adjustment for multiple comparisons. Differences in log2 serum antibody 
titers between different time points within groups were tested with a paired-sample t test. 
Differences in duration of faecal F4+ E. coli excretion between groups was tested using one-
way ANOVA. Differences between groups in lymphocyte proliferation were analyzed with 
the Kruskal-Wallis test. P<0.05 was considered as statistically significant.  
 
RESULTS 
 
In vitro FaeG expression 
Overall, insertion of a Kozak sequence in pcDNA1/faeG19 significantly increased the 
FaeG expression. As can be seen in Table 2, pcDNA1/faeGK induced a 1.6- to 4.5-fold 
increase in expression. Usage of pWRG7079 instead of pcDNA1 further enhanced this 
expression in 293T and COS-7 cells. However, only in COS-7 cells, this increase was 
significant compared to the expression by pcDNA1/faeGK. Expression in both porcine cell 
lines was not improved by pWRG7079. In fact, expression became similar again to the 
expression induced by pcDNA1/faeG19. Codon-optimization of FaeG in pWRGFaeG resulted 
in the highest expression in COS-7 as well as in 293T cells, whereas expression in SK-6 and  
 
Cell 
line  
  
 
Constructs 
 
Total FaeG expression (ng/ 2x105 cells) at a 
 
 
24h                                 48h                           72h                               96h 
 
FaeG in SN (% of total FaeG expression) at: 
  
  
24h                   48h              72h          96h 
Optimized expression / unoptimized 
expression at b
 
 
24h               48h             72h              96h 
COS-7 pcDNA1/faeG19 1.6 ± 0.6 3.8±0.5 5.8±1.1 6.8±1.4 0.0±0.0 61.2±13.5 61.9±7.8 89.4±8.1         
  pcDNA1/faeGK 7.7±2.2 (1) 7.9±1.1 (1) 14.2±3.1 (1) 12.7±3.3 0.0±0.0     
        
        
                
       
        
          
        
  
            
      
           
       
         
       
29.5±8.3 55.0±8.5 93.4±2.1 4.5±0.1 2.1±0.3 2.5±0.2 2.4±0.6 
  pWRGFaeG 21.0±3.5 (1,2) 36.7±4.8 (1,2) 47.1±6.8 (1,2) 52.3±9.1 (1) 18.4±8.7 31.7±8.5 50.6±9.2 67.3±7.3 9.4±1.4 10.0±1.5 8.5±1.0 8.3±1.9
  pWRGFaeGopt 22.4±1.4 (1,2) 41.8±1.4 (1,2) 55.2±4.8 (1,2) 54.5±11.6 (2,3) 16.1±7.5 31.2±4.7 56.2±8.1 76.8±6.9 11.2±1.3 11.5±1.1 10.4±1.6 10.2±2.3
                            
293T pcDNA1/faeG19 6.8±2.3 33.0±10.9 57.5±16.1 50.5±10.1 0.0±0.0 9.0±5.3 3.1±1.0 8.3±3.0
  pcDNA1/faeGK 17.8±4.0 (1) 60.9±11.5 94.9±20.5 (1) 93.6±15.7 (1) 0.0±0.0 5.2±1.8 4.4±1.8 7.5±0.2 2.6±0.6 1.7±0.2 1.8±0.2 1.9±0.3 
  pWRGFaeG 38.5±8.7 (1) 86.0±12.1 (1) 98.3±20.7 112.6±21.5 (1) 11.5±2.0 30.4±11.0 31.4±9.2 32.8±2.0 5.7±0.5 2.5±0.4 1.9±0.3 2.3±0.3 
  pWRGFaeGopt 
 
71.5±14.4 (1,3) 
 
137.6±10.6 (1,2,3)
 
166.6±28.7 (1,2,3)
 
157.4±26.5 (1,2)
 
7.5±2.5 27.8±10.8 17.4±2.2 33.3±3.2 9.5±0.6 4.3±1.0 3.6±0.9 3.2±0.4
 
SK-6 pcDNA1/faeG19 14.7±5.4  21.5±2.7 29.8±0.5 32.4±8.1 0.0±0.0 15.5±5.1 38.4±5.9 56.7±5.8         
  pcDNA1/faeGK 27.4±8.1 (1) 43.2±3.3 (1,3) 47.2±2.9 (1,3) 49.1±10.8 (1) 
 
0.9±0.9 15.2±3.0 43.1±6.0 68.5±7.0 2.1±0.3 2.1±0.2 1.6±0.1 1.6±0.1
pWRGFaeG 16.1±4.1 15.9±4.5 26.5±6.9 27.0±8.7 13.2±10.3 40.9±9.8 76.9±3.1 84.6±5.7 1.2±0.1 0.9±0.3 0.9±0.2 0.9±0.2
  pWRGFaeGopt 35.6±8.1 (1,3) 37.7±8.0 41.2±9.7 (3) 42.1±7.8 (3) 13.6±8.5 44.1±5.2 72.1±2.7 84.9±4.6 2.7±0.3 1.9±0.6 1.4±0.3 1.5±0.4 
                            
PK-15 pcDNA1/faeG19 11.7±2.8 22.0±7.0 24.9±6.2 30.1±9.1 1.1±1.1 16.4±3.4 26.8±3.6 43.9±3.5
  pcDNA1/faeGK 22.5±7.8 37.6±10.5 (1) 44.5±16.0 54.7±18.9 0.4±0.4 13.0±2.1 30.8±4.0 54.9±4.3 1.7±0.3 2.0±0.4 1.6±0.3 1.6±0.3
  pWRGFaeG 19.2±4.0 (1) 17.0±1.9 21.9±2.7 24.1±7.0 9.5±7.0 36.9±8.7 65.0±4.4 81.7±7.1 1.8±0.2 1.4±0.7 1.0±0.2 0.9±0.1
  pWRGFaeGopt 41.1±10.2 (1,2,3) 39.1±7.7 (1,3) 43.0±9.8 (1) 50.3±15.0 (1,3) 17.2±7.0 43.6±5.6 60.9±5.7 76.7±9.2 3.6±0.2 2.5±0.8 1.8±0.2 1.7±0.1
Table 2: Influence of expression optimization on the in vitro FaeG expression in COS-7, 293T, SK-6 and PK-15  cells 
a The calculated total includes FaeG expressed in cell lysates and FaeG expressed in supernatant (SN). The numbers 1, 2, and 3 in parentheses indicate 
significant increases (P < 0.05) compared to pcDNA1/faeG19, 
pcDNA1/faeGK, and pWRGFaeG, respectively. 
b Values are ratios. Optimized expression is the total amount of FaeG expressed after transfection with pcDNA1/faeGK, pWRGFaeG, or pWRGFaeGopt. 
Unoptimized expression is the total amount of FaeG detected 
after transfection with pcDNA1/faeG19. Results are the means of 4 transfections ± SEM. 
                                                           Chapter 4: Optimization of an FaeG DNA vaccine in pigs 
PK-15 cells increased again towards the level of pcDNA1/faeGK. Only 24 h after transfection 
of the porcine cell lines, expression was higher. Taken together, vector-optimization improved 
the expression up to 1.2-, 1.8-, 5.7-, 10.0-fold and both vector- and codon-optimization 
increased the expression up to 2.7-, 3.6-, 9.5-, 11.5-fold in SK-6, PK-15, 293T and COS-7 
cells, respectively, in comparison with pcDNA1/faeG19 (Table 2). 
Following transfection with the secretion constructs pWRGFaeG and pWRGFaeGopt, no 
correlation was seen between the total amount of FaeG expressed and the amount secreted in 
the supernatant. The fraction of FaeG in supernatant increased with time, whereas this 
increase was less pronounced for the total FaeG expression, but remained remarkably lower 
for 293T cells. Transfection with the non-secretion constructs pcDNA1/faeG19 and 
pcDNA1/faeGK hardly resulted in FaeG in the supernatant after 24 h, but from then on, the 
percentage of FaeG in the supernatant also increased with time.  
 
In vivo immunogenicity of the FaeG DNA vaccines and adjuvant effect of the LT vectors  
All pigs were ID injected with pcDNA3-rpGM-CSF 1 week before the first DNA 
vaccination as we previously reported that this injection enhanced the induction of F4-specific 
immune responses (Melkebeek et al., 2006). To evaluate the influence of expression 
optimization on the immunogenicity of the FaeG DNA vaccine in pigs, we opted for 
pcDNA1/faeG19 and pWRGFaeG because we already used these constructs in an 
immunization experiment (Verfaillie et al., 2004; Melkebeek et al., 2006) and for 
pWRGFaeGopt because it gave the highest FaeG expression in porcine cells. In addition, we 
evaluated the influence of the LT vectors as LT has previously been shown to induce a 
mucosal immune response when applied to the skin (Enioutina et al., 2000; Glenn et al., 
2000).  
 
F4-specific immune responses following intradermal DNA vaccination 
ID DNA vaccination did not induce an F4-specific serum IgM response, whereas a 
statistically significant F4-specific serum IgA response was only detected in the 
pWRGFaeGopt group, from 2 weeks after the second immunization onwards. Nevertheless, 
most groups showed an IgG response of which the height and speed of onset increased in the 
order pcDNA1/faeG19, pWRGFaeG, pWRGFaeGopt (Figure 1). Indeed, none of the pigs of 
the pcDNA1faeG19 and the pWRG7079 group showed F4-specific serum IgG following 
DNA vaccination, whereas in the pWRGFaeG group, F4-specific IgG was observed in 1 pig 
on day 14 ppi and in 6 on 7 pigs 3 weeks after the second immunization. Even more pigs 
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Figure 1: Mean F4-specific serum IgA, IgG and IgM titers following 2 ID immunizations (black arrows) with 
pcDNA1/faeG19, pWRGFaeG, pWRGFaeGopt, pWRGFaeGopt plus the LT vectors or pWRG7079 (controls), 
an oral F4 protein boost (all pigs, gray arrows) and an F4+ ETEC challenge (double arrow). Shown are 
significant differences (P<0.05) of the pWRGFaeGopt group with (1) the pcDNA1/faeG19 group, (2) the control 
and the pcDNA1/faeG19 group, (3) the control, pcDNA1/faeG19 and the pWRGFaeG group, (4) all other 
groups, and of the pWRGFaeGopt + LT group with (5) the pcDNA1/faeG19 group, (6) the control and the 
pcDNA1/faeG19 group, (7) the control, pcDNA1/faeG19 and the pWRGFaeG group and (8) all other groups. 
Significant differences between time points are mentioned in the text. 
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showed F4-specific IgG in the pWRFaeGopt group, namely 4 on 7 pigs on  day 14 ppi and all 
animals on day 28 ppi. Addition of the LT vectors to pWRGFaeGopt further enhanced this 
response so that 5 on 6 pigs were positive on day 14 ppi and the whole group on day 21 ppi. 
Consequently, the F4-specific serum IgG titer was significantly higher in the pWRGFaeGopt 
+ LT and the pWRGFaeGopt groups on days 28, 35 and 43 and days 21, 28 and 35 ppi, 
respectively, than in the other groups.  
F4-specific proliferation of PBMC collected at day 35 ppi was only observed in the LT 
supplemented group (p<0.05) (Figure 2). Medium proliferation was 482 ± 235 [mean counts 
per minute (cpm) ± standard error of the mean (SEM)] and was not significantly different 
between the groups.  
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Figure 2: F4-specific proliferation of PBMC at day 35 ppi. Results are presented as cpm + 
SEM. * indicates significant differences (P<0.05) between the pWRGFaeGopt + LT group 
and the other groups. 
 
 
Oral booster immunization with F4 fimbriae 
To demonstrate priming of the intestinal mucosal immune system by the intradermal DNA 
vaccination, all pigs received an oral boost with F4. This boost slightly increased the mean 
F4-specific IgM titer within each group, but no significant differences were observed between 
the groups. The F4-specific serum IgA titer increased in only 1 pig of the pWRGFaeGopt 
group (titer 80), 1 of the LT group (titer 15) and 3 of the pWRGFaeG group (titers ranging 
from 15 to 40). No significant difference was seen between groups. However, a significant 
increase of the F4-specific serum IgG titer did occur in the pWRGFaeGopt + LT group at day 
49 ppi.  At that day, a 4.5-fold increase in the mean F4-specific IgG titer was observed in this 
group, compared to a 2-, 1.4-, 1.1- and 1.1-fold increase in the pWRGFaeGopt, the 
pWRGFaeG, the pcDNA1/faeG19 and the control group, respectively. In the latter group, 
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only the F4R+ control pigs showed this increase. Such a difference in response between F4R+ 
and F4R- pigs was not observed for the FaeG DNA primed pigs. 
To localize and quantify the antibody response following the F4 boost 3 pigs of each FaeG 
DNA vaccinated group and 2 control pigs were euthanized at day 49 or 50 ppi. One pig in 
each of these groups was F4R-  as shown in the in vitro villus adhesion assay. The most 
important difference between groups were observed in the spleen and to a lesser extent in the 
Mes LN (Figure 3). In the spleen, no IgG ASC could be observed for the control and the 
pcDNA1/faeG19 group, while all tested pigs of the 3 pWRG groups showed IgG ASC. 
Furthermore, the number of F4-specific IgG ASC increased in the order pWRGFaeG, 
pWRGFaeGopt, pWRGFaeGopt + LT group with medians of 6, 16 and 46 ASC/5x106 MC, 
respectively. Such a difference was not observed for IgM and IgA ASC, except for the 
pcDNA1/faeG19 group which showed a higher IgM response (Figure 3).  
Also in GALT, F4-specific IgG ASC could only be detected in the FaeG DNA primed 
animals. In the LP, high numbers of F4-specific IgG and low numbers of F4-specific IgM 
ASC were observed in 1 pig of the pWRGFaeG (44 and 8 ASC/5x106 MC, respectively) and 
1 pig of the pWRGFaeGopt group (82 and 6 ASC/5x106 MC, respectively) (Figure 3). These 
pigs were both F4R+. In the Mes LN, a low F4-specific IgG response could be detected in 2 
pWRGFaeG (7 and 13 ASC/5x106 MC) and 2 pWRGFaeGopt + LT primed pigs (8 and 21 
ASC/5x106 MC), irrespective of the F4R status. IgG ASC were nearly absent (< 5 ASC/5x106 
MC) in the Mes LN of the other DNA primed pigs (Figure 3) and in the IPP and JPP of all 
pigs (data not shown). Low numbers of F4-specific IgM (0 to 12 ASC/5x106 MC) and IgA 
ASC (0 to 14 ASC/5x106 MC)  could be detected in the IPP, JPP and Mes LN and in all 
GALT, respectively, independent of DNA priming (data not shown). 
In the intestinal contents, F4-specific IgA and IgG antibodies could be detected in the 
duodenum of the F4R+ pWRGFaeG pig that showed F4-specific IgG ASC in its LP and 
throughout the small intestine of the 2 F4R+ pigs of the pWRGFaeGopt group (titers of 2 to 
16, data not shown).  
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 Figure 3: F4-specific ASC per 5x106 MC in the spleen, LP and Mes LN at day 49 or 50 ppi. 
Pigs were ID immunized with DNA and orally boosted with F4 fimbriae as shown in Figure 
1. F4R- pigs are represented in grey. 
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F4+ ETEC challenge 
To determine if the induced F4-specific immune response was protective, the remaining 
pigs were intragastrically challenged with F4+ ETEC at days 51 and 52 ppi. The in vitro villus 
adhesion assay showed that 1 pig of the control group and 1 pig of the pcDNA1/faeG19 group 
were F4R-. Data from these pigs were not further considered. 
All groups excreted F4+ E. coli after challenge. Compared to the control group, excretion 
was significantly reduced in the pWRGFaeGopt group at day 7 and in the pWRGFaeGopt + 
LT group at days 6 and 7 post challenge (pc). Moreover, the duration of the faecal F4+ E. coli 
excretion was reduced in the pWRGFaeGopt + LT group compared to the control group with 
at least 2 days (P=0.081) (Figure 4).  
After challenge, the serum IgM titer increased 1.7-fold (day 58 ppi) in the control group, 
whereas almost no increase occurred in the DNA primed groups (Figure 1). Furthermore, a 
significant increase in mean serum IgG titer could be observed in the control group (P=0.025) 
at day 55 ppi. Insignificant increases occurred in the DNA primed groups, except for the 
pWRGFaeGopt and the pWRGFaeGopt + LT group. Here, the IgG titer remained 
significantly higher for the pWRGFaeGopt group till day 55 and for the pWRGFaeGopt + LT 
till day 71 ppi. The serum IgA titer slightly increased in all groups, except for the 
pWRGFaeGopt + LT group (Figure 1).  
 
 
 
Figure 4: Mean F4+ E. coli excretion per g faeces (log10 + SEM) following intragastric 
challenge with F4+ E. coli at days 51 and 52 ppi. Pigs were ID primed with DNA and orally 
boosted with F4 fimbriae as shown in Figure 1. * indicates significant differences (P<0.05) in 
excretion with the control group. 
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DISCUSSION 
 
Introducing a ‘Kozak’ consensus sequence for translation initiation (Kozak, 1987) into 
prokaryotic genes has been suggested to increase their expression level in eukaryotic cells 
(Garmory et al., 2003). Hereby, especially the presence of a purine (G/A) at the -3 and a G at 
the +4 position is supposed to be important (Kozak, 1997). As pcDNA1/faeG19 contains a T 
at -3 and an A at the +4 position, it was not surprising that insertion of a Kozak sequence 
improved the FaeG expression. The further improvement observed with the pWRG7079 
vector in COS-7 and 293T cells may be due to the presence of the intron A, which acts as an 
enhancer of the CMV IE promoter (Chapman et al., 1991; Wang et al., 2006), and/or to the 
use of the BGH polyA instead of the SV40 polyA used by pcDNA1 (Montgomery et al., 
1993; Norman et al., 1997). Presence of the tPA coding sequence could also have contributed 
as its AUG start codon is flanked by an A at -3 and a G at the +4 position. Furthermore, it 
should be mentioned that the tPA leader sequence directs FaeG to the secretory pathway, 
making it a target for N-glycosylation. Indeed, the FaeG contains 3 putative N-glycosylation 
sites. Nevertheless, although N-glycosylation of the FaeG has been demonstrated to occur in 
plants, it did not abolish the immunogenic character of the FaeG in that study (Joensuu et al., 
2006). Furthermore, as pWRGFaeG is far more immunogenic than pcDNA1/faeG19, there is 
no evidence that N-glycosylation would interfere with the immunogenicity of the FaeG in our 
study. Moreover, antibodies induced following immunization of pigs with pWRGFaeG were 
able to block adhesion of F4+ ETEC to porcine intestinal villi, indicating that they retained 
their biological activity (unpublished results). A positive influence of the pWRG7079 vector 
on expression was not observed for the PK-15 and the SK-6 cell line. Possibly, by improving 
transcription initiation and termination, the process of translation might have become rate 
limiting. Indeed, codon-optimization significantly increased the FaeG expression in these cell 
lines and in 293T cells, but not in COS-7 cells. Furthermore, COS-7 cells showed the highest 
increase in FaeG expression by using pWRG7079, suggesting that transcription rather than 
tRNA availability and/or mRNA stability were the rate limiting factors in these cells. 
Moreover, the fact that codon-optimization also appeared to be successful in the human cell 
line was not unexpected since the preferred codon usage in pigs is very similar to that in 
humans (Nakamura et al., 2000).  
In accordance with the increasing FaeG expression in vitro, F4-specific antibody responses 
were better induced in the order pcDNA1/faeG19, pWRGFaeG, pWRGFaeGopt. The failure 
of pcDNA1/faeG19 to induce an F4-specific serum antibody response is most likely due to 
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the absence of FaeG secretion, limiting the amount of antigen available for B cell priming. 
Furthermore, it can not be ruled out that differences in CpG motifs between the vectors as 
well as due to codon-optimization influenced the immunization. Indeed, it is well known that 
CpG added to a vaccine can have an adjuvant effect on the immunization via interaction with 
Toll-like receptor 9. Changes in the CpG content might thus result in changes in the adjuvant 
effect of the DNA vaccine. However, it should be mentioned that the potential adjuvant effect 
of CpG in the vaccine is still a matter of discussion  in large animals. While studies in mice 
demonstrated enhanced humoral responses by inserting CpG motifs in the vector backbone 
(Ma et al., 2002), the insertion of up to 88 ruminant-specific CpG motifs did not 
quantitatively affect the humoral response in cattle (Pontarollo et al., 2002).  
F4-specific lymphocyte proliferation of PBMC could only be demonstrated in the group 
that received the LT vectors. A positive effect of LT on cellular responses was also observed 
by Arrington et al (2002) evaluating the same vectors for their adjuvant effect in mice. In 
their study, augmented cellular responses were accompanied by a Th1-modulating effect and 
were not due to CpG motifs in the vectors, but mainly resulted from the expressed LTA and B 
subunits. In our study, addition of the LT vectors enhanced the serum IgG response, but 
abolished the serum IgA response observed following immunization with pWRGFaeGopt. 
These results were confirmed by an IgA capture ELISA (data not shown), eliminating the 
possibility that the higher IgG levels in the pWRGFaeGopt + LT group competed with 
binding of IgA in ELISA. Although cytokine expression profiles and IgG subclass ratios 
remain to be tested, a likely explanation could be the induction of a Th1-like response by 
addition of the LT vectors, as observed in mice. Indeed, Th1 is less favourable for IgA 
responses. Intradermal injection of the LT vectors was well tolerated by the pigs, as a mild 
local reaction could only be demonstrated in 3 out of 6 pigs. This reaction resolved by day 7 
(data not shown).  
The oral F4 administration induced a secondary serum IgG response in the pWRGFaeGopt 
and especially in the pWRGFaeGopt + LT group. This response was independent of the F4R 
status, which was not completely unexpected since oral F4 administration has previously been 
shown to prime systemic responses in both F4R+ and F4R- pigs (Van den Broeck et al., 2002). 
Studying the ASC in different tissues revealed that the antibody response was mainly induced 
systemically. Only few pigs showed an intestinal mucosal immune response with antibodies 
which were mainly IgG instead of IgA. Normally sIgA provides the primary defense against 
intestinal pathogens like ETEC. Nevertheless, priming with pWRGFaeGopt significantly 
reduced the faecal F4+ E. coli excretion, whereas co-administration of the LT vectors 
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additionally reduced the duration of faecal excretion. The reason for this partial protection is 
not clear but the IgG response might play a role. Indeed, a study by Yu et al (2002) 
demonstrated protection of mice against an oral LT challenge by passive infusion of serum 
derived anti-LT IgG. It has been demonstrated that IgG can be transported towards the 
intestinal lumen via the bidirectional IgG transporting neonatal Fc receptor (FcRn) (Dickinson 
et al., 1999). Expression of the FcRn receptor has been demonstrated on the intestinal 
epithelium of young and of adult humans and pigs (Israel et al., 1997; Stirling et al., 2005). 
FcRn mediated IgG transport might explain the presence of F4-specific IgG in the intestinal 
contents of some DNA primed pigs. Once in the intestinal lumen, IgG could contribute to 
protection by neutralizing adhesins so inhibiting bacterial colonisation. Indeed, oral 
administration of milk derived anti-CFA/I IgG has protected human volunteers against a 
CFA/I+ ETEC infection (Freedman et al., 1998).  
In conclusion, our results showed that optimization of the expression construct and co-
administration of the LT vectors strongly enhanced the immunogenicity of our FaeG DNA 
vaccine in pigs. Nevertheless, the ID FaeG DNA prime-oral F4 boost immunization mainly 
induced a systemic IgG response, failing to prevent F4+ E. coli excretion upon challenge. For 
the development of a vaccination strategy which can prevent postweaning diarrhea, further 
optimizations are required. Inclusion of other immunomodulators, like vitamin D3, which has 
been shown to modulate systemic responses towards mucosal ones in pigs as well as in mice 
(Enioutina et al., 1999, 2000, Van der Stede et al., 2001, 2003, 2004) or strategies which 
enable delivery of the DNA vaccine to the intestinal mucosa might result in the induction of 
the local intestinal mucosal response that is needed. 
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ABSTRACT 
 
We previously showed that an intradermal (ID) FaeG DNA prime (2x) - oral F4 protein 
boost immunization induces a systemic response and weakly primes a mucosal IgG response 
in pigs, especially when plasmid vectors encoding the A and B subunit of the E. coli thermo-
labile enterotoxin (LT) are added to the DNA vaccine. In the present study, we evaluated 
whether addition of 1alpha,25-dihydroxyvitamin D3 (vitD3) to the DNA vaccine could further 
enhance this mucosal priming and/or modulate the antibody response towards IgA. To further 
clarify priming of systemic and mucosal responses by the ID DNA vaccination, we firstly 
compared the localization of the F4-specific antibody response in pigs that were orally 
boosted with F4 to that in pigs that received a third ID DNA immunization and secondly 
evaluated cytokine mRNA expression profiles after ID DNA vaccination. The ID DNA prime 
(2x) -oral F4 boost immunization as well as the 3 ID DNA vaccinations induced mainly a 
systemic response, with a higher response observed following the heterologous protocol. Co-
administration of vitD3, and especially of the LT vectors, enhanced this response. 
Furthermore, only the heterologous immunization resulted in a weak mucosal priming, which 
appeared to require the presence of the LT vectors or vitD3 as adjuvants. In addition, the LT 
vectors strongly enhanced the FaeG-specific lymphocyte proliferation and this was 
accompanied by the absence of an IL-10 response. However, despite two DNA 
immunizations in the presence of these adjuvants and an oral F4 boost, we failed to 
demonstrate the secretory IgA response needed to be protective against enterotoxigenic E. 
coli.  
 
INTRODUCTION 
 
Enterotoxigenic E. coli (ETEC) that express F4 (K88) fimbriae are an important cause of 
diarrhoea in recently weaned piglets. The F4 fimbriae are long proteinaceous appendages 
mainly composed of several hundreds identical FaeG subunits. They enable the bacteria to 
adhere to F4-specific receptors (F4R) on the intestinal epithelium and subsequently to 
colonize the small intestine (Nagy et al., 1985). Presence of the F4R is genetically determined 
and F4R negative (F4R-) pigs are resistant to an F4 positive (F4+) ETEC infection (Rutter et 
al., 1975). It was previously shown that oral immunization of F4R+ weaned pigs with F4 
fimbriae resulted in an antigen-specific secretory IgA (sIgA) response at the intestinal 
mucosa, protecting these pigs against a subsequent F4+ ETEC challenge (Van den Broeck et 
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al., 1999a). However, to prevent post-weaning diarrhoea, an F4-specific intestinal mucosal 
immune response should already be primed during the suckling period, often in the presence 
of F4-specific maternal antibodies. These lactogenic antibodies will hamper the use of F4 as a 
vaccine. Several studies have shown that DNA vaccines, in contrast to conventional vaccines, 
can successfully prime immune responses in the presence of maternal antibodies (Hassett et 
al., 1997; Fischer et al., 2003; Van Loock et al., 2004). Therefore, we hypothesized that 
priming with an FaeG DNA vaccine during the suckling period combined with an oral F4 
protein boost immediately after weaning could be an interesting approach. However, in a 
previous study a parenteral DNA prime - oral F4 boost induced a good systemic response, but 
was weak in priming mucosal immunity, failing to completely prevent F4+ E. coli 
colonization. Furthermore, addition of plasmid vectors encoding the LTA and LTB subunits 
to the FaeG DNA vaccine enhanced the IgG response, but did not result in the sIgA response 
that is desired to completely prevent an F4+ ETEC infection. Nevertheless, a significant 
reduction was obtained in the amount of F4+ ETEC excreted as well as in the duration of 
faecal F4+ ETEC excretion (Melkebeek et al., 2007).  These data suggest that the systemic 
DNA immunization is weak in priming mucosal responses. Previous studies showed that a 
systemic immunization could  induce an intestinal mucosal IgA response in mice (Enioutina 
et al., 1999, 2000) and in pigs (Van der Stede et al., 2001, 2004) if 1alpha,25-
dihydroxyvitamin D3 (vitD3) was used as adjuvant. 
Therefore, we examined in the present study whether addition of vitD3 could enhance the 
mucosal priming by the FaeG DNA vaccination and/or whether it could modulate the 
antibody response towards IgA in the ID DNA prime – oral F4 boost immunization. 
Furthermore, to gain insight in the way systemic and mucosal responses are primed by the ID 
DNA vaccination, we compared the localization of the F4-specific antibody response in pigs 
that were orally boosted with F4 to that in pigs that were reimmunized ID with DNA and we 
evaluated cytokine mRNA expression profiles in the local draining lymph nodes after the ID 
DNA priming.  
 
MATERIAL AND METHODS 
 
Animals 
Forty-nine conventionally bred pigs (Belgian Landrace x Piétrain), seronegative for 
antibodies against F4 as determined by ELISA, were weaned at the age of 4 weeks. 
Subsequently, they were housed in isolation units. From one day before weaning, all animals 
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were orally treated with colistine (150,000 U/kg body weight; Colivet, Prodivet 
Pharmaceuticals, Eynatten, Belgium) during 5 successive days to prevent E. coli infections 
during the weaning period 
 
Isolation of F4 fimbriae 
F4 fimbriae were isolated from the ETEC strains GIS26, serotype 0149:K91:F4ac, 
LT+STa+STb+, and IMM01, serotype 0147:F4ac, LT+STb+ as described by Van den Broeck et 
al (1999a). The protein concentrations of the fimbrial solutions were determined by the 
bicinchoninic acid reaction with bovine serum albumin as a standard (ICN Biomedicals, 
Belgium) and the purity was assessed using a Coomassie stained 15% SDS-PAGE and the 
Image Master 1D prime software (Amersham Pharmacia Biotech, Belgium). GIS26 F4 
fimbriae were used for the oral immunization of pigs. The IMM01 strain carries F4 fimbriae 
with an FaeG sequence identical to the GIS26 strain, but fimbriae isolated from this strain 
have a higher purity, containing no flagellin (Verdonck et al., 2004). Therefore, IMM01 
fimbriae were used for the FaeG-specific ELISA and ELIspot assays and, after sterilization by 
filtration through a 0.2 µm filter, in an FaeG-specific lymphocyte proliferation assay.  
 
Plasmids and 1α,25(OH)2D3
The pcDNA3-rpGM-CSF plasmid consists of the cDNA encoding the porcine GM-CSF 
cloned in the pcDNA3.1zeo expression vector.  
The pWRGFaeGopt vaccine was constructed as previously described (Melkebeek et al., 
2007). This construct consists of a codon optimized faeG cloned into the pWRG7079 vector 
behind a tPA signal sequence, allowing the extracellular secretion of the encoded FaeG. The 
pJV2004 and pJV2005 plasmids consist of the pWRG7054 vector encoding the A and B 
subunit of the thermolabile enterotoxin of E. coli (LT), respectively, behind a tPA signal 
sequence to allow their extracellular secretion (Arrington et al., 2002). All plasmids were 
propagated in E. coli DH5α and large-scale purification of the plasmids was conducted by 
Qiagen Endofree plasmid kits (Qiagen GmbH, Germany). After determining purity and 
concentration by measuring the OD at 260 and 280 nm, the plasmids were stored at –20°C.  
1α,25(OH)2D3 (vitD3) (Sigma), was dissolved in absolute ethanol at a concentration of 200 
µg/ml and stored at 4° C. 
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Hereto, 23 pigs were used (Table 1). One week postweaning, they were divided into 4 
groups and were all injected intradermally (ID) at the left site of the neck with 250 µg of 
pcDNA3-rpGM-CSF. Seven and 28 days later (days 0 and 21 post primary immunization 
(ppi)), the pigs were ID immunized at this site (at the pcDNA3-rpGM-CSF injection site) with 
500 µg of pWRGFaeGopt (n=7, pWRGFaeGopt group), pWRGFaeGopt supplemented with 
100µg pJV2004 and 100µg pJV2005 (collectively referred to as the LT vectors) (n=7, 
pWRGFaeGopt + LT group), pWRGFaeGopt supplemented with 5 µg of vitD3 (n=5, 
pWRGFaeGopt + vitD3 group) or the empty pWRG7079 vector (n=4, pWRG7079 group). At 
day 42 ppi, 4 pigs of both the pWRGFaeGopt and the pWRGFaeGopt + LT group and 2 pigs 
of both the pWRGFaeGopt + vitD3 and the pWRG7079 group received an identical ID 
booster immunization, whereas the remaining pigs (3 pigs of each immunized group and 2 
pigs of the pWRG7079 group) were orally boosted with 1 mg F4 fimbriae diluted in 10 ml 
PBS during 3 successive days (day 42, 43 and 44 ppi, respectively). The animals were 
deprived of food and water from 3h before till 2h after the oral immunization. The F4-specific 
humoral immune response was analyzed weekly by determining the F4-specific IgG, IgA and 
IgM titer in the serum of all pigs starting from day -7 till day 48 ppi. In order to localize and 
quantify the antibody response, the pigs were euthanized 6 or 7 days after the third 
immunization (day 48 or 49 ppi, respectively) for enumeration of the F4-specific IgG, IgA 
and IgM antibody-secreting cells (ASC) in the lymph node draining the DNA vaccination site 
(cervical superficial dorsal lymph node (Cerv LN)), the mesenteric LN (Mes LN), the ileal 
and jejunal Peyer’s patches (IPP and JPP), the jejunal lamina propria (LP) and the spleen. To 
evaluate the induction of an F4-specific cellular response, an F4-specific lymphocyte 
proliferation assay was performed on spleen monomorphonuclear cells (MC). Since the F4 
receptor (F4R) is essential for inducing an intestinal IgA response, the presence of the F4R 
was determined on small intestinal villi as earlier described.  
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A first experiment was performed to confirm the induction of an F4-specific systemic 
immune response by ID immunization with pWRGFaeGopt or pWRGFaeGopt in 
combination with the LT vectors as well as the priming of an F4-specific intestinal mucosal 
IgG response by ID immunization with these vectors followed by an oral F4 boost as seen in a 
previous study (Melkebeek et al., 2007). Furthermore, we wanted to evaluate if the 
immunomodulating adjuvant vitD3 could enhance the mucosal priming by the FaeG DNA 
vaccine and/or modulate the induced response towards an IgA response.  
Experiment 1 
Experimental procedure 
 
Group Day -7 DNA vaccine  
(days 0 and 21 ppi) 
Third immunization  
(day 42 ppi) 
Total 
number 
of pigs 
F4R+ 
pigs 
F4R- 
pigs 
pWRG7079 
(control) 
pcDNA3-rpGM-CSF    pWRG7079 pWRG7079
oral F4 
2 
2 
1 
1 
1 
1 
pWRGFaeGopt 
(FaeG) 
pcDNA3-rpGM-CSF    
   
 
pWRGFaeGopt pWRGFaeGopt
Oral F4 
4 
3 
3 
1 
1 
2 
pWRGFaeGopt+LT (LT) pcDNA3-rpGM-CSF pWRGFaeGopt+LT pWRGFaeGopt+LT
oral F4 
4 
3 
3 
1 
1 
2 
pWRGFaeGopt+vitD3 
(vitD3) 
pcDNA3-rpGM-CSF pWRGFaeGopt+vitD3 pWRGFaeGopt+ 
vitD3  
oral F4 
2 
3 
1 
2 
1 
1 
         Table 1: Experimental design of experiment 1 
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Experiment 2 
A second experiment was performed to examine the induction of cellular immune 
responses (FaeG-specific lymphocyte proliferation and cytokine mRNA expression) in the 
local draining lymph node (Cerv LN) following priming with the FaeG DNA vaccine and to 
evaluate the influence of the intradermal LT vectors or vitD3 on these cellular responses. 
Hereto, 26 pigs were used (Table 2). One week after weaning, 6 pigs were ID injected in the 
neck with sterile PBS (PBS group) and the other pigs with 250µg of pcDNA3-rpGM-CSF. 
Seven and 28 days later (days 0 and 21 ppi), the pigs were ID injected at the same site with 
PBS (pigs from the PBS group) or 500 µg of pWRGFaeGopt (n=5, pWRGFaeGopt group), 
pWRGFaeGopt supplemented with 100µg of each LT vector (n=6, pWRGFaeGopt + LT 
group), pWRGFaeGopt supplemented with 5 µg of vitD3 (n=5, pWRGFaeGopt + vitD3 
group) or pWRG7079 (n=4, pWRG7079 group). The pigs were euthanized 24 or 48 hours 
after the second immunization (psi) as shown in Table 2 and for each pig the cervical 
superficial dorsal LN was collected at the left site (Cerv LN) and the right site (control Cerv 
LN) of the neck to analyze cytokine expression profiles. Cerv LN MC isolated at 48 hours psi 
were also used in an F4-specific lymphocyte proliferation assay. 
 
Table 2: Experimental design of experiment 2 
Group  Total 
number 
of pigs 
Day -7 Days 0 and 21 
ppi 
Number 
of pigs 
at 24h 
psi 
Number 
of pigs at 
48h psi 
PBS 6 PBS PBS 3 3 
pWRG7079 4 
 
pcDNA3- rpGM-CSF pWRG7079 2 2 
pWRGFaeGopt 5 
 
pcDNA3- rpGM-CSF pWRGFaeGopt 3 2 
pWRGFaeGopt+LT 6 pcDNA3- rpGM-CSF pWRGFaeGopt
+LT 
2 4 
pWRGFaeGopt+vitD3 5 pcDNA3- rpGM-CSF pWRGFaeGopt
+vitD3 
2 3 
 
 
 
In both experiments, plasmids were diluted in 1 ml sterile PBS and both the ID injection 
with pcDNA3-rpGM-CSF as the ID immunizations were performed by multiple injections. 
Euthanasia of all pigs was performed by intravenous injection of pentobarbital (24 mg/kg; 
Nembutal, Sanofi Santé Animale, Brussels, Belgium) followed by exsanguinations.  
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Spleen, Cerv LN, Mes LN, JPP, IPP and LP MC 
MC were isolated from the spleen, Cerv LN, Mes LN (jejunal and ileal), JPP, IPP and LP 
as described by Verdonck et al. (2002) and finally resuspended in leukocyte medium [RPMI-
1640 (GIBCO BRL) supplemented with penicillin (100 IU/ml) (GIBCO BRL), streptomycin 
(100µg/ml) (GIBCO BRL), kanamycin (100 µg/ml) (GIBCO BRL), L-glutamin (200 mM) 
(GIBCO BRL), sodiumpyruvate (100mM) (GIBCO BRL), non-essential aminoacids (100 
mM) (GIBCO BRL), 2-mercaptoethanol (5x10-5 M) (GIBCO BRL) and either 5% serum of a 
colostrum-deprived pig for the lymphocyte proliferation assay or 10% FCS for the ELISPOT 
assay]. Cerv LN MC were also resuspended in TRIzol Reagent (Invitrogen, Merelbeke, 
Belgium) (Cerv LN) to analyze cytokine mRNA expression.  
 
RNA extraction and RT-PCR 
RNA was extracted from 107 MC/sample using TRIzol Reagent following the 
manufacturer’s protocol. Reverse transcription was performed as described by Verfaillie et al. 
(2005). The oligonucleotide primers described by Verfaillie et al. (2005) were used for the 
detection of the porcine cytokines IL-2, IL-4, IL-6, IL-10, TGF-β, IFN-γ, TNF-α and of 
cyclophilin cDNA. Oligonucleotide primers used for the detection of β-actin and GAPDH 
cDNA were designed from the published nucleic acid sequences available from the 
GenBank/EMBL databases using the primer3 software 
(http://frodo.wi.mit.edu/cgibin/primer3/primer3_www.cgi) (Table 3).  
Real-time PCR reactions were carried with the LightCycler and the LightCycler-faststart 
DNA Master SYBR Green I kit (Roche, Mannheim, Germany). The reactions for IL-2, IL-4, 
IL-6, IL-10, TGF-β, IFN-γ, TNF-α and of cyclophilin were performed as described by 
Verfaillie et al (2005). For β-actin and GAPDH, the reaction mixture was made following the 
manufacturer’s protocol using 3 mM MgCl2. After heating the samples at 95° C for 10 min, 
the temperature cycling  consisted of denaturation at 94° for 15 s, annealing at 53° C 
(GAPDH) or 60° C (β-actin) for 5 s, and extension at 72° C for 14 s. For β-actin 35 cycles and 
for GAPDH 40 cycles were performed. Fluorescence acquisition was measured at 85°C in 
single mode. Melting curve analysis was done at 65-98°C with continuous fluorescence 
acquisition. As an additional control of specificity, PCR products were subjected to agarose 
gel electrophoresis. Quantification occurred using external standards of cDNA and the copy 
number of each sample transcript was determined with the aid of the LightCycler software. 
Cyclophilin, GAPDH and β-actin were used as constitutively expressed reference genes and a 
normalization factor (NF) was calculated as the geometric mean of the copy numbers of these  
 102 
  Chapter 5: Comparison of immune responses 
Table 3 :Oligonucleotide primers and fragment length of PCR products for different porcine 
cytokines 
cytokine Primers (5’-3’) Length 
PCR 
fragment 
Genbank 
accession 
number 
 
IL-1α 
 
 
(S) TGCCAGCTATGAGCCACTTCC 
(AS) TGACGGGTCTCGAATGATGCT 
 
 
336 
 
X52731 
 
IL-2 
 
 
(S) GATTTACAGTTGCTTTTGAAG 
(AS) GTTGAGTAGATGCTTTGACA 
 
 
338 
 
X56750 
 
IL-4 
 
 
(S) TACCAGCAACTTCGTCCA 
(AS) ATCGTCTTTAGCCTTTCCAA 
 
 
311 
 
F68330 
 
IL-6 
 
 
(S) ATGAGAATCACCACCGGTCTTG 
(AS) TGCCCCAGCTACATTATCCGA 
 
 
310 
 
M86722 
 
 
IL-10 
 
 
(S) CCATGCCCAGCTCAGCACTG 
(AS) CCCATCACTCTCTGCCTTCGG 
 
 
295 
 
L20001 
 
IFN-γ 
 
 
(S) ATGTACCTAATGGTGGACCTC 
(AS) CTCTCTGGCCTTGGAACATAG 
 
 
360 
 
X53085 
 
TGF-β 
 
 
(S) GACCCGCAGAGAGGCTATAG 
(AS) GAGCCAGGACCTTGCTGTAC 
 
 
399 
 
Y00111 
 
TNF-α 
 
 
(S) CAAGGACTCAGATCATCGTCTCA 
(AS) CATACCCACTCTGCCATTGGA 
 
 
100 
 
X54859 
 
Cyclophilin 
 
 
(S) TAACCCCACCGTCTTCTT 
(AS) TGCCATCCAACCACTCAG 
 
 
368 
 
F14571 
 
Β-actin 
 
 
 
(S) ACGTGGACATCAGGAAGGAC 
(AS) ACATCTGCTGGAAGGTGGAC 
 
210 
 
U07786 
 
GAPDH 
 
(S) GGGCATGAACCATGAGAAGT 
(AS) AAGCAGGGATGATGTTCTGG 
 
230 
 
AF017079 
(S) : sense ; (AS) : antisense 
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3 genes to determine the uniformity of the reverse transcription and as a reference for 
quantification of cytokine mRNA.  The relative amounts of cytokine-expression were 
calculated as a ratio of the copy number of the target cytokine over the NF and results are 
presented as the ratio of the relative amount of the target cytokine in the immunized Cerv LN 
over the relative amount of the target cytokine in the control Cerv LN (=(copy number of 
target cytokine in the Cerv LN / NF in the Cerv LN) / (copy number of target cytokine in the 
control Cerv LN / NF in the control Cerv LN)).  
 
FaeG-specific lymphocyte proliferation assay. 
To determine the FaeG-specific lymphocyte proliferation, a proliferation assay as 
described by Van der Stede et al (2003) was performed on spleen or Cerv LN MC by adding 
F4 fimbriae (final concentration of 15 µg/ml), medium (negative control) or concanavalin A 
(ConA, final concentration of 10 µg/ml, positive control) to the wells of a 96-well plate 
(Cellstar, Greiner bio-one, Wemmel, Belgium) containing 5x105 cells/well (final volume of 
200 µl). After 72 h at 37 °C in 5% CO2, cells were pulse-labelled with 3H-thymidine 
(1 µCi/well) (Amersham ICN, Bucks, UK) and 18 h later, they were harvested onto glass fibre 
filters. The radioactivity incorporated into the DNA was measured with a β-scintillation 
counter (Perkin-Elmer, Life Science, Brussels, Belgium). 
 
ELISA for FaeG-specific serum IgG, IgA and IgM antibodies 
FaeG-specific titers were determined by an indirect ELISA on serum sampled as described 
by Van den Broeck et al. (1999b). Hereto, the wells of a 96-well microtitre plate (NUNC, 
Polysorb Immuno Plates, Roskilde, Denmark) were coated with IMM01 F4 fimbriae at a 
concentration of 5 µg/ml in PBS. After 2 h incubation at 37° C, the remaining binding sites 
were blocked overnight at 4° C with PBS supplemented with 0.2% Tween® 80 (Merck 
Eurolab, Leuven, Belgium). Subsequently, the sera were added for 1 h at 37° C in series of 2-
fold dilutions in ELISA dilution buffer (PBS, pH 7.4 + 0.2 % Tween® 20 + 3 % BSA), 
starting at a dilution of 1/10. Then, optimal dilutions of anti-swine IgM-, IgA- or  IgG-specific 
MAb (28.4.1, 27.8.1 and 23.3.1b, respectively, Van Zaane and Hulst, 1987) in ELISA dilution 
buffer were added to the wells for 1 h at 37° C. Thereafter, rabbit anti-mouse HRP-conjugated 
serum (Dako, Denmark) optimally diluted in ELISA dilution buffer and supplemented with 
2% pig serum was added for 1 h at 37° C. Finally, ABTS (Roche Diagnostics, Brussels, 
Belgium), containing H2O2, was added and after 30 minutes incubation at 37° C, the optical 
density was measured spectrophotometrically at 405 nm (OD405). Between each incubation 
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step, the plates were washed 3 times with ELISA washing buffer (PBS, pH 7.4 + 2% Tween 
20). Cut-off values were calculated as the mean OD405 of all sera (dilution 1/10) on day 0 ppi 
increased with three times the standard deviation and were 0.16, 0.23 and 0.63 for IgA, IgG 
and IgM, respectively. The antibody titer was the inverse of the highest dilution which still 
had an OD405 higher than the calculated cut-off values. 
 
Elispot assay for FaeG-specific IgG, IgA and IgM ASC 
F4-coated plates were prepared as described for the ELISA. Thereafter, MC suspensions at 
a concentration of 107cells/ml were added (100 µl/well) and plates were incubated for 14 h at 
37° C in a humidified 5% CO2 atmosphere. Subsequently, the cells were removed by six 
washes with ELISA washing buffer whereafter wells were sequentially incubated for 1 h at 
37° C with the anti-swine IgM-, IgA- or IgG-specific MAb and with a rabbit anti-mouse 
HRP-conjugated serum. Between these steps, the plates were washed 3 times with ELISA 
washing buffer. Subsequently, a substrate solution, consisting of 4 volumes of 3-amino-9-
ethylcarbazole (AEC)  (Sigma) working solution (0.67 ml AEC stock solution (0.4% in 
dimethylformamide) in 10 ml Na acetate (0.1 M, pH 5.2) + 10 µl 30% H2O2) and 1 volume of 
3% low-melting-point agarose (BIOzym, Landgraaf, The Netherlands) was added. After 
overnight incubation in the dark at room temperature, spots were counted with an inverted 
microscope. For each MC suspension, spots in 5 wells (106 MC/well) were counted to obtain 
the number of isotype-specific ASC/5 x 106 MC. Results are presented as the mean number of 
ASC per 5x106 MC ± SEM.  
 
Statistical analysis 
Statistical analysis was done using SPSS 12.0 for Windows. Analysis of differences 
between the groups in log2 serum antibody titers was done using General Linear Model 
(Repeated Measures Analysis of Variance) using the Bonferoni adjustment for multiple 
comparisons. Differences between groups in lymphocyte proliferation and in relative increase 
in cytokine expression at the immunization site were tested for statistical significance with the 
Kruskal-Wallis Test. P ≤ 0.05 was considered as statistically significant.  
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RESULTS 
 
A. EXPERIMENT 1: FaeG-specific antibody responses following DNA vaccination 
 
F4R characterization of the pigs 
As shown in Table 1, the in vitro villous adhesion assay demonstrated that 6 of the 11 pigs 
that were orally boosted with F4 and 4 of the 12 pigs that were ID boosted with DNA lacked 
the F4R.  
 
FaeG-specific serum antibody response following 2 intradermal DNA vaccinations 
Pigs were immunized ID with DNA at days 0 and 21 ppi. Since pre-injection with 
pcDNA3-rpGM-CSF enhances both humoral and cellular responses in pigs (Melkebeek et al., 
2006), all pigs received an ID injection with this plasmid seven days before the first 
immunization (Table 1). 
FaeG-specific serum IgG was already observed after 1 immunization with pWRGFaeGopt 
and addition of LT enhanced this IgG response (Figure 1). VitD3 was a less powerfull 
adjuvant, enhancing the IgG response to a lesser extend. Control animals vaccinated with 
pWRG7079, did not show an IgG response. Consequently, the mean FaeG-specific IgG titer 
was significantly higher in the pWRGFaeGopt + LT than in the pWRGFaeGopt and the 
pWRG7079 group and in the pWRGFaeGopt + vitD3 group than in the pWRG7079 group 
from 7 days after the second immunization (day 28 ppi) till the third immunization (day 42 
ppi).  
Levels of FaeG-specific IgA and IgM antibodies remained very low (mean titers ≤ 18 in all 
groups).  
 
FaeG-specific responses following an oral F4 boost or a third ID DNA vaccination   
To determine if the ID DNA vaccination induced an FaeG-specific intestinal mucosal 
antibody response or primed the gut-associated lymphoid tissues (GALT), pigs were either 
immunized a third time with DNA (day 42 ppi) or obtained an oral boost with 1 mg F4 
fimbriae during 3 successive days (day 42, 43 and 44 ppi) (Table 1). Mucosal and systemic 
responses were analyzed 6 or 7 days later. 
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Figure 1: FaeG-specific serum IgG, IgA and IgM titers following 2 ID immunizations with 
pWRGFaeGopt (n=7), pWRGFaeGopt + LT (n=7), pWRGFaeGopt + vitD3 (n=5) or 
pWRG7079 (controls, n=4) (days 0 and 21 ppi, black arrows). Significant differences 
(P<0.05) between the pWRGFaeGopt + LT group and the pWRGFaeGopt and the control 
group and between the pWRGFaeGopt + vitD3 group and the control group are indicated with 
*. Results are presented as means ± SEM. 
 
 
 
 
The FaeG-specific serum antibody response 
Both the oral F4 boost and the ID DNA vaccination further enhanced the FaeG-specific 
serum IgG titers in all the FaeG DNA primed groups, irrespective of the F4R status of the 
animals, whereas the pWRG7079 animals remained negative (Figure 2).  
None of the groups showed increased FaeG-specific serum IgA or IgM titers following the 
DNA or the F4 boost (data not shown).  
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Figure 2: Mean FaeG-specific serum IgG titer at the day of the third immunization (day 42 
ppi) and 6 days later (day 48 ppi). Pigs were immunized as shown in Table 1. 
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Localization of the FaeG-specific antibody response 
FaeG- specific ASC were mainly detected in the Cerv LN (Figure 3) and to a lesser extend 
in the spleen (Figure 4). In the control group, no FaeG-specific ASC were identified in the 
Cerv LN whereas a background of FaeG-specific IgM was identified in the spleen after the 
third injection with pWRG7079 (negative controls, 16-21 ASC/5x106 MC) as well as after the 
oral F4 immunization (18-44 ASC/5x106 MC).  
In all FaeG DNA vaccinated groups, the third ID DNA vaccination induced mainly FaeG-
specific IgG (7-305 ASC/ 5x106 MC) and to a lesser extend IgM ASC (3-92 ASC/ 5x106 MC) 
in the Cerv LN whereas mainly IgM (15-209 ASC/ 5x106 MC) and to a lesser extend IgG 
ASC (0-39 ASC/ 5x106 MC) were induced in the spleen. Moreover, the numbers of FaeG-
specific ASC in the Cerv LN and the spleen were comparable for the three FaeG DNA 
vaccinated groups. For FaeG-specific IgA, lower numbers of ASC could only be detected in 
the Cerv LN of most animals in all vaccinated groups (0-29 ASC/5x106 MC). 
In the pWRGFaeGopt group, the oral F4 boost induced comparable FaeG-specific antibody 
responses in the Cerv LN and the spleen as the third ID DNA immunization. Indeed, similar 
mean numbers of FaeG-specific IgG ASC were detected in the Cerv LN of orally and ID 
boosted pigs (122 and 131 ASC/ 5x106 MC, respectively). In addition, also mainly FaeG-
specific IgM ASC were found in the spleen of the orally boosted pigs of this group. In the 
pWRGFaeGopt + LT and the pWRGFaeGopt + vitD3 group however, the oral F4 seemed to 
“boost” the systemic antibody response stronger than the third ID DNA immunization did. 
Indeed, in the Cerv LN of these groups, larger numbers of FaeG-specific IgG ASC were 
detected in the orally boosted pigs (143-696 and 69-854 ASC/ 5x106 MC for the 
pWRGFaeGopt + LT and the pWRGFaeGopt + vitD3 group, respectively) than in pigs that 
were immunized 3 times with DNA. Moreover, the FaeG-specific ASC in the spleen of the 
orally boosted pigs were mainly IgG (39-96 and 28-53 ASC/ 5x106 MC for the 
pWRGFaeGopt + LT and the pWRGFaeGopt + vitD3 group, respectively), whereas it was 
meanly IgM following the third DNA immunization. After the oral F4 boost, FaeG-specific 
IgA ASC could not be detected in the Cerv LN. However, few FaeG-specific IgA ASC could 
be detected in the spleen of all three FaeG DNA primed groups (0 to 4 ASC/ 5x106 MC, 
respectively). 
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 Figure 3: FaeG-specific IgM, IgA and IgG ASC/5x106 MC in the Cerv LN 6 or 7 days 
(day 48 or 49 ppi) after the third ID DNA vaccination or the oral F4 boost. Pigs were 
immunized as shown in Table 1. 
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Figure 4: FaeG-specific IgM, IgG and IgA ASC/5x106 MC in the spleen 6 or 7 days (day 48 
or 49 ppi) after the third ID DNA vaccination or the oral F4 boost. Pigs were immunized as 
shown in Table 1. 
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In the GALT, low numbers of IgA and IgM ASC could be detected in the orally boosted 
pigs of the pWRG7079 control group (up to 3 and 12 ASC/5x106 MC, respectively) whereas 
higher numbers were seen in some FaeG DNA primed orally boosted pigs. Indeed, high 
numbers of IgM ASC could be detected in the IPP, JPP and Mes LN of one F4R-positive pig 
primed with pWRGFaeGopt + vitD3 (10-173 ASC/ 5x106 MC). An improved intestinal IgM 
response by DNA priming could also be observed in the LP of two F4R-negative pigs of the 
pWRGFaeGopt + LT group (21 and 35 ASC/ 5x106 MC), and in the IPP and JPP of one of 
these pigs and of one pig of the pWRGFaeGopt group (up to 31 and 28 ASC/ 5x106 MC, 
respectively). For these pigs, the numbers of IgA ASC were between 0 and 7 ASC/5x106 MC 
in the IPP, JPP and Mes LN and up to 25 ASC/5x106 MC in the LP.  
The oral F4 boost seemed to weakly induce an IgG response in the GALT of DNA primed 
pigs. Indeed, IgG ASC could be detected in the GALT of some of the FaeG DNA primed 
pigs, whereas none of the control pigs showed IgG ASC in their GALT (Figure 5). However, 
only in the F4R-positive pig of the pWRGFaeGopt + vitD3 group with high numbers of 
intestinal IgM ASC, the numbers of FaeG-specific IgG ASC were consistently high in all 
examined GALT (22-346 ASC/ 5x106 MC). In all other DNA primed pigs which received an 
oral F4 boost, except for one pig of the pWRGFaeGopt group, the numbers of IgG ASC were 
between 1 and 14 in the Mes LN. This was irrespective of the F4R status of the animals and 
occurred in higher numbers in both adjuvanted groups. In the other GALT, FaeG-specific IgG 
ASC could be detected in low numbers (1 to 4 ASC/ 5x106 MC) (Figure 5). This was mainly 
seen in the pWRGFaeGopt + LT group and more sporadically in both other DNA primed 
groups.  
After three ID DNA immunizations, none of the pigs showed a clear FaeG-specific IgG, 
IgA or IgM response in their GALT (data not shown).  
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Figure 5: FaeG-specific IgG, IgA or IgM ASC/5x106 MC in the LP, IPP, JPP and MLN 6 or 7 
days (day 48 or 49 ppi) after the oral F4 boost. Pigs were primed by 2 ID DNA 
immunizations as shown in Table 1.  
 
 
B. EXPERIMENT 2: Cellular responses following DNA vaccination 
 
Cytokine expression profiles in the local draining lymph node  
To assay cytokine mRNA expression profiles following DNA vaccination,  induction of 
IL-1α, IL-6, TNF-α (pro-inflammatory cytokines), IL-2, IFN-γ (Th1-like cytokines), IL-4, IL-
10 (Th2-like cytokines) and TGF-β (Th3-like cytokine) mRNA expression was evaluated 24 
and 48 h psi (Figure 6, Table 2). 
At 24h psi, a proinflammatory cytokine mRNA expression could already be observed after 
injection of the empty pWRG7079 vector for TNF-α, IL-1 and IL-6 (1.6-, 3.2- and 9.4-fold, 
respectively) and to a lesser extend after PBS injection for IL-1 and IL-6 (1.5-and 6.7-fold 
increase, respectively).  Only the IL-6 mRNA expression was increased more strongly by the 
FaeG expression (pWRGFaeGopt group, 18.3-fold). A similar increase in IL-6 mRNA 
expression could also be observed in the pWRGFaeGopt + vitD3 group (14.5-fold), but not in 
the pWRGFaeGopt + LT group, as the mean increase in IL-6 mRNA expression in this group 
(3.7-fold) was even lower than in the control groups. At 48h psi, the IL-6 mRNA expression 
was already strongly decreased, whereas the IL-1 mRNA expression was increased in the 
vitD3 group. TNF-α mRNA expression remained similar in most groups. 
For IL-10, IFN-γ and TGF-β mRNA, effects were most pronounced 48h psi. Expression of 
TGF-β mRNA expression was increased following FaeG DNA vaccination and addition of 
LT and vitD3 enhanced this increase. A strong increase in IL-10 mRNA expression could be 
observed for one pig of the pWRG7079, the pWRGFaeGopt and the pWRGFaeGopt + vitD3 
group, whereas none of the pigs from the LT adjuvanted groups showed this increase. For 
IFN-γ, a strong increase in mRNA expression could only be observed for one pig of each 
adjuvanted group.  
IL-2 and IL-4 mRNA were hardly detected and are therefore not shown.  
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Figure 6: Cytokine mRNA expression (TNF-α, IL-6, IL-1, TGF-β, IL-10 and IFN-γ) at 24 and 
48h psi. Pigs are immunized as shown in Table 2. Increases in cytokine mRNA expression by 
ID DNA vaccination are given as a ratio (=(copy number of target cytokine in the Cerv LN / 
NF in the Cerv LN) / (copy number of target cytokine in the control Cerv LN / NF in the 
control Cerv LN))  
 
 
 
FaeG-specific lymphocyte proliferation 
To analyze cellular (memory) immune responses following ID DNA vaccination, MC 
isolated from the Cerv LN 48h psi or from the spleen 6 or 7 days after the third immunization 
(pigs from experiment 1) were restimulated in vitro with F4 (Figure 7).  
At 48h psi, a strong FaeG-specific proliferation could only be observed in MC from the 
Cerv LN of 3 on 4 pWRGFaeGopt + LT (cpm between 36921 and 134394) and 1 on 3 
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pWRGFaeGopt + vitD3 vaccinated pigs (73606 cpm). Interestingly, for each pig that showed 
a strong increase in IL-10 mRNA expression, the FaeG-specific proliferation was decreased 
more than 1.7 fold compared to spontaneous medium proliferation  (data not shown).  
Also for spleen cells isolated after three DNA immunizations, FaeG-specific lymphocyte 
proliferation was best induced in the pWRGFaeGopt + LT group. Indeed, a clear FaeG-
specific proliferation (cpm > 5000) could be observed for 3 on 4 pigs of this group (cpm 
between 8420 and 23167), compared to 1 on 4 pigs of the pWRGFaeGopt and 1 on 2 pigs of 
the pWRGFaeGopt + vitD3 group (cpm of 7758 and 8254, respectively). Moreover, in both 
the Cerv LN after 2 DNA immunizations and the spleen after 3 ID DNA vaccinations, the 
mean cpm value was significantly higher in the pWRGFaeGopt + LT group than in the 
pWRGFaeGopt group. After the oral F4 boost, a clear FaeG-specific proliferation was only 
seen in 1 on 3 pigs of the pWRGFaeGopt + LT group (18483 cpm).  
Spontaneous proliferation was 2260 ± 431 for the Cerv LN and 1888 ± 213 for the spleen. 
 
 
Cerv LN 
 
 
Figure 7: FaeG-specific proliferation of Cerv LN MC at 48h psi (A) and spleen MC 6 or 7 
days (day 48 or 49 ppi) after the third immunization. Pigs were immunized as shown in Table 
2 and Table 1, respectively. * indicates a significant difference between the pWRGFaeGopt + 
LT group and all other groups (P≤0.05) 
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or IgM response could not be observed in the present study. This was in contrast to our 
previous data where a low FaeG-specific IgA response could additionally be observed after 
ID pWRGFaeGopt immunization, but not when the LT vectors were added (Melkebeek et al., 
2007). These contradicting findings might result from differences in origin of the pigs. 
Indeed, individual variation in immune responses, including Ig isotype responses, has been 
described for outbred pigs and has been attributed to differences in genetic background and 
environmental factors (Crawley et al., 2003, Wilkie and Mallard, 1999). A second reason 
could be an unnoticed minor contact with F4. Indeed, it has been described that intestinal 
priming can result in an IgA response following parenteral immunization (Svennerholm et al., 
1980). Although farms were carefully selected for absence of F4+ ETEC related problems, 
litters were tested to be F4-seronegative and pigs were orally treated with colistine to prevent 
infection during the weaning period, a risk for such a contact can not absolutely be excluded.   
Our inability to demonstrate a serum IgM reponse is likely due to the high cut off value in 
the IgM ELISA. An IgM background is often observed when young animals are tested. This 
is likely non-specific as even for gnotobiotic piglets, cut off values near 0.4 could be observed 
in F4-specific serum IgM ELISA (recent unpublished data from our lab). Furthermore, also in 
lymphoid tissues, a background of IgM ASC is often observed (Van den Broeck et al., 1999b; 
Verdonck et al., 2002; Snoeck et al., 2006a), even for F4R- pigs which are resistant to F4+ 
ETEC infection. 
After both the third ID DNA immunization and the oral F4 boost, antibody responses were 
mainly located systemically. After the ID DNA boost, responses in the adjuvanted groups 
were not better than those in the pWRGFaeGopt group, suggesting that other tissues, such as 
the bone marrow, might account for the higher serum IgG titer in these groups. Indeed, a 
study by Bianchi et al. (1999) demonstrated that the bone marrow is the major site of IgG 
production in pigs, containing 40% of all IgG secreting cells.  
The presence of low numbers of IgA ASC in the Cerv LN following three intradermal 
DNA vaccinations is in line with our previous data indicating that ID DNA vaccination 
preceded by GM-CSF DNA injection primes a serum IgA response that can be boosted 
systemically (Melkebeek et al., 2006) but not mucosally (Melkebeek et al., 2007). An IgA 
response following systemic immunization was also seen in earlier studies in pigs (Van der 
Stede et al., 2002) and was more efficiently induced by immunizing in the neck compared to 
the back. The dorsal superficial cervical LN draining the neck region is connected to lymph 
nodes draining mucosal sites (mandibular and medial retropharyngeal LN draining tonsils and 
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nasal mucosa), which might be more beneficial for the induction of IgA (Vanderpooten et al., 
1997). 
Compared to the ID DNA boost, the oral F4 boost was clearly more immunogenic for the 
adjuvanted groups, as judged by an enhanced isotype switching towards IgG in the spleen and 
increased numbers of IgG ASC in the Cerv LN. This is in agreement with other studies 
demonstrating that prime-boost immunizations by alternating routes and/or immunization 
forms are as immunogenic or more immunogenic than homologous prime-boost 
immunizations (Baca-Estrada et al, 2000; McCluskie et al, 2002, Lauterslager et al., 2003). 
As observed previously (Melkebeek et al., 2007), boosting of systemic responses in 
parenterally primed pigs by oral F4 administration appeared to be independent of the F4R 
status of the pigs.  
Besides inducing a systemic response, parenteral immunization, for example with live 
attenuated pathogens (Coffin et al., 1995) or in the presence of immunomodulating adjuvants 
like vitD3, enterotoxins or chemical enhancers of cAMP (Enioutina et al., 1999, 2000; Van 
der Stede et al., 2004) has also been demonstrated to induce IgA ASC in the GALT. In our 
study however, an intestinal mucosal antibody response was nearly undetectable following ID 
DNA immunization. After the oral boost, the intestinal FaeG-specific IgA and IgM response 
were variable and an improvement by DNA priming could only be observed for a few pigs. In 
line with our previous results (Melkebeek et al., 2007), IgG ASC could be detected in the Mes 
LN of the DNA primed and especially of the adjuvanted groups. Moreover, although the 
presence of the F4R is required to induce IgA and IgM ASC in the Mes LN and other GALT 
of naïve pigs following multiple oral F4 administrations (Van den Broeck et al., 1999a), 
intestinal responses in DNA primed – orally boosted pigs were independent of the F4R status, 
suggesting an increased responsiveness of the parenterally primed animals to oral 
immunization. In contrast to other studies in mice and pigs demonstrating that vitD3 enhances 
IgG but also IgA responses in the inductive sites of the GALT following parenteral 
immunization (Enioutina et al., 1999, 2000; Van der Stede et al., 2004), addition of vitD3 to 
the FaeG DNA vaccine failed to prime for the intestinal mucosal IgA response that is desired 
to protect piglets against an F4+ ETEC infection.  
In a second experiment, we evaluated the induction of cellular responses following ID 
DNA vaccination. A clear FaeG-specific lymphocyte proliferation could only consistently be 
observed in the presence of the LT vectors. A strong positive influence of these vectors on the 
antigen-specific cellular response has previously been described (Arrington et al., 2002; 
Melkebeek et al., 2007). This might result from a higher phenotypic and functional 
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maturation of APC (Bagley et al., 2002; Martin et al., 2002), resulting in a better antigen-
presentation in the presence of LT and thus in a higher number of FaeG-specific memory 
lymphocytes and/or from a different subset of T(h)-cells and/or cytokine-profile after 
immunization. For the latter, evidence was obtained by analyzing cytokine mRNA profiles in 
the Cerv LN. 
Pro-inflammatory cytokines were already weakly induced by the injection on itself (PBS 
group) and even slightly more by the DNA vector, with only the IL-6 mRNA expression 
being further up regulated by the FaeG expression. FaeG expression also resulted in an 
increased TGF-β mRNA expression, especially when an adjuvant was added. TGF-β has been 
suggested to be involved in the mucosal homing of immunocompetent cells (Enioutina et al., 
1999) and is known to play a role in the isotype switching towards IgA (Lebman et al., 1990; 
Iwasato et al., 1994). For the expression of IL-10 (Th2-like) and IFN-γ (Th1-like) mRNA, a 
high variability could be observed among the animals. Furthermore, in line with other studies 
in pigs (Suradhat et al., 2003; Reddy et al., 2000), expression of IL-4 (Th2-like) and IL-2, 
could not be detected. It has been speculated that in pigs other molecules may substitute 
functionally for classical murine cytokines, like IL-4 and perhaps IL-2 (Reddy et al., 2000). 
IL-4 function might be substituted by IL-13 (Reddy et al., 2000), which has not been 
measured here. Consequently, we were not able to attribute a typical Th-cytokine profile to 
FaeG DNA vaccination and/or the LT vectors and vitamin D3. What we did observe was a 
suppression of the FaeG-specific lymphocyte proliferation with increased IL-10 mRNA 
levels. This is in line with studies in man and cattle demonstrating that IL-10 inhibits Th1- 
and Th2-cell proliferation in these species (Del Prete et al., 1993; Brown et al., 1994). 
Moreover, although IL-10 mRNA expression was highly variable, the absence of a clear IL-
10 response in the LT group might at least have contributed to the strong FaeG-specific 
proliferation observed in the presence of the LT vectors. Furthermore, IL-10 synergizes with 
TGF-β to increase the efficiency of IgA switching (Defrance et al., 1992), while IL-6, 
together with IL-5 acts to enhance the IgA secretion (Snoeck et al., 2006b). So, although no 
serum IgA response could be observed in the present study (as discussed above), suppression 
of both IL-6 and IL-10 mRNA expression by the LT vectors might explain the suppressed 
serum IgA response in our previous study (Melkebeek et al., 2007). 
In conclusion, even after the oral F4 boost, priming of an intestinal mucosal antibody 
response remained weak, varied among the pigs and seemed to require co-administration of 
the LT vectors or vitD3. Moreover, even in presence of these adjuvants, we failed to 
demonstrate the secretory IgA response that is needed to be protective against ETEC. 
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Therefore, further research should be directed towards enhancing the IgA response following 
DNA vaccination. 
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GENERAL DISCUSSION 
 
It was previously shown that oral immunization of weaned F4-receptor positive (F4R+) 
pigs with F4 fimbriae results in an antigen-specific secretory IgA (sIgA) response at the 
intestinal mucosa, protecting these pigs against a subsequent F4+ ETEC challenge (Van den 
Broeck et al., 1999a). However to prevent postweaning diarrhea (PWD), the immune system 
should already be primed during the suckling period. Most suckling pigs have maternal 
antibodies against F4 fimbriae, hampering the use of F4 fimbriae as a vaccine. As DNA 
vaccines produce antigen endogenously, maternal antibodies can not interfere with the 
induction of cellular immunity by these vaccines. Therefore, we suggested that priming with a 
DNA vaccine encoding the adhesive subunit of F4, the FaeG, could be an interesting 
approach to obtain protective immunity against PWD. 
The best route to induce an intestinal mucosal immune response is the oral route. However, 
oral administration of ‘naked’ DNA vaccines is difficult due to the harsh environment of the 
gastrointestinal tract. Parenteral vaccination seems more appropriate, but tends to stimulate 
the systemic rather than the mucosal immune system. In efforts to improve mucosal immune 
responses to naked DNA vaccines, heterologous prime – boost strategies combining 
parenteral DNA vaccination with mucosal delivery of live attenuated microorganisms or 
protein-based vaccines have been proposed. Furthermore, studies in mice (Enioutina et al, 
1999; 2000; Glenn et al., 1998) and pigs (Van der Stede et al., 2001; 2004) demonstrated that 
co-administration of immunomodulators, such as 1α,25-dihydroxyvitamin D3 (vitD3), 
choleratoxin (CT) or the E. coli thermolabile enterotoxin (LT), to systemic protein vaccines 
not only improved systemic antibody responses but also resulted in the induction of an 
intestinal mucosal IgA response. In mice, this was at least partly due to an altered migration 
of antigen-carrying APC, resulting in their localization at intestinal immune induction sites  
where mucosal antigen-specific IgA and IgG ASC are induced. 
The aim of the present thesis was to determine if parenteral DNA vaccination in the 
presence or absence of immunomodulating adjuvants could reach the intestinal mucosal 
immune system, either on itself or in a heterologous parenteral DNA prime – oral F4 protein 
boost protocol. As our previous pcDNA1/faeG19 DNA vaccine induced only marginal 
immune responses following parenteral immunization of pigs, the immunogenicity of our 
FaeG DNA vaccine needed to be improved first.  
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Optimization of the FaeG DNA vaccine 
 
Systemic humoral responses: IgG and IgM 
 
When intramuscular (IM) needle injection and intradermal (ID) gene gun delivery of our 
previous pcDNA1/faeG19 DNA vaccine were compared in pigs, the IM route appeared to be 
superior with respect to priming of humoral responses (Verfaillie et al., 2004). The same was 
observed by Deml and colleagues in mice (2001), whereas opposite results are obtained in 
most other studies comparing both techniques in mice (Stasikova et al., 2003), monkeys 
(Lodmell et al., 2001) and pigs (Barfoed et al., 2004). These contradicting findings suggest 
that besides the delivery route and method, the encoded antigen also contributes to the 
outcome of the immunization. Besides in the inoculation route, gene gun delivery additionally 
differs from IM needle injection in the lower amount of plasmid DNA and consequently of 
CpG motifs applicated, and in an increased efficacy of cell transfection which may both 
influence strength and type of immune response. Indeed, gene gun immunization generally 
induces a Th2-like response, whereas a predominantly Th1-like response is induced by IM as 
well as ID needle injection in mice (Barry and Johnston, 1997; Feltquate et al., 1997). This 
has been ascribed to the delivery of different danger signals to APC following each 
immunization route. While danger signals of IM DNA vaccination only result from CpG 
motifs and are Th1-like, an additional Th-1 like danger signal is delivered by the physical 
trauma of ID injection, whereas the process of gold particle bombardment, which only gives a 
weak trauma, delivers the most important danger signal following gene gun immunization, 
resulting in a Th2-like response (Liu et al., 2005). Despite these observations in mice, we 
again observed a better priming of humoral responses in pigs by the IM route when IM needle 
injection of pWRGFaeG was compared to ID needle injection as shown in chapter 2.  
However when GM-CSF DNA was administered one week before the first ID DNA 
vaccination, priming of the serum IgG response was enhanced and became superior to IM 
immunization (chapter 2). Therefore, we opted for ID DNA vaccination with GM-CSF pre-
treatment in all our following studies. GM-CSF has received considerable attention as an 
adjuvant for DNA vaccines given its role not only as a growth and differentiation factor for 
APC but also as a chemo-attractant for these cells. In line with studies in mice (Bowne et al., 
1999; Haddad et al., 2000), a further analysis of the adjuvant effect of the GM-CSF gene 
showed an expansion of APC at the immunization site, but also at the immune induction site 
until day 4 after FaeG DNA vaccination (chapter 3). These findings suggest not only that 
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direct transfection of  APC and/or the uptake of the expressed antigen by these cells might be 
increased, but also that the immune response can be induced earlier when GM-CSF DNA is 
delivered prior to DNA vaccination. Regarding the latter, it would be interesting to know 
whether the adjuvant effect remains when the GM-CSF gene is co-delivered with the DNA 
vaccine. Several studies in mice (Yoon et al., 2006) as well as in pigs (Cedillo-Baron et al., 
2001; Somasundaram et al., 1999; Dufour et al., 2000) have indeed reported an improved 
potency of DNA vaccines when the GM-CSF gene was co-administered. Nevertheless, an 
enhanced density of APC at the immunization site will only be achieved from a few days after 
the immunization in presence of the GM-CSF gene onwards, which can result in an enhanced 
uptake of the expressed antigen by these cells but is unlikely to improve their direct 
transfection. Studies comparing both methods are necessary to determine whether this has a 
large impact on the induction of systemic responses. However, since priming of mucosal 
responses following parenteral immunization is believed to result from the migration of 
antigen-pulsed APC to mucosal inductive sites (Enioutina et al., 1999, 2000, 2007) (as further 
will be discussed), we choose to deliver the GM-CSF gene in advance to obtain both effects 
in order to target as much APC as possible.  
As DNA vaccination requires the in vivo expression of the encoded antigen, the level of 
protein expression has a direct impact on the magnitude of the induced response 
(Montgomery et al., 1993). Therefore, we aimed to optimize the FaeG expression by (1) 
inserting  a ‘Kozak’ consensus sequence for eukaryotic translation initiation into 
pcDNA1/faeG19 (Kozak, 1987) (pcDNA1/faeGK), (2) using the pWRG7079 vector 
containing intron A which acts as an enhancer of the CMV IE promoter (Chapman et al., 
1991; Wang et al., 2006), the BGH polyadenylation site (polyA) which is more favourable for 
expression than the SV40 polyA used by pcDNA1 (Montgomery et al., 1993; Norman et al., 
1997) and the human tissue plasminogen activator signal sequence to allow extracellular 
secretion of the encoded antigen (pWRGFaeG) and (3) adjusting the codon-usage of the 
bacterial faeG to that of highly expressed porcine genes (pWRGFaeGopt) (chapter 4). As 
expected, the in vitro FaeG expression increased in the order pcDNA1/faeG19, 
pcDNA1/faeGK, pWRGFaeG, pWRGFaeGopt. Following ID immunization with 
pcDNA1/faeG19, pWRGFaeG and pWRGFaeGopt, an  F4-specific serum IgG response could 
be observed of which not only the height but also the  speed of onset was improved in line 
with increasing FaeG expression, already resulting in an F4-specific antibody response two 
weeks after the first immunization with pWRGFaeGopt. Rapid induction of an F4-specific 
immune response might be of critical importance as an effective vaccine against PWD should 
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already induce protective immunity at weaning, when pigs are approximately 4 weeks old. 
Besides a better antigen expression, the presence of an extracellular secretion signal in the 
pWRG7079 vector might be beneficial for the induction of humoral responses as it increases 
the amount of circulating antigen available for Ig receptors and activation of B cells. 
However, it is not clear whether this will be an advantage in the presence of maternal 
antibodies. Maternal antibodies will bind the antigen released by transfected cells, thereby 
masking B cell epitopes and hindering the induction of humoral responses in a similar manner 
as following conventional vaccination (reviewed by Bot and Bona, 2002). Therefore, B cell 
responses are unlikely to be induced in the presence of high titers of maternal antibodies. 
Furthermore, uptake of antigen-maternal antibody complexes by APC via the FcRγ receptor 
generally doesn’t lead to efficient antigen presentation following conventional vaccination in 
young animals. However, DNA vaccines might activate these APC via CpG motifs to 
effectively process immune complexes and present class I- and II-restricted epitopes in an 
immunogenic form (Bot and Bona, 2002). In this regard, antigen-secretion would improve the 
induction of T cell responses and therefore priming of memory responses. However, studies 
comparing the efficacy of DNA vaccines encoding secreted and non-secreted antigens in 
presence of maternal antibodies remain to be done to prove this hypothesis.  
Addition of plasmid vectors encoding the A and B subunits of the E. coli thermolabile 
enterotoxin (LT) (together called the LT vectors), and to a lesser extend of 1α,25-
dihydroxyvitamin D3 (vitD3) further improved systemic F4-specific humoral responses, as 
evidenced by an increased serum IgG response (chapter 4 and chapter 5) and an enhanced 
isotype switching from IgM to IgG in the spleen after an oral F4 boost (chapter 5). 
Although a clear IgM response could be observed in the local draining cervical lymph node 
(Cerv LN) as well as in the spleen following DNA vaccination (chapter 5), an F4-specific 
serum IgM reponse could not be observed in any of our studies. This is likely due to the high 
cut off value in the IgM ELISA. An IgM background is often observed when young animals 
are tested and is probably non-specific as even in gnotobiotic piglets, cut off values near 0.4 
could be observed using an F4-specific serum IgM ELISA (unpublished data) and a low 
background of F4-specific IgM ASC is seen in lymphoid tissues of non-immunized animals 
(Van den Broeck et al., 1999b; Verdonck et al., 2002). However compared to the situation in 
serum, we observe less problems due to background when looking at IgM responses in target 
lymphoid tissues as the antibody response is localized in these tissues shortly after 
immunization, often resulting in antigen-specific IgM ASC numbers that clearly exceed the 
background. Furthermore, other tissues like the bone marrow and other peripheral lymph 
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nodes might have contributed to the observed serum antibody response. We did not examine 
these tissues, which might explain the absence of a correlation between the situation in serum 
and that in lymphoid tissues.   
 
Systemic cellular responses 
 
Comparing IM and ID needle injection of the FaeG DNA vaccine revealed that the ID 
route is superior to induce cell-mediated immunity against F4 (chapter 2). The same was 
observed by Verfaillie and colleagues (2004) when the IM injection of pcDNA1/faeG19 was 
compared to gene gun delivery and might reflect the better immune surveillance function of 
the skin compared to muscle. Skin contains many specialized antigen-presenting cells (APCs) 
[e.g. Langerhans cells (LC) in the epidermis, and dendritic cells (DC) and macrophages in the 
dermis] which have been shown to be essential for the induction of cellular immune responses 
after DNA vaccination (Casares et al., 1997; Fu et al., 1997; Iwasaki et al., 1997), whereas 
clearly less comparable cells are present in muscles. These APC are involved in T cell 
priming in at least 3 different ways: they can capture antigen secreted by other transfected 
cells, resulting in MHC class II-restricted presentation, pick up antigen from transfected cells 
by an as yet ill-defined mechanism, resulting in MHC class I-restricted “cross”-presentation 
or they can be transfected themselves, resulting in MHC class I presentation of plasmid 
encoded antigens (Takashima and Morita, 1999). That enhancing the number of APC at the 
immunization site by delivering the GM-CSF gene prior to DNA vaccination further improves 
the cellular response supports this theory (chapter 2).  
An improvement in induction of F4-specific cellular responses by expression optimization 
or co-administration of vitD3 could not be demonstrated as a clear FaeG-specific lymphocyte 
proliferation was only consistently observed in the presence of the LT vectors as can be seen 
in chapters 4 and 5. The absence of a positive effect of vitD3 on proliferation is in agreement 
with the study in pigs evaluating the influence of vitD3 on IM F4 protein immunization (Van 
der Stede et al., 2003). Moreover in vitro, a suppressive effect on T cell proliferation has been 
described for vitD3 (van Etten and Mathieu, 2005; Bhalla et al., 1986).   
The positive effect of the LT vectors on the induction of cellular responses by DNA 
vaccination was also observed by Arrington et al (2002) in mice. They showed that the 
adjuvant effects were caused by the assembled LT holotoxin and to a lesser extend by the 
LTB subunit and not by CpG motifs in these vectors since the LTA vector on itself, but also 
the LTB vector on itself when the signal sequence was deleted, had no adjuvant effects. 
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However, Arrington vaccinated via the gene gun whereas we used ID needle injection to 
deliver the LT vectors. As CpG motifs exert their immunostimulatory potential by a pathway 
involving receptor-mediated endocytosis of the CpG-containing DNA into immune cells 
(macrophages, DC, and B cells), gene gun immunization may possibly bypass this signaling 
mechanism because of the direct intracellular deposition of the plasmid (Haynes, 1999). 
Therefore, we can not exclude a possible CpG effect in our study.  
In mice, the enhanced cellular immunity using the LT vectors was accompanied by a Th1-
modulating effect (Arrington et al., 2002). Conversely, vitD3 has been shown to suppresses 
production of Th1 cytokines (van Etten and Mathieu, 2005; Bhalla et al., 1986; Reichel et al., 
1987) and to favor the production of Th2 cytokines such as IL-4 and IL-10 (Daynes and 
Araneo, 1994; Daynes et al., 1996; Cantorna et al., 1998; Adorini et al., 2001) as well as of 
the Th3 cytokine TGF-β (Fukaura et al., 1996; Weinreich et al., 1999). To determine the 
cytokine profile in pigs, expression of IL-1α, IL-6, TNF-α (pro-inflammatory cytokines), IL-
2, IFN-γ (Th1-like cytokines), IL-4, IL-10 (Th2-like cytokines) and TGF-β (Th3-like 
cytokine) mRNA was evaluated in the Cerv LN (chapter 5). We were not able to attribute a 
typical Th-cytokine profile to FaeG DNA vaccination and/or the LT vectors and vitD3 as a 
high variability could be observed in IL-10 (Th2-like) and IFN-γ (Th1-like) mRNA 
expression, whereas expression of IL-4 (Th2-like) and IL-2 (Th1-like) could not be detected. 
The absence of a detectable IL-2 and IL-4 mRNA expression is in line with other studies in 
pigs (Suradhat et al., 2003; Reddy et al., 2000). It has been speculated that other cytokines 
might substitute functionally for these classical cytokines in pigs (Reddy et al., 2000). IL-13 
may substitute IL-4 in steering Th2 differentiation (Reddy et al., 2000). Indeed, IL-13 shares 
many functional properties with IL-4, including stimulation of murine B cells, inhibition of 
pro-inflammatory cytokine production, induction of IL-1 receptor antagonist by 
monocyte/macrophages and the regulation of isotype class switching in B cells to IgE 
synthesis (De Waal Malefyt et al., 1993; Cocks et al., 1993; Defrance et al., 1994). These 
shared functions are due to a common receptor chain (Wills-Karp, 2004). For IL-2, a 
substitute has not yet been proposed. 
We did observe an increased IL-6 and TGF-β mRNA expression by the FaeG DNA 
vaccination. Both the LT vectors and vitD  further enhance the TGF-β mRNA expression, 
whereas the LT vectors also seem to suppress IL-6 mRNA expression.  
3
Although IL-10 mRNA expression was highly variable, increased IL-10 mRNA levels 
were consistently accompanied by a suppression of FaeG-specific lymphocyte proliferation. 
This is in agreement with studies in man and cattle demonstrating inhibited Th1- and Th2-cell 
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proliferation by IL-10 (Del Prete et al., 1993; Brown et al., 1994). Moreover, the absence of a 
clear IL-10 response in the LT group might at least have contributed to the strong FaeG-
specific proliferation observed in this group.  
 
Priming of a serum IgA response 
When the IM and the ID route in the absence of GM-CSF were compared, only IM 
injection resulted in a secondary serum IgA response following an IM F4 protein boost. 
However, when the GM-CSF gene was given 7 days prior to the IM DNA vaccination, than 
this immunization resulted in an even more efficient priming for IgA (chapter 2). Further 
enhancement of the IgA response was obtained by vector-codon-optimization of the DNA 
vaccine resulting in a vaccine-induced IgA response in serum (chapter 4) or Cerv LN (chapter 
5).  
The better IgA response observed in chapter 4 than in chapter 5 might result from 
differences in environmental factors encountered by the pigs, or alternatively from an 
unnoticed minor contact with F4. Indeed, it has been described that intestinal priming can 
result in an IgA response following parenteral immunization (Svennerholm et al., 1980). 
Although farms were carefully selected, litters were tested to be F4-seronegative and pigs 
were orally treated with colistine to prevent infection during the weaning period, a risk for 
such a contact can not absolutely be excluded.  
Although parenteral immunization preferentially induces an IgG response, induction of a 
systemic IgA response was also seen in earlier studies in pigs (Vanderstede et al., 2002, 
Vanderpooten et al., 1997) and was more efficient by immunizing in the neck compared to 
the back. This might be explained by the fact that the dorsal superficial cervical LN (draining 
the neck region) is connected to lymph nodes draining the tonsils and the nasal mucosa, which 
might be more beneficial for  IgA induction (Vanderpooten et al., 1997).  
When LT or vitD3 are added to parenteral protein vaccines, an IgA-modulating effect can 
be observed (Daynes and Araneo, 1994; Daynes et al., 1996; Enioutina et al., 1999, 2000; Yu 
et al., 2002; Van der Stede et al., 2001, 2004). However, adding the LT vectors to the 
optimized DNA vaccine abolished the serum IgA response (chapter 4), whereas no increase in 
IgA response could be observed when vitD3 was added (chapter 5). It is possible that either 
GM-CSF pre-treatment, the presence of CpG motifs and/or by the slow and continuous 
expression of low antigen/LT doses following DNA vaccination promotes different APC or 
T-lymphocyte functions, neutralizing the effect of vitD3 and the expressed LT. Furthermore, 
the nature of the expressed antigen might have influenced the immunomodulating effect. 
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Indeed, although vitD3 enhanced the IgA response to human serum albumin (Van der Stede et 
al., 2001, 2004), it did not enhance the IgA response to F4 fimbriae in pigs (Van der Stede et 
al., 2003). In addition, as IL-10 is involved in IgA isotype switching (Defrance et al., 1992) 
and IL-6 acts to enhance the IgA secretion (Snoeck et al., 2006b), suppression of these 
cytokines by the LT vectors might explain the suppressed IgA response by these vectors.  
 
Priming of an intestinal mucosal immune response by parenteral DNA vaccination  
 
VitD3 and LT have been demonstrated to promote the induction of mucosal immune 
responses following parenteral delivery of protein antigens (Enioutina et al., 1999, 2000; 
Glenn et al., 1998; Van der Stede et al., 2001, 2003, 2004). This has been ascribed to their 
ability to alter the migratory properties of antigen-loaded DC, allowing them to bypass 
sequestration in the local draining lymph node and to traffic to the Peyer’s patches, where 
antigen-specific IgA and IgG ASC are induced (Enioutina et al., 2000). However, in the 
presence of the LT vectors or vitD3, we could not consistently demonstrate an intestinal 
mucosal response following DNA vaccination (chapter 5). Similarly, even though the group 
of Daynes observed mucosal responses in mice that were quantitatively and qualitatively 
similar to those induced by oral immunization in the presence of cholera toxin as adjuvant 
when they included vitD3 in a parenteral protein vaccine, they failed to observe mucosal 
antibodies following parenteral DNA vaccination in the presence of vitD3 (Kriesel et al., 
1996). As already suggested for the absence of a serum IgA response, it is conceivable that 
either GM-CSF pre-treatment, the presence of CpG motifs and/or the slow and continuous 
production of low antigen amounts following DNA vaccination might have counteracted the 
immunomodulating effect of both adjuvants. Indeed, while GM-CSF and CpG motifs have 
been described to activate DC, vitD3 tends to delay full DC maturation (Berer et al., 2000; 
Griffin et al., 2000, 2003). Whether any relationship exists between the mechanisms 
underlying the ability of LT or vitD3 to promote the generation of mucosal responses is 
uncertain. For the mucosal adjuvant properties of LT, the ability to elevate cAMP levels 
seems to be important. Enioutina et al (2000) hypothesized that this might be due to the 
capacity of cAMP to stimulate the expression of 1,α-hydroxylase, which converts the normal 
circulating 25(OH)D3 into the active 1,25(OH)2D3 form, referred to as vitD3 in this thesis. 
Although cAMP activity could be demonstrated following in vitro transfection of Caco2 cells 
with the LT vectors (Arrington et al., 2002), it is likely that formation of a functional AB5 LT 
holotoxin and thus elevation of cAMP levels is less efficient in vivo, explaining the absence of 
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a mucosal adjuvant effect by these vectors. In addition, the slow and continuous production of 
low amounts of the LTA and LTB subunits and/or the assembled LT might be less effective 
than the short-term presence of the larger amount of LT administered with protein antigens. 
However, significant mucosal antibody responses have been observed in  rabbits and 
monkeys following IM DNA vaccination when the encoded antigen was fused to CTLA-4 
(Jia et al., 2006). CTLA-4 binds the B7 (CD80/86) costimulatory molecules on the surface of 
APC, thereby targeting the fused antigen to these cells. Whether any relationship exists 
between the mechanisms underlying the ability of CTLA-4, vitD3 and cAMP to promote 
priming of mucosal responses is unclear, but the function of CTLA-4 additionally highlights 
the key role of APC in the priming of mucosal responses following parenteral immunization. 
As combining a CTLA-4 fusion to GM-CSF pre-treatment could further enhance APC 
targeting in our model, this might be an interesting approach to obtain mucosal priming. 
Furthermore, the ability of DNA-transfected APC to bypass the local draining lymph node has 
been demonstrated (La Cava et al., 2000). In that study, ID DNA vaccination in the presence 
of an inflammatory adjuvant resulted in APC-mediated transport of DNA beyond the draining 
LN to distant sites such as the spleen. Moreover, when a second site of inflammation was 
induced, plasmid DNA accumulated at this distal site. These data suggest that coupling 
parenteral DNA vaccination and an intestinal inflammatory stimulus might be more effective 
to target the immune response to the intestinal mucosa.  
Another strategy that has been applied successfully to improve the induction of mucosal 
responses following parenteral DNA vaccination includes the delivery of a mucosal boost 
with live attenuated microörganisms or protein-based vaccines (Weeratna et al., 2000; Lasaro 
et al., 1999, 2004). In the present thesis, oral F4 administration boosted the serum IgG, but 
not the serum IgA response that was induced by pWRGFaeGopt (chapter 4). Although the 
IgG response remained mainly localized in the systemic lymphoid tissues, a weak mucosal 
IgG response could be observed (chapter 4 and chapter 5). This mucosal response varied 
considerably among the pigs whereas low numbers of IgG ASC were more consistently 
detected in the Mes LN of most DNA primed pigs, especially if the LT vectors or vitD3 were 
added. In contrast to the situation in naïve (unprimed) pigs where oral F4 administration to 
F4R- pigs fails to induce a mucosal response and is less efficient to prime a systemic response 
than in F4R+ pigs (Van den Broeck et al., 1999a), induction of these systemic and mucosal 
IgG responses was independent of the F4R status. This is consistent with other reports 
demonstrating the induction of immune responses following oral immunization of 
parenterally primed, but not of naïve animals (Lauterslager et al., 2001, 2003), indicating an 
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increased responsiveness of the parenterally primed animals to oral immunization. Possible 
explanations for this increased responsiveness might include an improved uptake of the 
antigen through the gut, an altered antigen-processing favouring immunoresponsiveness 
rather than oral tolerance and an enhanced capability of the primed immune system to react to 
small quantities of antigen entering the body. Nevertheless, only strongly F4R+ pigs showed 
high numbers of IgG ASC in their LP and low levels of IgG antibodies in their intestinal 
contents. 
Following the oral boost, intestinal FaeG-specific IgA and IgM responses were variable 
and an improvement by DNA priming could only be observed for a few pigs, mostly when the 
LT vectors or vitD3 were added (chapter 4 and chapter 5).  
Although sIgA generally provides the primary defence against intestinal pathogens, 
parenteral priming with pWRGFaeGopt followed by an oral F4 protein boost marginally but 
significantly reduced the faecal F4+ E. coli excretion, whereas co-administration of the LT 
vectors additionally reduced the duration of faecal excretion following an F4+ ETEC 
challenge one week after the oral F4 boost (chapter 4). This partial protection might be 
attributed to the IgG response. Indeed, a study by Yu and colleagues (2002) demonstrated 
protection of mice against an oral LT challenge by passive infusion of serum derived anti-LT 
IgG. IgG can be transported towards the intestinal lumen via the bidirectional IgG 
transporting neonatal Fc receptor (FcRn) (Dickinson et al., 1999), which might explain the 
presence of F4-specific IgG in the intestinal contents of some pigs immunized by the 
heterologous protocol. Expression of this FcRn receptor has been demonstrated on the 
intestinal epithelium of both young and adult humans and pigs (Israel et al., 1997; Stirling et 
al., 2005). Once in the intestinal lumen, IgG could contribute to protection. In one study, oral 
administration of milk derived anti-CFA/I IgG protected human volunteers against a CFA/I+ 
ETEC infection (Freedman et al., 1998). However in general, the ability of pathogen-specific 
IgG to protect against infection at the mucosal surfaces is rather limited. It can neutralize 
bacteria, mediate antibody-dependent cellular cytotoxicity and activate complement, but 
unlike sIgA, IgG is poorly equipped to prevent bacterial attachment to the mucosal surface or 
to trap bacteria in mucus (Robert-Guroff, 2000). 
Although several studies have demonstrated the successful induction of mucosal immunity 
by parenteral DNA vaccination followed by a heterologous mucosal boost, virtually all these 
studies were done in mice (Weeratna et al., 2000; Lasaro et al., 1999, 2004). A possible 
reason for the better results obtained in those studies may be the higher dose of DNA used 
relative to the size of the animal’s intestine. Indeed, although the total intestinal mass of the 
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mouse is much smaller than that of a pig, the dose of DNA they used to prime mucosal 
responses was only 5 times lower than the dose we used (Lasaro et al., 1999, 2004). However, 
it remains to be determined whether using larger DNA doses would allow more successful 
priming of the intestinal mucosal immune system in our pig model. In agreement with our 
results, Yuan et al (2005) also failed to protect pigs against rotavirus infections by 
intramuscular (IM) priming with DNA followed by an oral boost with attenuated human 
rotavirus (AttHRV). However, they did observe protection when the oral AttHRV was given 
to prime and the IM DNA vaccine to boost the immune response in pigs. This protection was 
associated with a higher serum IgA and a higher intestinal IgA and IgG response. Similarly, 
Eo and colleagues (2001) observed excellent mucosal responses by priming IN with a 
recombinant vaccinia virus vector (rvac) and boosting systemically with a DNA vaccine, but 
not by systemic DNA priming and mucosal boosting with rvac or by systemic rvac priming 
and mucosal boosting with the DNA vaccine. These data indicate that the anatomic site where 
initial APC-T cell interactions occur determines the success to induce a mucosal response. 
However, as stated before, mucosal delivery of ‘naked’ DNA vaccines is not ideal due to the 
harsh enzymatic environment and the limited transport across the mucosal epithelium. 
Nevertheless, in rodents, DNA vaccines have been proven to be capable of inducing 
protective mucosal IgA responses when strategies are used to overcome these barriers. These 
strategies include the use of formulations protecting the DNA from degradation and/or 
targeting the DNA to mucosal inductive sites (Wu et al., 2001; O’Hagan et al., 2004; Alpar et 
al., 2005; Wang et al., 2005) and the use of live bacterial carriers to deliver the DNA vaccine 
to mucosa-associated lymphoid tissues (Schoen et al., 2004)  and are discussed in detail in 
chapter 1. However, as these studies have almost exclusively been performed in rodents, their 
potential in large animal models such as the pig remains to be investigated.  
 
Main conclusions and future perspective 
 
DNA vaccines have received considerable attention after the initial demonstration in the 
early 90’s that unformulated plasmid DNA could result in in vivo expression of the encoded 
protein after IM injection (Wolff et al., 1990) and induce both humoral and cellular responses 
against human pathogens (Ulmer et al., 1993; Fynan et al., 1993; Wang et al., 1993; Davis et 
al., 1994). However although these initial vaccines generally worked well in mice, they were 
often less immunogenic in large animals and humans. Since then, new formulations, new 
adjuvants, new delivery methods and more sophisticated constructs have been developed to 
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improve the potency of these vaccines (Laddy and Weiner, 2006; Liu et al., 2006; Leitner et 
al., 1999). At present, DNA vaccines finally start to gain a position on the market. However, 
future challenge remains to make these vaccines more potent and cheaper to manufacture 
before they can be routinely used.  
In this thesis, we demonstrated that the immunogenicity of the parenteral FaeG DNA 
vaccine in pigs could be greatly improved by determining the optimal delivery route, pre-
treatment of the immunization site with GM-CSF DNA and optimizing the FaeG expression. 
Nevertheless, even in the presence of immunomodulators and/or an oral protein boost, 
parenteral immunization with this vaccine induced mainly a systemic IgG response, failing to 
prevent F4+ E. coli excretion upon challenge. To induce the sIgA response that is needed to 
prevent postweaning diarrhoea by DNA vaccination, strategies targeting the intestinal mucosa 
might prove to be more effective. Although oral DNA vaccination is still in its infancy, the 
use of live bacterial carriers to deliver the DNA vaccine to the gut-associated lymphoid 
tissues (GALT) (Schoen et al., 2004) and formulations to protect the DNA against 
degradation and to target it to mucosal inductive sites have had some success in rodents. 
Regarding the latter, PLG microparticles smaller than 10 µm in diameter have been used as 
these are actively taken up by M cells of the Peyer’s patches and by APC and thus appear able 
to facilitate the presentation of DNA to the intestinal mucosal immune system (Chen et al., 
1998; Herrmann et al., 1999; O’Hagan et al., 2004). However, it seems unlikely that uptake 
of these microparticles into the GALT is sufficient to allow the successful development of 
oral vaccines in large animals (O’Hagan et al., 2004). Alternatively, the bioadhesive chitosan 
nanoparticles have successfully been used for oral delivery of DNA in mice (Chew et al., 
2003). These are also taken up by M cells (van der Lubben et al., 2001, 2002) but additionally 
interact with mucin (Lehr et al., 1992), providing an intimate contact with the mucosal 
membrane and promoting more efficient uptake. However, their potential in large animals 
remains to be tested. In addition, coating of microparticles with M cell ligands could be an 
interesting approach to allow more efficient targeting to the GALT. However, in contrast to 
other species, lectins specific for the apical surface of porcine M cells have not yet been 
identified. Nevertheless, the σ1 protein of reovirus and the invasin of Yersinia, both 
exploiting the membrane protein β1-integrin, apically located on M cells, to gain entry into 
the host (Maginnis et al., 2006; Clark et al., 1998; Schulte et al., 2000), may be used for 
selective targeting to M cells. Wang et al (2003) and Wu et al (2001) have already 
demonstrated that the reovirus σ1 protein can be used for selective targeting of DNA-
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polylysine complexes to nasal M cells. However, although the σ1 protein also binds Peyer’s 
patch M cells (Amerongen et al., 1994; Clark et al., 1995), it has not been tested in oral 
delivery systems yet. In addition, in rodents and rabbits, Peyer’s patches M cells selectively 
bind and endocytose sIgA (Mantis et al., 2002). This receptor may be conserved among 
species and may also be exploited for selective targeting to M cells. Zhou et al (1995) and 
Velez et al (1997) have already demonstrated that selective targeting to M cells can be 
achieved by coating carrier liposomes with IgA. Consequently, oral immunization of suckling 
pigs with our optimized FaeG DNA vaccine using a micro- or nanoparticle system coated 
with one of these M cell ligands might be promising.  
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SUMMARY 
 
Enterotoxigenic E. coli (ETEC) that express F4 (K88) fimbriae are an important cause of 
disease, weight loss and mortality in newly weaned piglets. The F4 fimbriae are long 
polymeric appendages mainly composed of several hundreds identical FaeG subunits. They 
enable the bacteria to colonize the small intestine and to produce enterotoxins resulting in 
diarrhoea. In our laboratory it has been demonstrated that oral administration of purified F4 
fimbriae to weaned piglets results in an antigen-specific secretory IgA (sIgA) response at the 
intestinal mucosa, protecting the piglets against a subsequent F4+ ETEC challenge. However 
to prevent postweaning diarrhoea (PWD), the immune system should already be primed 
during the suckling period. Most suckling pigs have maternal antibodies against the F4 
fimbriae, hampering their use as a vaccine.  
As DNA vaccines produce their encoded antigen endogenously, maternal antibodies won’t 
interfere with the induction of cellular immunity by these vaccines. Therefore, we suggested 
that priming with a DNA vaccine encoding the FaeG could be an interesting approach to 
obtain protective immunity against PWD. 
The best route to induce an intestinal mucosal immune response is the oral route. However, 
oral DNA vaccination has to overcome several problems to be effective. These problems 
include depurination by low pH in the stomach, enzymatic degradation by DNases in the gut, 
crossing the mucus layer and transport through the epithelial barrier to reach the intestinal 
mucosal inductive sites. Parenteral DNA vaccination is easier, but tends to stimulate a 
systemic rather than a mucosal IgA response. However, studies in mice and pigs demonstrated 
that co-administration of immunomodulators, such as 1α,25-dihydroxyvitamin D3 (vitD3), 
cholera toxin or the E. coli thermolabile enterotoxin (LT), with parenteral protein vaccines not 
only improved systemic antibody responses but also induced an intestinal mucosal IgA 
response. These immunomodulators alter the migratory properties of antigen-pulsed antigen-
presenting cells (APC), resulting in their preferential localization at the Peyer’s patches where 
antigen-specific mucosal responses are initiated. 
In the present thesis, we questioned if parenteral FaeG DNA vaccination could prime an 
intestinal mucosal immune response when immunomodulating adjuvants and/or a mucosal F4 
boost were included. The FaeG DNA vaccine previously developed at our lab induced 
marginal immune responses following parenteral immunization of pigs. In order to enlarge the 
chance for successful mucosal priming, several strategies were applied to enhance the 
immunogenicity of our DNA vaccine. Furthermore, given the critical role of APC in the 
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induction of mucosal immunity by parenteral immunization, granulocyte-macrophage colony-
stimulating factor (GM-CSF), a well known chemo-attractant of APC was included in our 
vaccination strategy. 
 
Chapter 1 reviews the present knowledge on DNA vaccines, with a focus on the potential 
of these vaccines in pigs. In a first part, the history of DNA vaccines, their principle, the 
mechanism by which they induce immune responses and their advantages compared to 
conventional vaccines are described. An important disadvantage is that DNA vaccines are 
mostly less immunogenic in large animals and humans than in mice. Therefore, in the second 
part, strategies applied to enhance the efficacy of DNA vaccines in pigs are summarized. In 
the last part of this chapter, the potential of DNA vaccines to induce a mucosal response is 
outlined. 
 
Chapters 2 to 5 present the experimental work of this thesis. The following questions were 
addressed: 
• What is the optimal route for parenteral FaeG DNA vaccination, the intradermal (ID) or the 
intramuscular (IM) route? 
• Does pre-treatment with plasmid encoded GM-CSF increase the immunogenicity of our 
parenteral DNA vaccine and is this associated with a chemo-tactic effect on APC? 
• Can the immunogenicity of the parenteral FaeG DNA vaccine further be enhanced by 
optimizing the FaeG expression? 
• Does parenteral priming with the optimized FaeG DNA vaccine in the presence or absence of 
vitD3 or plasmids encoding the A and B subunits of LT (together called the LT vectors), either 
on itself or in a parenteral DNA prime – oral F4 protein boost protocol, prime the intestinal 
mucosal IgA response needed to protect pigs against PWD?  
 
In chapter 2, IM and ID injection of pWRGFaeG were compared for their capacity to 
prime systemic cellular and humoral responses in weaned piglets in order to determine the 
optimal route for parenteral FaeG DNA vaccination. In addition, the adjuvant effect of 
plasmid DNA encoding the porcine GM-CSF was determined on ID DNA vaccination by 
delivering it 7 days prior to the first immunization, as plasmid encoded GM-CSF has been 
shown to attract APC to the injection site in mice with a maximal effect on day 7. The IM 
route induced better humoral responses since IgG titers were raised earlier and a weak serum 
IgA response was primed, whereas the ID route was superior in inducing cell-mediated 
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immunity, as demonstrated by a lymphocyte proliferation assay. ID delivery of the GM-CSF 
gene one week before the first ID DNA vaccination further enhanced the F4-specific cellular 
as well as humoral immune responses and even resulted in a more efficient priming of the IgA 
response than the IM immunization.  
 
Therefore, we further evaluated the adjuvant effect of plasmid DNA encoding the porcine 
GM-CSF on APC in pigs (chapter 3). We demonstrated that ID delivery of the GM-CSF gene 
7 days prior to ID FaeG DNA vaccination significantly increases the number of epidermal 
CD1+ cells (Langerhans’ cells, skin DC) at the immunization site. This was accompanied by 
an enhanced  percentage of APC at the immune induction site until 4 days after FaeG DNA 
vaccination. These findings suggest not only that direct transfection of  APC and/or the uptake 
of the expressed antigen by these cells might be increased, but also that the immune response 
can be induced earlier when GM-CSF DNA is delivered prior to DNA vaccination. 
Furthermore, since priming of mucosal responses following parenteral immunization is 
believed to result from the migration of antigen-pulsed APC to mucosal inductive sites, 
increasing APC numbers might improve our chance on successful mucosal priming. 
Therefore, we opted for ID DNA vaccination with GM-CSF pre-treatment in our following 
studies. 
 
 
In chapter 4, it was examined if optimizing the FaeG expression and/or inclusion of the LT 
vectors could further enhance the immunogenicity of our ID FaeG DNA vaccine. In addition, 
priming of an F4-specific intestinal mucosal immune response was assessed in an intradermal 
(ID) DNA prime - oral F4 boost protocol. To optimize the FaeG expression, first, a ‘Kozak’ 
consensus sequence for eukaryotic translation initiation was inserted into pcDNA1/faeG19 
(pcDNA1/faeGK). Then, the pcDNA1 vector was replaced by pWRG7079 (pWRGFaeG). As 
pcDNA1, this vector contains the CMV IE promoter, but in addition it contains the associated 
intron A, which acts as an enhancer for this promoter and, instead of the SV40 
polyadenylation site (polyA) of pcDNA1, it contains the more favourable BGH polyA for 
transcriptional termination. In addition, pWRG7079 contains the human tissue plasminogen 
activator (tPA) signal sequence to allow extracellular secretion of the encoded antigen. 
Finally, the codon-usage of the bacterial faeG was adjusted to that of highly expressed porcine 
genes (pWRGFaeGopt). As expected, the in vitro FaeG expression increased in the order 
pcDNA1/faeG19, pcDNA1/faeGK, pWRGFaeG, pWRGFaeGopt. Subsequently, 
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pcDNA1/faeG19, pWRGFaeG and pWRGFaeGopt were tested for their immunogenicity in 
weaned pigs in an ID DNA prime – oral F4 protein boost model. Following ID DNA 
vaccination, an F4-specific serum IgG response could be observed of which not only the 
height but also the  speed of onset was improved in line with increasing FaeG expression. 
Consequently, an F4-specific IgG response could already be observed as soon as two weeks 
after the first immunization with pWRGFaeGopt. Furthermore, only this vector-codon-
optimized construct induced a serum IgA response. The LT vectors additionally enhanced the 
antibody response and were necessary to observe an F4-specific cellular response, but 
abolished the serum IgA response. These vectors were added because LT has been described 
to direct the systemic response towards a mucosal IgA response in mice. Here, however, the 
ID FaeG DNA prime – oral F4 boost immunization resulted mainly in a systemic IgG 
response. Only few pigs showed an intestinal mucosal immune response with antibodies 
which were mainly IgG instead of IgA. Normally sIgA provides the primary defence against 
intestinal pathogens like ETEC. Nevertheless, priming with pWRGFaeGopt significantly 
reduced the faecal F4+ E. coli excretion, whereas co-administration of the LT vectors 
additionally reduced the duration of faecal excretion. These findings suggest a role for IgG in 
this partial protection. 
 
In chapter 5, we evaluated if addition of vitD3 to the DNA vaccine could further enhance 
mucosal priming and/or modulate the antibody response towards IgA in our ID DNA prime 
(2x) – oral F4 protein boost model. Furthermore, to evaluate the need for the oral F4 boost in 
the induction of mucosal immunity, the heterologous ID DNA prime (2x)- oral F4 protein 
boost immunization was compared to a homologous ID pWRGFaeGopt DNA vaccination 
(3x). A systemic IgG response was induced by both protocols and was higher following the 
heterologous protocol. Co-administration of the LT vectors, and to a lesser extend of vitD3, 
enhanced this response. However, although LT and vitD3 were shown to direct a systemic 
response towards a mucosal IgA response when added to parenteral protein vaccines, we 
could not demonstrate an intestinal mucosal response following parenteral DNA vaccination, 
regardless of the presence of the LT vectors or vitD3. Furthermore, vitD3 did not enhance the 
systemic IgA response induced by pWRGFaeGopt. After the oral F4 boost, a weak mucosal 
IgG response could be observed. This mucosal response varied considerably among the pigs 
whereas low numbers of IgG antibody-secreting cells (ASC) were more consistently detected 
in the mesenteric lymph nodes of the DNA primed pigs, especially if the LT vectors or vitD3 
were added. However, despite two DNA immunizations in the presence of these adjuvants 
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and an oral F4 boost, we failed to demonstrate the secretory IgA response needed to be 
protective against enterotoxigenic E. coli. In a second experiment, the induction of cytokine 
mRNA expression and lymphocyte proliferation were evaluated following ID DNA 
vaccination in the presence or absence of the LT vectors or vitD3. A clear FaeG-specific 
lymphocyte proliferation could only consistently be observed in the presence of the LT 
vectors. When cytokine mRNA expression was evaluated in the local draining lymph nodes, 
an increase in IL-6 and TGF-β mRNA expression was observed by pWRGFaeGopt 
vaccination. Both the LT vectors and vitD  further enhance the TGF-β mRNA expression, 
whereas the LT vectors also seem to suppress IL-6 mRNA expression. Although IL-10 
mRNA expression was 
3
highly variable, increased IL-10 mRNA levels were consistently 
accompanied by a suppression of FaeG-specific lymphocyte proliferation. This is in 
agreement with studies demonstrating inhibited T-helper (Th)1- and Th2-cell proliferation by 
IL-10 in man and cattle. Moreover, the absence of a clear IL-10 response in the LT group 
might at least have contributed to the strong FaeG-specific proliferation observed in this 
group. Furthermore, as IL-10 is involved in IgA isotype switching and IL-6 acts to enhance 
the IgA secretion, suppression of these cytokines by the LT vectors might explain the 
suppressed IgA response observed by these vectors in chapter 4.  
 
The final chapter, (chapter 6) represents the general discussion, conclusions and future 
perspectives with respect to the obtained results. In this thesis, we demonstrated that the 
immunogenicity of the parenteral FaeG DNA vaccine in pigs could greatly be improved by 
determining the optimal delivery route, pre-treatment of the immunization site with GM-CSF 
DNA and optimizing the FaeG expression. Nevertheless, even in the presence of 
immunomodulators and/or an oral protein boost, parenteral immunization with this vaccine 
mainly induced a systemic IgG response, failing to prevent F4+ E. coli excretion upon 
challenge. To induce the sIgA response that is needed to prevent postweaning diarrhoea by 
DNA vaccination, the oral route might prove to be more effective. Although oral DNA 
vaccination is still in its infancy, the use of live bacterial carriers to deliver the DNA vaccine 
to the gut-associated lymphoid tissues (GALT) and formulations to protect the DNA against 
degradation and to target it to mucosal inductive sites have been proposed. Especially 
strategies that selectively target the DNA to M cells might be promising.  
 
 
 141 
 
  Samenvatting 
SAMENVATTING 
 
Enterotoxigene Escherichia coli (ETEC) die F4 (K88) fimbriae tot expressie brengen zijn 
een belangrijke oorzaak van ziekte, gewichtsverlies en sterfte bij pasgespeende biggen. De F4 
fimbriae zijn lange polymeren die voornamelijk opgebouwd zijn uit een honderdtal identieke 
FaeG subeenheden. Ze laten de bacteriën toe om de dunne darm te koloniseren en 
enterotoxines te produceren die resulteren in diarree. In ons laboratorium is reeds aangetoond 
dat orale toediening van gezuiverde F4 fimbriae aan gespeende biggen een F4-specifieke 
secretorische IgA (sIgA) respons induceert ter hoogte van de intestinale mucosa die de biggen 
beschermt tegen een F4+ ETEC challenge infectie (Van den Broeck et al., 1999a). Om 
speendiarree (PWD) te kunnen voorkomen dient het immuunsysteem echter reeds “geprimed” 
te worden tijdens de zoogperiode. De meeste zogende biggen hebben maternale antistoffen 
tegen de F4 fimbriae die het gebruik van deze fimbriae als vaccin belemmeren. 
Aangezien DNA vaccins hun antigeen de novo aanmaken binnenin de getransfecteerde 
gastheercel gaan maternale antistoffen niet interfereren met het induceren van cellulaire 
immuniteit door deze vaccins. Daarom veronderstellen we dat immunisatie van zogende 
biggen met een DNA vaccin dat codeert voor het FaeG een interessante aanpak zou kunnen 
zijn om bescherming te induceren tegen PWD. 
De beste route om een intestinale mucosale immuunrespons te induceren is de orale route. 
Om effectief te kunnen zijn moeten orale DNA vaccins echter eerst verschillende problemen 
overwinnen. Deze problemen omvatten depurinatie door de lage pH in de maag, enzymatische 
degradatie door DNasen in de darm, doorheen de mucus laag geraken en doorheen het 
epitheel getransporteerd worden om de immunologische inductieplaatsen in de darm te 
kunnen bereiken. Parenterale immunisatie is gemakkelijker maar zal eerder een systemische 
dan een mucosale IgA respons induceren. Desondanks hebben studies in muizen en biggen 
aangetoond dat toevoegen van immunomodulatoren, zoals 1α,25-dihydroxyvitamine D3 
(vitD3), cholera toxine of het E. coli thermolabiel enterotoxine (LT) aan parenterale 
proteïnevaccins niet alleen de systemische antistoffenrespons verbetert maar ook resulteert in 
een intestinale mucosale IgA respons. Deze immunomodulatoren wijzigen het migratie 
patroon van antigeen-getransfecteerde antigeen-presenterende cellen (APC) waardoor deze 
zich bij voorkeur ter hoogte van de Peyerse platen gaan lokaliseren, waar ze de antigeen-
specifieke mucosale immuunrespons gaan initiëren.  
In deze thesis hebben we nagegaan of parenterale FaeG DNA vaccinatie een intestinale 
mucosale immuunrespons kan “primen” indien immunomodulerende adjuvantia en/of een 
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mucosale F4 “boost” toegevoegd worden. Het FaeG DNA vaccin dat eerder ontwikkeld was 
in ons labo induceerde marginale immuunresponsen na parenterale immunisatie van biggen. 
Om de kans op een succesvolle mucosale priming te verhogen werden verschillende 
strategieën toegepast om de immunogeniciteit van dit DNA vaccin te verhogen. Omwille van 
de kritische rol van APC in het induceren van een mucosale respons na parenterale 
immunisatie werd bovendien ook de granulocyt-macrofaag kolonie-stimulerende factor (GM-
CSF), een welgekend chemo-attractant van APC ingevoegd in onze vaccinatiestrategie.   
 
Hoofdstuk 1 geeft een overzicht van de huidige kennis over DNA vaccins, met de nadruk 
op het potentieel van deze vaccins bij varkens. In het eerste deel worden de geschiedenis van 
DNA vaccins, hun principe, de manier waarop ze een immuunrespons induceren en hun voor- 
en nadelen ten opzichte van conventionele vaccins beschreven. Een belangrijk nadeel is dat 
DNA vaccins meestal minder immunogeen zijn bij grote diersoorten en de mens dan bij 
muizen. Daarom wordt in het tweede deel een samenvatting gegeven van de strategieën die 
reeds toegepast zijn om de doeltreffendheid van DNA vaccins bij biggen te verhogen. Het 
laatste deel van dit hoofdstuk beschrijft het potentieel van DNA vaccins om een mucosale 
immuunrespons te induceren.   
 
In de hoofdstukken 2 tot 5 wordt het experimentele werk van dit onderzoek weergegeven. 
Deze thesis had tot doel de volgende vragen te beantwoorden.   
• Wat is de optimale route voor parenterale FaeG DNA vaccinatie, de intradermale (ID) of de 
intramusculaire (IM) route? 
• Kan voorbehandeling met plasmide gecodeerd GM-CSF de immunogeniciteit van ons 
parenteraal DNA vaccin verhogen en is dit geassocieerd met een chemo-tactisch effect op 
APC? 
• Kan de immunogeniciteit van het parenteraal FaeG DNA vaccin verder verhoogd worden door 
optimalisatie van de FaeG expressie? 
• Kan parenterale priming met het geoptimaliseerd FaeG DNA vaccin in de aan- of afwezigheid 
van vitD3 of plasmides coderend voor de A en B subeenheden van LT (samen de LT vectoren 
genoemd), op zichzelf of in combinatie met een orale F4 proteine boost, de intestinale 
mucosale IgA respons induceren die nodig is om biggen te beschermen tegen PWD?  
 
In hoofdstuk 2 werd de capaciteit van IM en ID injectie van pWRGFaeG om systemische 
cellulaire en humorale immuunresponsen te induceren bij gespeende biggen vergeleken met 
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als doel de optimale toedieningsweg te bepalen voor parenterale FaeG DNA vaccinatie. 
Eveneens werd het aduvans effect nagegaan van plasmide DNA coderend voor het porciene 
GM-CSF op ID DNA vaccinatie door dit 7 dagen voor de eerste immunisatie toe te dienen, 
aangezien aangetoond is dat plasmide gecodeerd GM-CSF APC aantrekt naar de injectieplaats 
bij muizen, met een maximaal effect na 7 dagen. De IM route induceerde betere humorale 
responsen aangezien IgG titers vlugger stegen en een zwakke IgA respons “geprimed” werd, 
terwijl de ID route superieur was in het induceren van celgemedieerde immuniteit, zoals 
aangetoond door een lymfocytenproliferatie test.  ID toediening van het GM-CSF gen 7 dagen 
voor de eerste ID DNA vaccinatie verbeterde zowel de F4-specifieke cellulaire als humorale 
immuunresponsen en resulteerde zelfs in een efficiëntere priming van de IgA respons dan de 
IM immunisatie. 
 
Daarom werd het aduvans effect van plasmide DNA coderend voor het porcine GM-CSF 
verder geëvalueerd op APC bij biggen (hoofdstuk 3). Er werd aangetoond dat ID toediening 
van het GM-CSF gen 7 dagen voor ID FaeG DNA vaccinatie het aantal epidermale CD1+ 
cellen (Langerhans’ cellen, DC van de huid) significant vermeerdert ter hoogte van de 
immunisatieplaats. Dit was vergezeld van een verhoogd percentage APC ter hoogte van de 
immunologische inductieplaats (drainerende lymfeknoop) tot 4 dagen na de FaeG DNA 
vaccinatie. Deze resultaten suggereren niet alleen dat directe transfectie van APC en/of 
opname van het geëxpresseerde antigeen door deze cellen verhoogd zou kunnen zijn, maar 
ook dat de immuunrespons sneller kan geïnitieerd worden als GM-CSF DNA toegediend 
wordt voor de DNA vaccinatie. Bovendien, aangezien verondersteld wordt dat priming van 
een mucosale respons na parenterale immunisatie het gevolg is van migratie van antigeen-
getransfecteerde APC naar mucosale inductieplaatsen, zal een stijgend aantal APC ook de 
kans op succesvolle mucosale priming verhogen. Daarom werd gekozen voor ID DNA 
vaccinatie voorafgegaan door GM-CSF injectie in de volgende studies. 
 
In hoofdstuk 4 werd nagegaan of optimalisatie van de FaeG expressie en/of inclusie van de 
LT vectoren de immunogeniciteit van het FaeG DNA vaccin verder kan verhogen. Eveneens 
werd priming van een F4-specifieke intestinale mucosale immuunrespons nagegaan in een 
“ID DNA prime (2x) - orale F4 boost” protocol. Om de FaeG expressie te optimaliseren werd 
eerst een “Kozak” consensussequentie voor eukaryote translatie-initiatie ingevoegd in 
pcDNA1/faeG19 (pcDNA1/faeGK). Vervolgens werd de pcDNA1 vector vervangen door 
pWRG7079 (pWRGFaeG). Deze vector bevat de “cytomegalovirus immediate early” 
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promotor, zoals pcDNA1, maar ook het geassocieerde intron A, dat werkt als een enhancer 
voor deze promotor en, in plaats van de “simian virus 40” polyadenylatie site (polyA) van 
pcDNA1, de gunstigere “bovine growth hormone” polyA voor terminatie van transcriptie. 
Bovendien bevat pWRG7079 ook de humane “tissue plasminogen activator” signaal 
sequentie voor extracellulaire secretie van het gecodeerde antigeen. Tenslotte werd het codon-
gebruik van het bacteriële faeG gen aangepast aan dat van sterk geëxpresseerde genen bij het 
varken (pWRGFaeGopt). Zoals verwacht steeg de in vitro FaeG expressie in de orde 
pcDNA1/faeG19, pcDNA1/faeGK, pWRGFaeG, pWRGFaeGopt. Vervolgens werd de 
immunogeniciteit van pcDNA1/faeG19, pWRGFaeG en pWRGFaeGopt getest bij gespeende 
biggen in een “ID DNA prime – orale F4 boost” protocol.  Na ID DNA vaccinatie werd een 
F4-specifieke serum IgG respons waargenomen waarvan niet alleen de sterkte maar ook de 
snelheid van aanzet verbeterd was in lijn met de stijgende FaeG expressie. Bijgevolg kon een 
F4-specifieke IgG respons zelfs al waargenomen worden vanaf de tweede week na de eerste 
immunisatie met pWRGFaeGopt. Bovendien induceerde enkel dit vector-codon-
geoptimaliseerde construct een serum IgA respons. Toediening van de LT vectoren versterkte 
de antistoffenrespons nog verder en was noodzakelijk om een F4-specifieke cellulaire respons 
te induceren, maar deed de IgA respons teniet. Deze vectoren werden toegediend omdat LT 
gekend is voor het richten van een systemische respons naar een mucosale IgA respons bij 
muizen. Hier resulteerde de “ID DNA prime – orale F4 boost” echter voornamelijk in een 
systemische IgG respons. Slechts enkele biggen vertoonden een intestinale mucosale 
immuunrespons met antistoffen die hoofdzakelijk IgG waren in plaats van IgA. Normaal 
gezien biedt sIgA de voornaamste bescherming tegen intestinale pathogenen zoals ETEC. 
Desondanks resulteerde priming met pWRGFaeGopt in een significant gereduceerde faecale 
F4+ E. coli excretie terwijl toediening van de LT vectoren eveneens de duur van de faecale 
excretie verminderde. Deze data suggereren een rol voor IgG in deze partiële protectie. 
 
In hoofdstuk 5 werd nagegaan of toediening van vitD3 aan het geoptimaliseerde DNA 
vaccin de mucosale priming verder kon versterken en/of de antistoffenrespons kon richten 
naar IgA in ons “ID DNA prime (2x) – orale F4 proteïne boost” model. Om het belang van de 
orale F4 boost na te gaan in de inductie van een mucosale respons werd het heterologe “ID 
DNA prime (2x) – orale F4 proteïne boost” protocol vergeleken met een homoloog ID DNA 
vaccinatie (3x) protocol. Een systemische IgG respons werd geïnduceerd door beide 
protocols, maar sterker door het heteroloog protocol. Toediening van de LT vectoren en, in 
mindere mate, van vitD3 versterkte deze respons. Hoewel van LT en vitD3 aangetoond is dat 
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ze een mucosale IgA respons induceren als ze toegediend worden aan parenterale proteïne 
vaccins konden we geen intestinale mucosale respons aantonen na parenterale DNA 
vaccinatie, onafhankelijk van de LT vectoren of vitD3. Bovendien versterkte vitD3 de 
systemische IgA respons geïnduceerd door pWRGFaeGopt niet. Na de orale F4 boost kon een 
zwakke mucosale IgG respons aangetoond worden. Deze mucosale respons varieerde 
aanzienlijk tussen de biggen, terwijl lage aantallen IgG antistoffen-secreterende cellen (ASC) 
meer algemeen konden gedetecteerd worden in de mesenteriale lymfeknopen van de DNA 
“geprimede” biggen, vooral als de LT vectoren of vitD3 toegevoegd waren. Ondanks 2 DNA 
vaccinaties in aanwezigheid van deze adjuvantia en een orale F4 boost slaagden we er echter 
niet in om de sIgA respons te induceren die nodig is om bescherming te bieden tegen 
enterotoxigenic E. coli. In een tweede experiment werd de inductie van cytokine mRNA 
expressie en lymfocytenproliferatie geëvalueerd na ID DNA vaccinatie in aan- of afwezigheid 
van de LT vectoren of vitD3. Een duidelijke FaeG-specifieke lymfocytenproliferatie kon enkel 
duidelijk aangetoond worden in aanwezigheid van de LT vectoren. Bij het aantonen van de 
cytokine mRNA expressie in de lokaal drainerende lymfeknopen werd een stijging in IL-6 en 
TGF-β mRNA expressie waargenomen na pWRGFaeGopt vaccinatie. Zowel de LT vectoren 
als vitD  versterkten de TGF-β mRNA expressie verder, terwijl de LT vectoren eveneens de 
IL-6 mRNA expressie leken te onderdrukken. Hoewel de IL-10 mRNA expressie sterk 
varieerde tussen de biggen
3
 werden verhoogde IL-10 mRNA niveaus steeds vergezeld door 
een onderdrukte FaeG-specifieke lymfocytenproliferatie. Dit is in overeenstemming met 
studies die een onderdrukte T-helper (Th)1- en Th2-cel proliferatie aantonen door IL-10 bij de 
mens en bij runderen. Bovendien zou de afwezigheid van een duidelijke IL-10 respons in de 
LT groep kunnen bijdragen aan de sterke FaeG-specifieke proliferatie die waargenomen werd 
in die groep. Aangezien IL-10 betrokken is in IgA isotype switching en IL-6 de IgA secretie 
bevordert zou de suppressie van deze cytokines door de LT vectoren ook de onderdrukte IgA 
respons kunnen verklaren die gezien werd in hoofdstuk 4.  
 
Het laatste hoofdstuk (hoofdstuk 6) bevat de algemene discussie, de voornaamste 
conclusies en de toekomst perspectieven. In deze thesis werd aangetoond dat de 
immunogeniciteit van het parenteral FaeG DNA vaccin bij biggen sterk verbeterd kon worden 
door de optimale toedieningsroute te bepalen, de immunisatieplaats voor te behandelen met 
GM-CSF DNA en de FaeG expressie te optimaliseren. Niettemin resulteerde parenterale 
immunisatie met dit vaccin hoofdzakelijk in een systemische IgG respons en slaagde er   zelfs 
in aanwezigheid van  immunomodulatoren en/of een orale proteïne boost niet in om een 
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mucosale IgA respons te induceren of bescherming te bieden tegen infectie met F4+ E. coli. 
Om de sIgA respons te induceren die nodig is om bescherming te bieden tegen PWD via 
DNA vaccinatie zou de orale route mogelijks effectiever kunnen zijn. Hoewel orale DNA 
vaccinatie nog in zijn kinderschoenen staat zijn het gebruik van levende bacteriële dragers om 
het DNA vaccin af te leveren aan het darmgeassocieerde lymfoïd weefsel en formulaties die 
het DNA vaccin beschermen tegen degradatie en het richten naar de mucosale 
immunologische inductieplaatsen reeds getest bij muizen. Voornamelijk strategieën die het 
DNA vaccin selectief richten naar M cellen zouden veelbelovend kunnen zijn. 
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